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Abstract
This thesis is concerned with the synthesis, characterisation, and purifi-
cation of 19 organoiridium(III) complexes, seventeen of which are novel.
The complexes are of the general structure [CpXIr(azopyridine)Z]A, where
the iridium centre is coordinated to either a pentamethyl-cyclopentadienyl
(Cp*) ligand, a tetramethyl(phenyl)-cyclopentadienyl Cpxph ligand, or a
tetramethyl(biphenyl)-cyclopentadienyl Cpxbiph ligand. The azopyridine acts
as an N,N-chelated bidentate ligand with a variety of substituents, the chem-
ical and biological e↵ects of which are investigated. Z represents a monoden-
tate halido ligand. In this work, complexes with chlorido and iodido ligands
in this position are investigated. A represents the counterion to the cationic
organoiridium complex. In this work, complexes bearing the hexafluorophos-
phate (PF6 ), Cl , and I  anions are investigated. X-ray crystal structures of
eight of the complexes are determined, confirming that the complexes adopt
the expected ’piano-stool’ configuration. The anticancer properties of these
complexes are thoroughly investigated in multiple cancer cell lines, revealing
that several are more potent than many clinically-utilised chemotherapeutics
including cisplatin (CDDP), as well as many previously reported metal-based
anticancer complexes. The mechanism of action (MoA) of this family of com-
plexes has been investigated, revealing an MoA based on the generation of
reactive oxygen species (ROS) and superoxide (SO) in addition to mitochon-
drial membrane depolarisation. Drugs with this MoA hold the potential to
selectively kill cancer cells over normal ones as cancer cells have higher levels
of basal ROS and are therefore more sensitive to perturbation of their ROS
balance. The charge, solubility, hydrophobicity, hydrolytic behaviour, and
mechanism of action (MoA) of these complexes can all be modified with small
synthetically trivial adjustments, resulting in highly potent complexes. This
demonstrates this family of complexes as an e↵ective and versatile platform
for drug design.
xi
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Chapter 1
Introduction
1.1 Cancer
According to Cancer Research UK, one in two people will develop cancer at
some point in their lives.1
Cancer is a disease characterised by unregulated, abnormal cell growth. Can-
cerous cells typically continue to grow and replicate, potentially spreading into
other parts of the body. These cells often bypass mechanisms of programmed
cell death and grow independent of the body’s signals. Significant cell repli-
cation forms a mass, or tumour. This is the first symptom of cancer.
Cancer cells can spread beyond the primary tumour site via local spread
through neighbouring tissues, via the lymphatic system, or via the blood ves-
sels. This is known as metastasis. Invasion of key organs such as the brain,
lungs, liver and kidneys can interfere with essential bodily functions, causing
death.
1.1.1 Risk Factors
In 2012, there were an estimated 8.2 million cancer-related deaths worldwide.
More than half of these occurred in countries with a medium or low human
1
development index, highlighting low wealth as a risk factor for cancer. Some
of the other most prevalent risk factors include tobacco, alcohol consumption,
obesity, poor diet, lack of exercise, exposure to carcinogens, exposure to radi-
ation, and oncogenic infection (such as Epstein-Barr virus infection, discussed
in Chapter 4).2,3
Age is one of the greatest risk factors for developing cancer, and half of all
cancers occur in people over the age of 70. As cancer arises from random
genetic mutations, the chance of a carcinogenic mutation occurring at some
point in one’s lifetime is higher the longer one’s life is. Another important
factor to consider is that as we age, the cells in our body accumulate damage
and the body becomes less able to repair e↵ectively. Over time, exposure
to environmental carcinogenic factors also accumulate and can lead to the
manifestation of cancer later in life.
Genetics also plays a significant part in cancer genesis and progression. In or-
der to facilitate carcinogenesis, the genes that regulate cell growth and division
must be altered.4 Over-expression of oncogenes, which promote cell growth and
survival, along with concurrent under-expression of tumour suppressor genes,
which inhibit cell replication, are typically required to transform a normal cell
into a cancer cell.
Whilst the vast majority of carcinogenic genetic abnormalities are random and
sporadic, approximately 3–10% of cancers are hereditary, i.e. caused by an
inherited gene or genes that significantly increase cancer risk. Prime examples
of this are the breast cancer-associated genes, BRCA1 and BRCA2, which are
associated with a >75% breast and ovarian cancer risk.5
Certain hormones can also play a part in cancer development. Sex-related
cancers in particular, such as breast or prostate cancer, are closely associated
with the levels of sex hormones present in the body. High levels of estrogen or
progesterone are associated with higher incidence of breast cancer, and high
levels of testosterone are associated with prostate cancer. These are associated
with other cancer risk factors, as the levels of these hormones are a↵ected by
ancestry, obesity, and level of exercise.6
2
1.1.2 Prevention
Unlike most diseases, anyone can develop cancer. There is no way to com-
pletely eliminate one’s risk of developing it, however there are many ways by
which to minimise it. An estimated >75% of cancers could be prevented by
avoiding, where possible, the risk factors mentioned previously.7,8
Three of the most prevalent and preventable risk factors are diet, tobacco, and
infection.
Diet is closely linked to obesity, which is another risk factor in itself. Stud-
ies have linked consumption of red meat and processed meats with increased
risk of breast, colon, prostate, and pancreatic cancers.9,10 A possible explana-
tion for this is that carcinogenic heterocyclic amines can be found in cooked
meats (Figure 1.1), especially well-done meats. Meats do, however, contain
many anticarcinogens, such as omega-3, polyunsaturated fatty acids, and con-
jugated linoleic acid, as well as important micronutrients such as selenium,
and vitamins B6, B12, and D.11,12
N N
N
NH2
2-Amino-1-methyl-6-
phenylimidazo[4,5-
b]pyridine
N
N
N
N
NH2
2-Amino-3,8-dimethylimidazo[4,5
-f]quinoxaline
N
N
N
NH2
2-Amino-3,4-dimethylimidazo[4,5
-f]quinoline
N
N
N
NH2
2-Amino-3methylimidazo[4,5
-f]quinoline
Figure 1.1: Four heterocyclic amines found in cooked ground beef. All four
are known carcinogens.13
A diet for minimising cancer risk would therefore include more fruits, veg-
etables, whole grains and fish with less red meat, animal fat, and refined
sugar. Maintaining a healthy weight would also contribute to minimising can-
cer risk.14
Exposure to tobacco is one of the most easily avoidable risk factors for cancer,
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in particular those of the mouth, larynx, lung, and pancreas. Over 50 of the
chemicals in cigarette smoke are carcinogens.15 Some of the most abundant
dangerous chemicals include acetaldehyde, which reacts with deoxyguanine,
forming DNA adducts; isoprene, which causes single- and double-strand breaks
in DNA; acrolein, which causes DNA-DNA crosslinks, DNA-protein crosslinks,
and forms DNA adducts; and 1,3-butadiene, which also forms DNA adducts
as well as inducing a global loss of DNA methylation, a↵ecting an organism’s
epigenetics (Figure 1.2).16–19
O
acetaldehyde isoprene
O
acrolein 1,3-butadiene
Figure 1.2: Four highly carcinogenic chemicals found in cigarettes at amounts
>100 µg per cigarette.16–19
Secondary smoke has also been closely linked to lung cancer and contains
many known carcinogens.13 Avoiding tobacco entirely is a highly e↵ective way
to lower one’s risk of developing cancer.
Some infections agents can contribute to the development of cancer. Infection
by human papillomavirus (HPV) is a significant risk factor for cervical can-
cers20 and hepatitis B and C infections are associated with liver cancer.21 There
are 200 types of human papilomaviruses and the level of cancer risk associated
with infection varies. The E6 and E7 oncoproteins of some of the high-risk
HPVs inactivate host p53 and retinoblastoma tumour suppressor genes, as
well as inducing centrosome abnormalities leading to aneuploidy (abnormal
number of chromosomes) and, consequently, genomic instability.
Hepatitis B and C cause carcinogenic DNA damage and chronic inflamma-
tion in the liver by the induction of excessive reactive oxygen species (ROS).
This subsequently triggers up-regulation of activation-induced cytidine deam-
inase (AICDA), which deaminates cytidine bases in DNA, converting them
into uracil. This causes DNA mismatches which can further contribute to
carcinogenesis.22
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Epstein-Barr virus (EBV) infects >90% of the global population asymptomat-
ically, however, in most hosts it remains dormant for the duration of their life,
only exprssing a small subset of its genes. In some cases, such as in an im-
munodeficient host, the virus can reactivate and begin expressing more of its
genome. Some of these are oncogenes and can lead to Burkitt’s lymphoma
(BL), Hodgekin’s lymphoma (HL), stomach cancer, and nasopharyngeal car-
cinoma (NPC).23
Other prominent viruses linked with cancer include herpesviruses, human T
cell lymphotropic virus, Merkel cell polyomavirus, and human immunode-
ficiency virus (HIV), which leads to acquired immune deficiency syndrome
(AIDS). HIV does not cause cancer directly, but is associated with Kaposi’s
sarcoma, non-Hodgekin’s lymphoma, anal cancer, and cervical cancer. As HIV
e↵ectively destroys the body’s immune system, it cannot fight o↵ the viruses
that cause these cancers and so they run rampant, leading to malignancies.24
Vaccines against HPV and Hepatitis B are available in many countries, however
no vaccines or treatments exist for many others. Avoidance of infection where
possible is the most e↵ective way to reduce cancer risk from infectious agents,
however this can be di cult for those that are more easily transmissible, such
as EBV.
Whilst minimising these risk factors can reduce the risk of cancer, there is
no way to completely eliminate one’s chances of developing it, as an element
of pure chance is involved in cancerous transformation. There are, however,
a variety of e↵ective treatments available, and being in good general health
increases your short- and long-term survival chance.
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1.1.3 Treatments
The long-term survival and quality of life of cancer patients has increased over
the recent years due to both improved diagnostics and treatments. The chance
of survival is highly dependent on the type of cancer and what stage it has
progressed to when diagnosed. Late-stage cancers are comparatively far more
di cult to treat. There are over 100 di↵erent cancers, typically named after
the organ from which the primary tumour arose. Survival varies enormously
between them, for example, the one-year net survival % for pancreatic cancer
is only 20.8%, whereas for testicular cancer it is as high as 99.1%.25 Whilst
many new and experimental treatments are being developed, most cancers are
treated by some form of surgery, radiotherapy, chemotherapy, or combinations
thereof.
When a patient is diagnosed with cancer, there are a wide variety of treatments
available to either destroy the cancer or to ease the symptoms, depending on
the nature of the cancer itself. Many di↵erent forms of surgery are utilised to
physically remove or destroy cancerous growths. Typically, it is carried out
with a scalpel, or similar equipment, however other forms of surgery are some-
times used. Laser surgery can be employed to carry out very precise destruc-
tion of cancer tissue, or to preemptively destroy abnormal growths that may
develop into cancer. Unfortunately, not all cancers can be treated surgically,
and removal of the primary tumour is a significantly less e↵ective treatment if
the cancer has already spread through local tissues or metastasised.
Many other treatments exist that can be used instead of, or in conjunction
with, surgery. One such treatment is radiotherapy. Radiotherapy uses high
doses of radiation to kill tumours, or to shrink them to ease surgical removal.
The radiation damages the cancer cells’ DNA, causing their growth to dra-
matically slow. In cases where the damage to the DNA is beyond repair, the
cancer cells die and are broken down by the body.
Radiotherapy can be applied either externally or internally. External beam
radiotherapy is carried out by a machine that aims a beam at the specific area
of the body containing the cancer. Typically, the beam will apply radiation
from many directions and angles, their vectors crossing at the point of the
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cancer. This maximises the dose of radiation received by the cancer whilst
minimising the radiation received by the surrounding healthy tissues. This
helps to reduce side-e↵ects.
Internal radiotherapy involves the insertion of a solid or liquid radiation source
into the body. Solid source radiotherapy is known as brachytherapy and is used
to treat the area harbouring the tumour. It may be used to apply low doses of
radiation over a period of days, or high doses over a span of minutes. Liquid
source radiotherapy is known as systemic therapy and can travel through the
blood, a↵ecting cancerous cells around the body. External beam radiotherapy
will not make a patient radioactive, however internal systemic radiotherapy
will cause the patient’s bodily fluids to give o↵ radiation for some time after
treatment.
Radiation therapy often has side e↵ects due to the damage it can cause to
healthy cells. The exact nature of these side e↵ects depends on the part of the
body being irradiated, however many patients receiving radiotherapy develop
significant fatigue. Additionally, there are limits on how much radiation an
area of the body can safely receive over a patient’s lifetime. Both of these
factors can hamper the e cacy of radiotherapy.
Chemotherapy is another highly-utilised form of cancer treatment involving
the use of anticancer drugs. It is often used alongside other treatments to
kill cancers or ease symptoms. Neoadjuvant chemotherapy is chemother-
apy applied before surgery or radiotherapy to reduce the size of a tumour.
Chemotherapy used to destroy cancer cells that remain after surgery or radio-
therapy is known as adjuvant chemotherapy. Chemotherapy is also an e↵ective
way of killing cancer cells that have spread from the primary tumour site to
other parts of the body.
Chemotherapy comes in a variety of forms, and the drug, or drugs, used depend
on the type and stage of the cancer being treated. Chemotherapeutics may
be administered orally, intravenously/intraarterially, by injection directly into
tissue, or topically as a cream.
Depending on the type and dose, chemotherapy may cause undesirable side-
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e↵ects. Chemotherapy typically targets fast-growing cancer cells, but can also
kill or slow the growth of other, healthy, fast-growing cells, such as those in
the mouth and intestinal lining, as well as hair follicles. This can lead to
mouth sores, nausea, and hair loss, respectively. To minimise side-e↵ects,
chemotherapy is often scheduled and carried out in cycles to allow the body
time to recover and repair any damage caused by the chemotherapy.
Cancers that were once susceptible can become resistant to some chemother-
apeutics, and there is still a great deal of room for improvement in terms
of increasing the range of treatable cancers and improving patient prognoses.
Clinical trials are regularly carried out to aid the development and assessment
of new potential chemotherapeutics. They can also be employed to treat can-
cers for which there is not yet a highly e↵ective treatment and to ultimately
improve the overall understanding of cancer. In this thesis, the anticancer
properties of a variety of complexes are investigated to evaluate their poten-
tial as possible chemotherapeutics towards entry into clinical trials.
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1.2 Precious Metal-based Anticancer Com-
plexes
A significant proportion of chemotherapy treatments utilise drugs containing
precious metals. Transition metals possess a number of properties that make
them particularly well-suited for the generation of e↵ective chemotherapeu-
tics.26 These include, but are not limited to, their various accessible redox
states, allowing for biological redox catalysis;27 their wide range of coordina-
tion geometry, allowing for three-dimensional design of shaped complexes to
fit molecular target sites;28 and their unique kinetic and thermodynamic prop-
erties, opening up avenues of design not accessible to organic compounds.29
Currently, ca. 40% of chemotherapy regimens utilise platinum drugs. In this
section, a selection of relevant platinum-, ruthenium-, osmium-, and iridium-
based anticancer therapeutics are described.
1.2.1 Platinum
Platinum-based chemotherapeutics began with the serendipitous discovery of
the anticancer properties of cisplatin (CDDP) cis-[Pt(NH3)2Cl2]. CDDP was,
in fact, first discovered by Michael Peyrone in 1844 and was known as Pey-
rone’s chloride. Its anticancer properties went undiscovered until 1965. Bar-
nett Rosenberg, whilst studying the e↵ects of electric fields on bacterial growth,
found that the platinum electrodes he was using were corroding in the test so-
lution, yielding the platinum(IV) complex [PtCl6]2 . This complex inhibited
cell growth. Furthermore, exposure to light caused this complex to exchange
ligands, forming a mixture of cis and trans isomers of [PtCl4(NH3)2]. Interest-
ingly, the cis isomer induced filamentous growth of the bacteria, the result of
replication defects that typically occur when bacteria respond to stress, such
as that which arises from DNA damage. The trans isomer, however, did not
induce filamentous growth. In the process of synthesising this salt, CDDP was
also synthesised and tested. This revealed that CDDP was even more e↵ec-
tive at inducing filamentous growth in the bacteria than the platinum(IV) salt
was.30 Rosenberg proceeded to show that CDDP could cure tumours in mice,
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leading to the discovery of a new class of antitumour agents.31
Since then, platinum-based anticancer complexes have become a key compo-
nent of chemotherapy. CDDP remains highly utilised in clinics even today, as
are its derivatives, carboplatin, oxaliplatin (Figure 1.3), and others. CDDP
platinates DNA, crosslinking guanine bases and inducing proapoptotic events.
The mechanism of action (MoA) of CDDP is discussed in more detail in Chap-
ter 4.
Pt
O
OH2N
H2N
O
O
Pt
Cl
ClH2N
H2N
O O
OO
Pt
H2
N
N
H2
Cisplatin
Carboplatin
Oxaliplatin
Figure 1.3: Clinically utilised platinum drug cisplatin (CDDP) and its deriva-
tives, carboplatin and oxaliplatin.
CDDP revolutionised cancer therapy. Before its discovery, the cure rate of tes-
ticular cancer was only 10%. CDDP-based treatment, combined with early de-
tection, has raised this to almost 100%. However, CDDP-based chemotherapy
still has a number of drawbacks, including the need for intravenous injection,
severe dose-limiting side-e↵ects, and intrinsic and acquired resistance of some
cancers to it. Improvements are being made to circumvent the drawbacks of
CDDP, such as the development of lipoplatin, a liposomal form of CDDP able
to persist in the body for ca. 120 h and fuse with tumour cell membrane,
resulting in greater antitumour activity.32
CDDP and its aforementioned derivatives are not the only e↵ective platinum-
based anticancer drugs. Many other platinum-based complexes have been
developed to overcome the drawbacks of CDDP and to attack cancers in new
ways.33 To generate a more e↵ective platinum anticancer complex, bulky car-
rier ligands were introduced to reduce the reactivity of platinum drugs to
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deactivating cellular molecules. A prominent example of this is picoplatin,
which, unlike CDDP, can be administered orally. Additionally, it has been
shown to retain cytotoxicity in CDDP- and oxaliplatin-resistant cancer cell
lines.34 Picoplatin (Figure 1.4), however, has been unsuccessful in phase III
clinical trials, indicating the need for further research and development in this
field.
N
Pt
Cl
Cl
NH3
Picoplatin
Figure 1.4: The chemical structure of the orally available CDDP-derivative,
picoplatin.
More recently, research into methyl-substituted oxaliplatin analogs has re-
sulted in complexes with improved therapeutic characteristics relative to ox-
aliplatin itself. KP1537 and KP1691 (Figure 1.5) showed superior cytotoxicity
to oxaliplatin in both platinum-sensitive and platinum-resistant cell lines,35 in
addition to increasing the life span of L1210 leukemic mice to a greater extent
than oxaliplatin.36
O O
OO
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H2
N
N
H2
KP1537
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KP1691
Figure 1.5: Oxaliplatin analogues KP1537 and KP1691 with in vivo antitu-
mour activity.
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1.2.2 Ruthenium
Ruthenium-based complexes o↵er another avenue for drug discovery. Ruthe-
nium complexes can bear six coordinating ligands, allowing for hexacoordinate
and octahedral geometry, in contrast to the square planar geometry typically
adopted by platinum anticancer drugs. Two of the most prominent ruthenium
anticancer drugs are NAMI-A and KP1019 (Figure 1.6). NAMI-A acts as a
pro-drug, taking advantage of ruthenium’s capability to be reduced by the
acidic environment in cancer cells where the drug is activated.37 NAMI-A acts
as an antimetastatic drug, rather than being directly cytotoxic. The MoA of
NAMI-A is currently thought to involve cell cycle disruption.38 NAMI-A also
possesses antiangiogenic activity,39 as well as selectively inhibiting metastasis,
particularly of lung cancers.40 This is thought to be due to its ability to bind
collagen.41 NAMI-A is the first ruthenium anticancer drug to reach human
clinical trials, however studies in patients with non-small cell lung cancer re-
vealed that NAMI-A administered in combination with the clinically-used drug
gemcitabine is less active after first line treatment than gemcitabine alone.42
KP1019
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ClCl
Cl Cl
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N
H
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-
Figure 1.6: Two ruthenium anticancer complexes that have reached human
clinical trials NAMI-A and KP1019 exhibiting octahedral geometry.
KP1019 exerts cytotoxicity by inducing apoptosis through disruption of the
cellular electron transport chain and depolarisation of the mitochondrial
membrane. Additionally, it down-regulates the anti-apoptotic factor bcl-2
whilst activating the apoptotic protein caspase-3, independent of p53 status.43
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KP1019 has shown potent cytotoxicity against transplanted chemoresistant
mouse colon carcinomas. KP1019 induced complete tumour responses in the
majority of tumours, whereas 5-fluorouracil produced only partial responses
against half the tumours and CDDP produced no responses.44,45 KP1019 is the
second ruthenium anticancer drug to reach human clinical trials. In a phase
I clinical trial on six patients with progressive solid tumours, intravenous ad-
ministration of KP1019 lead to disease stabilisation in five patients with no
dose-limiting toxicity.46
RAPTA complexes (Figure 1.7) are characterised by their 1,3,5-triaza-7-
phosphatricyclo-[3.3.1.1]decane (PTA) ligand, which confers high water solu-
bility.47 RAPTA complexes, unlike classical antitumour agents, show only low
levels of DNA binding. Instead, they interact strongly, and selectively, with
proteins, such as the histone core in chromatin, leading to cytoxicity.48 RAPTA
complexes have been demonstrated to interfere with enzymes essential to tu-
mour targeting and drug deactivation to overcome drug resistance. RAPTA
complexes, unfortunately, tend to exhibit low in vivo cytotoxicities, however
they do exert a strong antiangiogenic and antimetastatic e↵ect in vivo.49,50
The antiangiogenic and antimetastatic e↵ects of RAPTA-C are thought to
be due to its localisation being primarily on the cell membrane, rather than
entering the cell.51 One of the great strengths of RAPTA complexes is their
extremely low toxicity, allowing them to be combined with other antitumour
agents without additional toxic side-e↵ects.52
RAPTA-C
RuCl
Cl P N
N
N
RuCl
H2N NH2
[(η6-p-cymene)Ru(II)(en)Cl]PF6
Figure 1.7: Two ruthenium anticancer complexes RAPTA-C and [(⌘6-p-
cymene)Ru(en)Cl]PF6 exhibiting piano stool geometry.
Another promising ruthenium-based class of potential anticancer therapeu-
tics are ruthenium arene ethylenediamine (RAED) compounds. Like many
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platinum-based agents, they form adducts selectively with guanine at N7.53,54
This site selectivity has been shown to be directed by hydrogen bonding of the
NH2 groups on the diamine ligand to exocyclic oxygens. RAED complexes ex-
hibit cytotoxicity at a similar level to carboplatin55 and are able to overcome
cross-resistance with CDDP in ovarian carcinoma models, as well as being
active in vivo.56
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1.2.3 Osmium
The precious heavy metal osmium is often associated with its extremely toxic
complex, osmium tetroxide. However, complexes of osmium can also be po-
tent anticancer agents without being overly toxic to healthy cells.57 Osmium
analogues of the ruthenium anticancer complexes NAMI-A and KP1019 have
been synthesised (Figure 1.8) and both show anticancer activity,58 however
they exhibit di↵erent biological properties to their ruthenium analogues. The
osmium analogue of NAMI-A, unlike NAMI-A itself, is inert to hydrolysis, a
step thought to be necessary for anticancer activity. It is, however, also more
potent than NAMI-A, suggesting that a hydrolysis-independent mechanism
contributes to its cytotoxicity.59
Osmium(IV) analogues of KP1019 have been synthesised with comparable
anticancer activity to KP1019 itself,60 however in the most similar analogue
the indazole ligands are coordinated to osmium at the N1 atom, in contrast
to the N2 atom in KP1019.61
KP1019  Os Analogue
Os
NAMI-A Os Analogue
ClCl
Cl Cl
S
N
HN
O
-
Os ClCl
Cl Cl
NH
HN
N
N
N
H
H
N
H
N
NH
-
Figure 1.8: Osmium analogues of the two ruthenium anticancer complexes
NAMI-A and KP1019 showing anticancer activity.
The osmium analogue of RAPTA-C has been synthesised (Figure 1.9) and
shown to have comparable activity to its ruthenium analogue.62 Unlike ruthe-
nium RAPTA complexes, osmium RAPTA analogues preferentially bind DNA,
however some of these are more toxic to healthy cells than cancers.63
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Figure 1.9: Osmium analogue of RAPTA-C and FY026, a potent in vivo
organoosmium complex.
Osmium-arene complexes have also shown potential as anticancer agents, ex-
hibiting cytotoxicity at the nanomolar level in multiple cell lines including
drug-resistant cancers. They have also been shown to delay cancer growth
in an in vivo colon xenograft in a mouse model with no observable toxic
side-e↵ects.64 Osmium arene complexes bearing azopyridine or iminopyridine
ligands can generate reactive oxygen species (ROS) in cells and can be poten-
tiated by co-administration with L-buthionine sulphoximine (L-BSO), which
reduces the level of the cellular antioxidant glutathione (GSH). Such complexes
have also been reported to induce S-phase cell cycle arrest.65 This suggests a
MoA for osmium arene complexes distinct from classical anticancer agents, in-
volving disruption of the redox balance of cancer cells.66–68 Osmium arene com-
plexes have been modified to interact with DNA. The incorporation of N,N- or
N,O-chelating ligands on osmium-biphenyl systems results in complexes that
hydrolyse and bind both adenine and guanine nucleobases, whereas complexes
with N,S-chelating ligands can bind histone proteins.69 This demonstrates that
the MoA of organoosmium complexes can be finely tuned by modification of
its chelating bidentate ligand.70–72
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1.2.4 Iridium
In contrast to osmium, the iridium analogue of NAMI-A, and the imidazolium
bisimidazole tetrachloro iridate(III) (IRIM) complex, which is the closest irid-
ium analogue to KP1019, are both biologically inactive (Figure 1.10),73,74 as
is the iridium analogue of RAPTA-C.75 Their lack of cytotoxicity is thought
to be due to its kinetic inertness conferred by the iridium centre relative to
ruthenium. Iridium complexes do, however, hold great potential as anticancer
agents when they break from the conventional drug designs.
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Figure 1.10: Biologically inactive iridium analogues of the ruthenium anti-
cancer complexes NAMI-A and RAPTA-C, and the IRIM complex, which has
significant structural similarity to KP1019.
Whilst iridium(I) complexes have been shown to exhibit anticancer activ-
ity,76,77 iridium(III) complexes have shown impressive cytotoxicity in various
cancer cell lines, with N,N-chelated polypyridyl complexes exhibiting micro-
molar potencies.78 A wide variety of iridium(III) anticancer complexes have
been developed in recent years, including Cp* complexes with N,N-, N,O-
and O,O-chelating ligands exhibiting micromolar activity.79 Further research
into unconventional iridium(III) complexes has produced complexes with N,N-
chelated pyrazole-based ligands with emissive theranostic properties and com-
parable activity to CDDP,80 DNA-binding lipophilic steroidal conjugates with
ca. 6⇥ the activity of CDDP,81 and cytotoxic, DNA-binding dinuclear iridium
complexes.82
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Variation of the Cp system, bidentate, and monodentate ligands of iridium(III)
complexes has also produced complexes with nanomolar potency (Figure 1.11).
Iridium(III) bipyridyl complexes with monodentate hydrosulphide adducts
readily oxidise GSH and exhibit nanomolar potency against A2780 ovarian car-
cinoma.83 The C,N-chelated complex ZL105 with pyridine as the monodentate
ligand displays extremely potent activity, attributed to the slow hydrolysis of
the Ir-py bond relative to the rapid hydrolysis of its Ir-Cl analogue, preventing
deactivation.84 Studies on both of these complexes indicate a ROS-based MoA.
Iridium(III) complex have also shown activity as biocatalysts. Iridium(III)
complexes bearing chlorine as a monodentate ligand have been shown to in-
terfere with the nicotinamide adenine dinucleotide (NAD+/NADH) hydride
transfer reactions in cells as a novel MoA by catalysing oxidation or reduction
transfer hydrogenation reactions.85,86
[(η5 -Cpxbiph)Ir(bpy)(SH)]PF6
Ir N
PF6
ZL105
N
Ir SH
PF6
N
N
Figure 1.11: Two Cpxbiph iridium(III) half-sandwich complexes with nanomolar
potency, bearing unconventional monodentate ligands. Both generate ROS in
cancer cells.
Research into new precious metal-based complexes has lead to the discovery
of many promising anticancer compounds, yet there is still much more to be
explored. Cancer is an extremely heterogeneous disease, and many cancers are
still very di cult to treat and can become resistant to current therapeutics.
Iridium(III) complexes represent a rich and still relatively untapped area to
be explored for the purpose of anticancer drug discovery.
In this work, novel iridium(III) complexes are designed, synthesised, and inves-
tigated in order to meet the growing need for e↵ective anticancer therapeutics.
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1.3 Aims
1. To synthesise, characterise, and purify a library of highly potent and
selective organoiridium(III) anticancer complexes bearing a variety of cy-
clopentadienyl ligands, bidentate azopyridine ligands, and monodentate
halido ligands.
2. To assess the anticancer activity of these complexes against various cancer
cell lines, thereby identifying structure-activity relationships which can inform
future drug synthesis.
3. To investigate the MoAs of these complexes, in particular their catalytic
oxidant activity on NADH, interactions with DNA, the cell cycle, mitochon-
dria, and their ability to generate ROS and SO.
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Chapter 2
Experimental Methods
2.1 Instrumentation
2.1.1 Nuclear Magnetic Resonance Spectroscopy
(NMR)
NMR data (1H, 13C and 2D experiments) were acquired in 5 mm NMR tubes
and carried out in the University of Warwick Department of Chemistry NMR
Spectroscopy Facility on either a Bruker Avance 300 MHz, Bruker Avance
III HD 300 MHz, Bruker Avance III 400 MHz, Bruker Avance III HD 400
MHz, Bruker Avance III HD 500 MHz, Bruker Avance 500 MHz or a Bruker
Avance III 600 MHz instrument. Experiments were carried out at 298 K un-
less otherwise stated. 1H-NMR chemical shifts were internally referenced to
residual hydrogens: CHD2CN (1.94 ppm) for acetonitrile-d3, C3HD5O (2.05
ppm) for acetone-d6, (CHD2)(CD3)SO (2.50 ppm) for DMSO-d6, CHD2OD
(3.49 ppm) for methanol-d4, C4HH7O2 (3.75 ppm) for 1,4-dioxane or CHCl3
(7.26 ppm) for chloroform-d3. 13C-NMR chemical shifts were internally refer-
enced to C3HD5O (29.84 ppm) for acetone-d6. Spectra were processed using
Bruker Topspin 3.2.
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2.1.2 Microwave Reactor
Some synthesis was performed using microwave-assisted chemistry to expand
the temperature and pressure range at which reactions could take place beyond
the limits of standard laboratory conditions. A CEM Discovery-SP microwave
reactor was used at conditions specified in the appropriate section.
2.1.3 Elemental Analysis
Elemental analysis of the percentage of carbon, hydrogen and nitrogen in sam-
ples was carried out on a CE-440 Exeter Elemental Analyzer by the Warwick
Analytical Service.
2.1.4 UV-Vis Absorption Spectroscopy
Absorption spectroscopy data were collected using a Varian Cary 300 UV-Vis
spectrometer using 1 cm path-length cuvettes. Experiments were carried out
at 298 K unless otherwise stated. The spectrometer was fitted with a PTP1
Peltier temperature controller to maintain or change the desired temperature
of the cuvette.
2.1.5 pH Measurements
All pH measurements were taken using a micro combination electrode filled
with a 3 M solution of KNO3 attached to a Mi 150 Bench Meter. The elec-
trode was calibrated using pH calibration solutions of pH 4.00, 7.01, and 10.01
purchased from HANNA Instruments. When not in use the electrode was left
to soak in a 3 M solution of KNO3.
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2.1.6 Linear Dichroism (LD)
Spectra were recorded using a Jasco J-815 spectropolarimeter adapted for
LD spectroscopy. Measurements were performed using a quartz capillary LD
Couette flow cell built by Crystal Precision Optics spinning at 3000 RPM.87,88
2.1.7 Circular Dichroism (CD)
Measurements were taken using a Jasco J-1500 Circular Dichroism Spectrom-
eter fitted with a PTC-517 Peltier Thermostatted Single Cell Holder, using 1
cm path-length quartz cuvettes (Starna UK).
2.1.8 Electrospray Ionisation Mass Spectrometry (ESI-
MS)
Data were recorded in the University of Warwick Department of Chemistry
Mass Spectrometry Facility on a Agilent 6130B single Quad using electrospray
ionization on solutions of samples dissolved in 0.5 mL MeOH. The mass spec-
trometer was operated in electrospray positive ion mode. Scanning range used
was either 50 – 500 m/z or 400 – 1000 m/z as appropriate for the sample.
2.1.9 Liquid Chromatography Mass Spectrometry (LC-
MS)
LC-MS experiments were carried out in the University of Warwick Department
of Chemistry Mass Spectrometry Facility on an amazon X Agilent system
coupled to a Bruker HCT-Ultra ETD II PTR PTM mass spectrometer. The
mass spectrometer was operated in electrospray positive ion mode with a scan
range of 50 – 2,000 m/z. Data were processed using Data Analytics 3.3 (Bruker
Daltonics).
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2.1.10 Inductively Coupled Plasma Optical Emission
Spectroscopy (ICP-OES)
Inductively coupled Plasma Optical Emission Spectroscopy (ICP-OES) exper-
iments were carried out on a PerkinElmer 5300 DV ICP-OES set to detect
193Ir at 224.268 nm. Calibrations carried out using iridium Specupure plasma
standards (Alfa Aesar, 1000 pm in 10% HCl) prepared at 0, 50, 100, 200, 300,
400, 500, 600 and 700 ppm in 3.6% nitric acid in double distilled 18.2 MilliQ
water purified using a using a Millipore Milli-Q water purification system and
a USF Elga UHQ water deionizer. Standards were spiked with NaCl so that
the final concentration matched that of the of the samples being analyzed
where appropriate.
2.1.11 Flow Cytometry
Flow cytometry experiments were carried out by Dr. Isolda Romero-Canelo´n
on a Becton-Dickinson FACScan flow cytometer. Data processed using Flowjo
software. Specific experimental conditions are described in the appropriate
section.
2.1.12 X-ray Crystallography (XRC)
X-ray di↵raction data were collected and processed by Dr. Guy Clarkson (De-
partment of Chemistry, University of Warwick). An Oxford Di↵raction Gemini
four circle system with a Ruby CCD area detector using Mo K↵ radiation was
used to obtain di↵raction data. The crystals were mounted in oil and held at
either 100 or 150 K with an Oxford Cryosystem Cobra. Data and generation
of structural images carried out in Mercury 3.3.
Single crystals of were grown from 1 mg of dissolved complex in MeOH and di-
ethyl ether or DCM and hexane unless stated otherwise in a vial-in-vial system
to facilitate vapour di↵usion. A suitable crystal was selected and mounted on
glass fibre with Fromblin oil and placed on an Xcalibur Gemini di↵ractometer
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with a Ruby CCD area detector. The crystal was kept at 150 K during data
collection. Using Olex2,89 the structure was solved with the ShelXT90 struc-
ture solution program using Direct Methods and refined with the ShelXL91
refinement package using Least Squares minimisation.
2.2 Materials
Solvents
All solvents used were HPLC-grade and were purchased from commercial
sources (Sigma Aldrich, Fischer Scientific).
Trifluoroacetic acid (TFA, 99.99%, spectrophotometric grade) and 1,4-dioxane
were purchased from Sigma Aldrich.
Triethylamine (TEA, HPLC-grade) was purchased from Fischer Scientific.
Materials for Ligand Synthesis
Nitrosobenzene, ammonium hexafluorophosphate, 2-aminopyridine, 4-
nitroaniline, 2-(5-Bromo-2-pyridylazo)-5-(diethylamino)phenol, 97%, 2-
hydrazinopyridine and p-benzoquinone were purchased from Sigma Aldrich.
4-(2-pyridylazo)-N,N-dimethylaniline and 3-hydroxypyridine purchased from
Alfa Aesar.
Sodium nitrite was purchased from Scientific Laboratory Supplies Ltd.
Aqueous tetramethylammonium hydroxide (extra pure 25% in water), 60%
Perchloric acid and formic acid were purchased from Fischer Scientific.
4-(2’-Pyridylazo)resorcinol, 97% was purchased from Acros Organics.
Materials for Iridium Dimer Synthesis
IrCl3•3H2O was purchased from Precious Metals Online (PMO pty Ltd,
Australia). Supplier confirms 50-56% Ir.
1,2,3,4,5-Pentamethylcyclopentadiene (95%), 2,3,4,5-tetramethyl-2-
cyclopentenone (95%), 4-bromobiphenyl (98%), n-butyllithium (1.6 M
in hexanes) and phenyllithium (1.6 M in dibutyl ether) were purchased from
Sigma-Aldrich (UK).
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Materials for Cell Biology
Petri-dish 10 ml (Greiner Bio One)
25 cm2 CELLSTAR culture flasks (Greiner Bio One)
75 cm2 CELLSTAR culture flasks (Greiner Bio One)
2 ml serological pipettes (Greiner Bio One)
5 ml serological pipettes (Greiner Bio One)
10 ml serological pipettes (Greiner Bio One)
25 ml serological pipettes (Greiner Bio One)
7 ml Bijoux tubes (Greiner Bio One)
Pipette controller/pipette aid (INTEGRA)
Trypsin-EDTA, 0.25% (Thermo Fisher Scientific, GibcoTM)
Dulbeccos Modified Eagle Medium (DMEM) (Thermo Fisher Scientific,
GibcoTM)
L-glutamine (Thermo Fisher Scientific, GibcoTM)
Cell Lines Used
A2780 human ovarian carcinoma (European Collection of Authenticated Cell
Cultures (ECACC))
A2780cis human ovarian carcinoma with acquired CDDP resistance (ECACC)
A549 human Caucasian lung carcinoma (ECACC)
MRC-5 normal human fetal lung fibroblasts (ECACC)
EBV-positive and -negative OE19 human Caucasian oesophageal carcinomas,
CNE1, CNE2, and SUNE-1 human nasopharyngeal carcinomas provided by
Dr. Chris Dawson, University of Birmingham.
Miscellaneous Materials
Deoxyribonucleic acid sodium salt from calf thymus, Type I, fibers (ctDNA)
purchased from Sigma Aldrich.
Geneticin (G418 Sulphate) was purchased from Fischer Scientific.
Quantofix peroxides test sticks were purchased from Sigma Aldrich.
Any further materials are specified in the appropriate section.
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2.2.1 Synthesis of the Starting Materials
Br
O
Figure 2.1: Synthesis of 3-biphenyl-1,2,4,5-tetramethyl-1,3-cyclopentadiene
(CpxbiphH)
Based on previously reported methods,92 a solution of 4-bromobiphenyl (18.65
g, 80 mmol) in dry THF (300 mL) was treated dropwise with n-butyl lithium
(50 mL, 80 mmol, 1.6 M in hexanes) and stirred at 195 K for 4 h. 2,3,4,5-
tetramethyl-2-cyclopentenone (14.31 mL, 96 mmol) was added and the reac-
tion was allowed to warm to ambient temperature whilst stirring over 18 h.
The resulting yellow solution was acidified with HCl (36%). The aqueous so-
lution was extracted with diethyl ether (2 x 50 mL), dried over anhydrous
MgSO4, filtered, allowed to air dry, the volume reduced under vacuum and the
resulting oily substance stored at 277 K for 18 h. The product was washed
once with cold hexane and filtered to leave a yellow/orange powder. A second
crop was obtained from the filtrate by crystallisation at 277 K. Yield: 15 g (69
%) 1H-NMR (400 MHz, CDCl3)  H = 7.67-7.62 (4H, m), 7.48-7.45 (2H, m),
7.37-7.35 (3H, m), 3.30-3.25 (1H, m), 2.12 (3H, s), 1.98 (3H, s), 1.92 (3H, s),
1.04 (2H, d, J = 7.5 Hz).
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O
Product A Product B Product C
Figure 2.2: Synthesis of 3-phenyl-1,2,4,5-tetramethyl-cyclopentadiene
(CpxphH)
Based on previously reported methods,93 a solution of 2,3,4,5-tetramethyl-
2-cyclopentenone (12 mL, 80 mmol) was treated dropwise with a solution
of phenyllithium (50 mL, 90 mmol, 1.8 M in dibutyl ether) under nitrogen.
The solution was kept at 273 K using ice water and NaCl. The reaction
was allowed to warm to ambient temperature whilst stirring over 18 h. The
resulting yellow solution was cooled by direct addition of ice and acidified
with HCl (36%). The aqueous solution was extracted with diethyl ether (3
x 50 mL) and washed once with brine then the combined organic portions
dried over anhydrous MgSO4, filtered and the solvents evaporated to dryness
under vacuum. The product was purified by distillation. Yield: 12.2 g (77 %)
1H-NMR (400 MHz, CDCl3)  H = 7.60-7.58 (0.17 H, m), 7.45-7.41 (0.17 H,
m), 7.38-7.33 (1.5 H, m), 7.27-7.23 (1.6H, m), 7.20-7.14 (1.1 H, m), 6.93-6.91
(0.36 H, m), 3.22-3.17 (0.48 H, m), 2.72-2.66 (0.19 H, m), 2.00 (1.5 H, s), 1.93
(1.4 H, s), 1.89 (0.6 H, s), 1.86 (2.1 H, s), 1.83 (1.17 H, s), 1.73 (0.6 H, s),
1.67 (1.2 H, s), 1.13 (0.7 H, d, J = 7.5 Hz), 0.95 (1.7 H, d, J = 7.5 Hz).
Three products are formed, hence the fractional integrals. The ratio of the
products is not 1:1:1 but for the purposes intended this mixture of products
is suitable for use in further synthesis as any of them will form the same
aromatic tetramethylcyclopentane ring when coordinated to an iridium centre
in the ways described in section 2.2.2.
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2.2.2 Synthesis of Iridium Dimers
IrCl3•3H2O
Figure 2.3: Synthesis of [(Cpxbiph)IrCl2]2
Based on previously reported methods,94 IrCl3•3H2O (0.8 g, 2.27 mmol) and
3-biphenyl-1,2,4,5-tetramethyl-1,3-cyclopentadiene (1.5 g, 5.46 mmol) were
placed in a microwave vial and dissolved in MeOH (10 mL), degassed with
N2 and the solution sonicated at ambient temperature for 5 min. The vial
was put in a microwave reactor (438 K, 150 W, 250 psi, 5 min). The reaction
was then allowed to reach ambient temperature and n-pentane (10 mL) was
added and the mixture stirred for 5 min. The contents of the vial were then
decanted onto a funnel with a frit filter under suction. The orange/red solid
collected on the filter was then placed in a beaker and stirred in diethyl ether
for 5 min before filtering again. This was repeated 3 times to yield a bright
red residue. (947 mg, 32 %) 1H-NMR (400 MHz d6-DMSO)  H = 7.76-7.66
(12H, m), 7.52-7.46 (4H, m), 7.43-7.37 (2H, m), 1.74 (12H, s), 1.71 (12H, s)
IrCl3•3H2O
Figure 2.4: Synthesis of [(Cpxph)IrCl2]2
Based on previously reported methods,92 IrCl3•3H2O (1.0 g, 2.84 mmol)
was placed in a microwave vial and dissolved in MeOH (10 mL), degassed
with N2 and the solution sonicated at ambient temperature for 5 min.
3-phenyl-1,2,4,5-tetramethyl-1,3-cyclopentadiene (1.3 g, 6.70 mmol) was
added and the vial put in a microwave reactor (438 K, 150 W, 250 psi, 5 min).
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The reaction was then allowed to reach ambient temperature and n-pentane
(10 mL) was added and the mixture stirred for 5 min. The contents of
the vial were then decanted onto a funnel with a frit filter under suction.
The orange/red solid collected on the filter was then placed in a beaker
and stirred in ether for 5 min before filtering again. This was repeated 3
times to yield a bright red residue. (688 mg, 22 %) 1H-NMR (400 MHz d6-
DMSO)  H = 7.62-7.56 (4H, m), 7.43-7.38 (6H, m), 1.72 (12H, s), 1.66 (12H, s)
IrCl3•3H2O
Figure 2.5: Synthesis of [(Cp*)IrCl2]2
Based on previously reported methods,95 IrCl3•3H2O (1.0 g, 2.84 mmol)
was placed in a microwave vial and dissolved in MeOH (10 mL), degassed
with N2 and the solution sonicated at ambient temperature for 5 min.
1,2,3,4,5-Pentamethylcyclopentadiene (2.8 g, 3.2 mL, 20.4 mmol) was added
and the vial put in a microwave reactor (438 K, 150 W, 250 psi, 5 min).
The reaction was then allowed to reach ambient temperature and n-pentane
(10 mL) was added and the mixture stirred for 5 min. The contents of the
vial were then decanted onto a funnel with a frit filter under suction. The
orange/red solid collected on the filter was then placed in a beaker and stirred
in ether for 5 min before filtering again. This was repeated 3 times to yield
a bright red residue. (1.0 g, 69 %) 1H-NMR (400 MHz d6-DMSO)  H = 1.63
(30H, s)
Figure 2.6: Synthesis of [(Cp*)IrI2]2
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A solution of [(Cp*)IrCl2]2 (200 mg, 0.25 mmol) in 20% MeOH:H2O was
heated to 353 K and the temperature maintained for 1 h. KI (4.16 g, 25.10
mmol) was added and the solution changed to a deep, cloudy orange. This
was kept overnight at 277 K. This was reduced to dryness under vacuum,
redissolved in DCM and filtered. The filtrate was recrystallized overnight at
277 K in DCM:diethyl ether, filtered and washed once with diethyl ether to
leave a dark red-orange ppt. (173 mg, 59 %) 1H-NMR (300 MHz, CDCl3)  H
= 1.83 (30H, s)
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2.2.3 Synthesis of Azopyridine Ligands
Where purchase of the desired ligand was either not possible or not financially
viable, ligands were instead synthesised from commercially available start-
ing materials as described (Figures 2.7 – 2.9) based on previous literature
reports.96
Figure 2.7: Synthesis of 4-(pyridin-2-yldiazenyl)phenol (azpyOH)
Benzoquinone (1.479 g, 13.6 mmol) was dissolved in water (100 mL) and
perchloric acid (9 mL). 2-hydrazinopyridine (1.493 g, 13.6 mmol) in water (20
mL) was added dropwise and the solution stirred at ambient temperature for
1 h. The solution turned reddish brown. The solution was filtered and washed
quickly with cold water (1 x 10 mL) to leave an orange crystalline ppt. This
was dissolved in MeOH (50 mL) and formic acid (5 mL) and ammonia gas
was bubbled through the mixture for 1 h. The mixture was left for 72 h and
red crystals formed. These were filtered out and dried under vacuum. Yield:
1.106 g (41 %) 1H-NMR (400 MHz 80% CD3CN:20% D2O)  H = 8.63 (1H, d,
J = 6.0 Hz), 8.35 (1H, d, J = 6.0 Hz), 7.92 (2H, d, J = 8.0 Hz), 7.75 (1H, m),
7.49 (1H, m), 7.00 (2H, d, J = 8.0 Hz)
Figure 2.8: Synthesis of 2-(phenyldiazenyl)pyridine (azpy)
2-Aminopyridine (200 mg, 2.13 mmol) and aqueous tetramethylammonium
hydroxide solution (2.5 mL) was put in a microwave vial and dissolved in
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pyridine (2.5 mL). To this was added nitrosobenzene (300 mg, 2.80 mmol) in
pyridine (5.0 mL) and the vial put in a microwave reactor (438 K, 150 W,
250 psi, 5 min). The solution was allowed to cool to 298 K and extracted
with toluene (3 x 5 mL). The toluene fraction was washed with brine, dried
with MgSO4 and as much solvent as possible was removed under vacuum.
The crude product was purified by column chromatography using silica and
a 2:1 mixture of cyclohexane/ethyl acetate as eluent (Rf of product = 0.68).
The product was clearly visible as a deep red band on the column. The pure
compound was dried under vacuum and stored at 277 K. Yield: 216.7 mg (62
%) 1H-NMR (400 MHz d6-DMSO)  H = 8.73 (1H, d, J = 6.0 Hz), 8.01 (1H,
t, J = 8.0 Hz), 7.96 (2H, m), 7.74 (1H, d, J = 8.0), 7.65 (3H, m), 7.60 (1H, d,
J = 6.0 Hz)
Figure 2.9: Synthesis of 6-((4-nitrophenyl)diazenyl)pyridin-3-ol (HOazpyNO2)
Sodium nitrite (6.8 g, 100 mmol) and 4-nitroaniline (13.8 g, 100 mmol) were
added to sterile distilled water (200 mL) and kept at 273 – 274 K in an NaCl
and ice-filled dewer. The resulting slurry was stirred vigorously and 35% HCl
(39.5 mL) was added slowly. This resulting slurry was added to a solution
of 3-hydroxypyridine (9.5 g, 100 mmol) and potassium hydroxide tablets (5.6
g, 100 mmol) dissolved in sterile distilled water (150 mL) and cooled to 273
– 274 K. This yielded a bright orange solution. 2 M potassium hydroxide
solution was added until to solution became basic and dark red. The dark
red reaction mixture was stirred at 273 – 274 K for 1 h. Acetic acid (25 mL)
was added slowly as the reaction was allowed to room temperature and the
resulting orange solution filtered under suction to complete dryness. The solid
orange precipitate was taken up in ethanol and treated with active carbon.
The resulting mixture was left to cool overnight at 277 K. The mixture was
then filtered, the volume of the filtrate was reduced under vacuum until the
onset of precipitation. The solution was then cooled at 277 K until the product
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precipitated out as a dark orange solid. Yield: 2.5 g (10 %) 1H-NMR (400
MHz d6-DMSO)  H = 8.42 (2H, d, J = 9.0 Hz), 8.27 (1H, d, J = 3.0 Hz), 8.06
(2H, d, J = 9.0 Hz), 8.84 (1H, ds, J = 9.0 Hz), 7.38 (1H, dd, J = 9.0, 3.0 Hz)
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2.2.4 Synthesis of Ir(III) Half-Sandwich Complexes
Figure 2.10: General synthesis scheme for Ir(III) complexes in this work
All the complexes in this work can be synthesised with high yields and purity
by stirring the appropriate dimer and ligand in commercially available anhy-
drous organic solvent following the scheme shown (Figure 2.10). The exact
conditions required to synthesise each complex are detailed in the correspond-
ing chapter in which they are first introduced.
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2.3 Methods
Unless specified otherwise data were processed using R,97 Origin 9.198 or Mi-
crosoft Excel.
2.3.1 Aquation Studies
Aquation studies were carried out by 600 MHz 1H-NMR of solutions of com-
plexes over 24 h in 10% d6-DMSO:D2O, 0.1% 1,4-dioxane at 310 K. All so-
lutions were pre-warmed to 310 K and spectra were taken approximately 10
min after addition to D2O. Experiments were carried out in parallel under the
same conditions with 120 mM NaCl to simulate the chloride concentration in
the cell medium used for in vitro cancer cell studies. The concentration of
complex used is described in the corresponding section.
2.3.2 LC-MS
Complexes were dissolved in acetonitrile. All LC-MS experiments (purity de-
termination/relative hydrophobicity and nucleotide binding) were carried out
in HPLC-grade H2O with varying percentages of acetonitrile at the gradient
shown in Figure 2.11. 0.1% TFA was added to both mobile phases. LC was
carried out on an Agilent 1200 equipped with a variable wavelength detector
and 100 µL loop using a 250 x 4.6 mm Agilent Zorbax Eclipse Plus C18 column
in reverse phase with a 5 µm pore size.
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Figure 2.11: Solvent gradient used for LC-MS experiments in this work.
2.3.3 Cancer Cell Studies
Of the cell lines used in this work, A2780 human ovarian carcinoma, A2780cis
human ovarian carcinoma with acquired CDDP resistance, A549 human Cau-
casian lung carcinoma, and MRC-5 normal human fetal lung fibroblasts were
obtained from the ECACC. EBV-positive and -negative OE19 human Cau-
casian oesophageal carcinomas, CNE1, CNE2, and SUNE-1 human nasopha-
ryngeal carcinomas provided by Dr. Chris Dawson, University of Birmingham.
2.3.3.1 Cell Maintenance
Cells grown in Roswell Park Memorial Institute medium (RPMI-1640) or Dul-
becco‘s Modified Eagle Medium (DMEM). Media were supplemented with 10%
foetal calf serum (FCS), 1% of 2 mM L-glutamine (20 µM) and 1% of 2 mM
penicillin/streptomycin (20 µM). All cell incubation was at 310 K in 5% CO2
humidified atmosphere. Cells were grown as adherent monolayers in either 25
cm2, 75 cm2, 175 cm2 culture flasks and split when approximately 90% conflu-
ence was reached by incubation with 0.25% trypsin/EDTA (0.1 mM trypsin,
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0.9 mM EDTA). EBV infected cell lines were subcultured in medium and sup-
plemented with 400 mg/ml Geneticin (G418 Sulphate) 12-24 h after plating.
2.3.3.2 Antiproliferative Activity
To carry out antiproliferative assays, cells were grown to approximately 90%
confluence before use. Medium was removed by suction and cells washed
twice with phosphate-bu↵ered saline (PBS). Cells were then incubated with
trypsin/EDTA for 5 min to create a cell suspension and medium was then
added to quench the activity of the trypsin to avoid damage to cells. A sin-
gle cell suspension was obtained by thorough mixing by pipette and the cell
concentration measured by haemocytometer. This suspension was diluted so
that 150 µL of cell solution per well resulted in cells seeded in 96-well plates
at 5,000 cells per well. Cells were incubated for 48 h then a solution of the
complex to be tested was prepared at 100 µM in 5% DMSO, 95% medium.
Five further dilutions were prepared at various concentrations from this solu-
tion and cells incubated with each concentration for 24 h. CDDP was used
as a positive control and prepared in the same way. Medium was used a the
negative control. Each concentration of complex was tested on 3 wells of two
plates, to check for intra-plate variation. Next, the complex solutions were
removed from the plate by aspiration and the plates incubated with 200 µL of
fresh medium for 72 h.
To measure cell survival percentages, the sulforhodamine B (SRB) assay was
used. The SRB assay is widely employed to investigate drug cytotoxicity
against cells in vitro.99 The SRB dye binds to the basic amino acid residues of
proteins and is an accurate measure of cell mass, and, by extrapolation, cell
survival.100 Cells were fixed with 50 µL of trifluoroacetic acid (TFA) at 277 K
for 1 h. The TFA was then removed by gentle washing with cold tap water and
the plates dried in air. Cells were stained with 50 µL of 0.4% SRB dye in 1%
acetic acid for 30 min at ambient temperature. The plates were then gently
washed with 1% acetic acid to remove excess dye and the plates dried again.
To solubilise the bound dye, 200 µL of 10 mM of pH 10.5 Tris base solution
was added to each well and the plates left for 1 hr whilst being gently tilted.
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Absorbance at 490 nm was measured for each well using a plate reader and
cell survival percentages calculated by comparison with the negative controls.
IC50 values were calculated by plotting the cell survival percentage against the
control and fitting a boltzmann sigmoidal curve to determine the midpoint.
In cases where a sigmoidal curve could not be well-fitted to the data points,
either the experiment was repeated with complex at di↵erent concentrations,
the IC50 determined to lie within a concentration range, or the data presented
in a non-IC50 format.
Antiproliferative screenings against A2780, OE19 and SUNE-1 cell lines carried
out by Dr. Isolda Romero-Canelo´n, Ji-Inn Song and Bindy Heer.
2.3.4 Flow Cytometry Experiments
Cells were seeded on 6-well plates at 1 million cells per well in complex-free
medium and incubated for 24 h at 310 K. The cells were then exposed to
an equipotent (at IC50 concentration) solution of complex for 24 h after which
the supernantant was removed and the cells washed with PBS. Cells were then
harvested using trypsin/EDTA and further treatment and staining carried out
as appropriate to the experiment. Finally, cell pellets were resuspended and
washed with PBS before analysis in a flow cytometer.
2.3.4.1 ROS and Superoxide Generation
After harvesting, cells were stained using a bu↵ered solution of green/orange
fluorescent reagents according to the instructions in the ROS/Superoxide de-
tection kit (Enzo Life Sciences). FL1 channel on the flow cytometer used to
measure total ROS. FL2 channel used to measure superoxide.
2.3.4.2 Mitochondrial Membrane Depolarisation
After harvesting, cells were stained using the JC10 mitochondrial mem-
brane potential assay kit according to the manufacturer’s instructions. FL2
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channel on the flow cytometer used to measure reduction in JC10 fluores-
cence. For positive controls cells were exposed to 1 µM carbonyl cyanide
3-chlorophenylhydrazone (CCCP) for 15 min. These experiments were carried
out at Sun Yat-sen University Cancer Center, Guangzhou, China.
2.3.4.3 Cell Cycle Analysis
After harvesting, cells were fixed using cold 70% EtOH. Propidium iodide
(PI)/RNase solution was used to stain cell DNA before flow cytometry. FL2
channel on the flow cytometer used to measure PI fluorescence.
2.3.4.4 Induction of Apoptosis
After harvesting, cells were stained using a bu↵ered solution of annexin V/PI
according to the instructions in the annexin V-FITC apoptosis detection kit
(Sigma-Aldrich). FL1 channel on the flow cytometer used to measure annexin
V fluorescence. FL2 channel used to measure PI fluorescence.
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Chapter 3
Anticancer Structure-Activity
Relationships
3.1 Introduction
Resistance to current anticancer therapeutics is a major clinical problem, as
are the side-e↵ects associated with many current treatments. By generating
novel chemotherapeutics we aim to widen the spectrum of treatable cancers,
overcome drug-resistance and reduce side-e↵ects, with the ultimate aim of
improving patient prognoses and quality of life.
Precious metal-based complexes have been a cornerstone of anticancer drug
development since the discovery of cisplatin (CDDP). Since then, other pre-
cious metals have been utilised in an e↵ort to explore more chemical space and
expand the range of available therapeutics to combat cancer. Complexes of
Pt, Ru, Rh, Os and Ir have all been reported to have anticancer properties,
however of these metals, Ir is the least explored in publications.101
Previous investigations into the properties of organoiridium anticancer drugs
have shown promise and potent complexes with a variety of mechanisms of ac-
tion (MoAs) have been generated. Despite this, an organoiridium anticancer
drug has yet to reach the clinics. An organoiridium azopyridine complex
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[CpxphIr(azpyNMe2)Cl]PF6 (Complex 2) has shown impressive cytotoxicity
against a panel of 60 cancer cell lines and has been associated with targeting
mitochondrial metabolism and increasing redox stress in cancer cells.102 Its
MoA is not yet fully understood, so in this chapter further research into its
MoA is carried out towards understanding how this complex kills cancer cells.
In this chapter an extensive and diverse library of a further 18 organoirid-
ium(III) azopyridine complexes are synthesised based on complex 2.
This library is comprised of families of complexes bearing 6 di↵erent bidentate
azopyridine ligands di↵ering only in the functional groups on the azopyridine
phenyl and pyridine rings. Within most of these families, Cpxbiph, Cpxph and
Cp* analogues are synthesised and investigated to test the e↵ect of the Cp
system within, and between, families. Additionally, analogues of selected com-
plexes are synthesised bearing di↵erent monodentate halido ligands or coun-
terions to assess the e↵ect of these structural features on their chemical and
biological properties.
The complexes synthesised were designed in this way so that structure-activity
relationships can be drawn between their functional groups and their anti-
cancer activity. By doing so, this research can guide future organoiridium
drug development towards generating complexes with greater anticancer po-
tency.
MoA studies are carried out on a subset of these complexes to assess their
solution chemistry, capacity to oxidise NADH, induce apoptosis, generate ROS
and depolarise the mitochondrial membrane. Finally, a thorough statistical
analysis is carried out on data from a large-scale pharmaco-genomic screen
of complex 2 against ca. 900 cell lines to further elucidate the MoAs of this
family of complexes.
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3.2 Experimental Methods
3.2.1 Synthesis and Characterization of Complexes
Complex X Y Z A R1 R2
1 Biph NMe2 Cl PF6 H H
2 Ph NMe2 Cl PF6 H H
3 Me NMe2 Cl PF6 H H
4 Me NMe2 I PF6 H H
5 Biph OH Cl PF6 H H
6 Ph OH Cl PF6 H H
7 Me OH Cl PF6 H H
8 Me OH Cl Cl H H
9 Me OH I PF6 H H
10 Me OH I I H H
11 Biph OH Cl PF6 H OH
12 Me OH Cl PF6 H OH
13 Biph H Cl PF6 OH H
14 Ph H Cl PF6 OH H
15 Me H Cl PF6 OH H
16 Biph NO2 Cl PF6 H H
17 Ph NO2 Cl PF6 H H
18 Me NO2 Cl PF6 H H
19 Biph NEt2 Cl PF6 Br OH
Figure 3.1: Overview of all complexes studied in this work. Lines separate
complexes of di↵erent families by azopyridine ligand.
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Complex 1 – [CpxbiphIr(azpyNMe2)Cl]PF6
N
N
N
Ir
Cl
PF6
N
[(Cpxbiph)IrCl2]2 (123 mg, 0.115 mmol, 1 mol. equiv.) and 4-(2-pyridylazo)-
N,N-dimethylaniline (azpyNMe2) (51 mg, 0.230 mmol, 2 mol. equiv.) were
dissolved in DCM (20 mL) and stirred overnight at ambient temperature.
The solvent was completely removed under vacuum in a rotary evaporator
and the compound redissolved in the minimum amount of MeOH. NH4PF6
(187 mg, 1.147 mmol, 5 mol. equiv.) was added and the solution stirred
then stored overnight at 277 K. The resulting mixture was filtered through a
frit and washed once quickly with cold MeOH (10 mL), the remaining solid
material collected and redissolved in DCM then filtered once more. Diethyl
ether was added to the filtrate until the onset of precipitation and the mixture
left to crystallise overnight at 277 K. Recrystallisation of 1 mg in the minimum
amount of MeOH/acetone and slow addition of diethyl ether by vapours using
a small vial with pierced lid in large vial of diethyl ether system over many
weeks yielded an x-ray quality crystal. This complex is novel.
Yield: 180 mg (90%)
1H-NMR (400 MHz, CD3CN):  H = 8.50 (1H, d, J = 5.5 Hz), 8.40 (1H,
d, J = 8.2 Hz), 8.17 (1H, t, J = 7.9 Hz), 8.07 (2H, d, J = 9.4 Hz), 7.74 – 7.71
(4H, m), 7.58 (1H, t, J = 6.7 Hz), 7.55 – 7.51 (2H, m), 7.47 – 7.43 (3H, m)
6.77 (2H, d, J = 9.5 Hz) 3.25 (6H, s), 1.73 – 1.70 (9H, m), 1.55 (3H, s).
13C-NMR-APT (125 MHz, acetone-d6):  C = 166.76 (s, C), 156.08 (s,
C), 149.82 (s, C), 143.74 (s, CH/CH3), 142.40 (s, C), 141.45 (s, C), 139.71
(C), 130.71 (s, CH/CH3), 130.53 (s, CH/CH3), 130.48 (s, CH/CH3), 129.75
(s, CH/CH3), 129.11 (s, CH/CH3), 129.06 (s, CH/CH3), 128.05 (s, C), 127.96
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(s, CH/CH3), 127.57 (s, CH/CH3), 127.50 (s, CH/CH3), 126.87 (s, CH/CH3),
126.80 (s, CH/CH3), 126.43 (s, CH/CH3), 123.80 (s, CH/CH3), 112.44 (s,
CH/CH3), 101.83 (s, C), 99.53 (s, C), 91.52 (s, C), 90.23 (s, C), 85.66 (s, C),
39.82 (s, CH/CH3), 9.17 (s, CH3), 9.08 (s, CH3), 8.50 (s, CH3), 7.96 (s, CH3).
ESI-MS (MeOH): m/z = 727.2 [M – PF6]+
Elemental Analysis: Calc‘d for 1•MeOH: C: 46.48, H: 4.35, N: 6.20. Found:
C: 46.14, H: 3.92, N: 6.38.
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Complex 2 – [CpxphIr(azpyNMe2)Cl]PF6
N
N
N
Ir
Cl
PF6
N
Synthesised as above using [(Cpxph)IrCl2]2 (141 mg, 0.154 mmol, 1 mol. equiv.)
and 4-(2-pyridylazo)-N,N-dimethylaniline (azpyNMe2) (69 mg, 0.306 mmol, 2
mol. equiv.). This complex has been previously reported.102
Yield: 172 mg (71%)
1H-NMR (400 MHz, CD3CN):  H = 8.46 (1H, d, J = 5.6 Hz), 8.40 (1H,
d, J = 8.2 Hz), 8.16 (1H, t, J = 7.8 Hz), 8.07 (2H, d, J = 9.4 Hz), 7.56 (1H,
t, J = 6.7 Hz), 7.52 – 7.43 (3H, m), 7.32 (2H, d, J = 7.2 Hz) 6.80 (2H, d, J =
9.5 Hz) 3.29 (6H, s), 1.72 (3H, s), 1.70 (3H, s), 1.68 (3H, s), 1.45 (3H, s)
13C-NMR-APT (125 MHz, acetone-d6):  C = 166.73 (s, C), 156.11 (s, C),
149.78 (s, CH/CH3), 143.74 (s, C), 142.39 (s, CH/CH3), 129.87 (s, CH/CH3),
129.74 (s, CH/CH3), 129.21 (s, CH/CH3), 129.08 (s, CH/CH3), 126.40 (s,
CH/CH3), 123.79 (s, CH/CH3), 112.47 (s, CH/CH3), 102.32 (s, C), 99.86 (s,
C), 91.32 (s, C), 89.97 (s, C), 85.55 (s, C), 39.85 (s, CH/CH3), 9.07 (s, CH3),
8.99 (s, CH3), 8.50 (s, CH3), 7.94 (s, CH3).
ESI-MS (MeOH): m/z = 651.1 [M – PF6]+
Elemental Analysis: Calc’d: C: 41.97, H: 4.53, N: 6.99 Found: C: 41.87, H:
3.81, N: 7.05.
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Complex 3 – [Cp⇤Ir(azpyNMe2)Cl]PF6
N
N
N
Ir
Cl
PF6
N
Synthesised as above using [(Cp*)IrCl2]2 (135 mg, 0.170 mmol). Recrystalli-
sation of 1 mg in the minimum amount of DCM and slow addition of pentane
by vapours using a small vial with pierced lid in large vial of n-pentane sys-
tem over many weeks yielded an x-ray quality crystal. This complex has been
previously synthesised.94
Yield: 198 mg (79%)
1H-NMR (400 MHz, CD3CN):  H = 8.50 (1H, d, J = 5.5 Hz), 8.40 (1H,
d, J = 8.2 Hz), 8.17 (1H, t, J = 7.9 Hz), 8.07 (2H, d, J = 9.4 Hz), 7.69 (1H, t,
J = 6.6 Hz) 6.93 (2H, d, J = 9.4) 3.32 (6H, s), 1.73 – 1.70 (9H, m), 1.58 (15H,
s)
13C-NMR-APT (125 MHz, acetone-d6):  C = 166.56 (s, C), 156.00 (s, C),
150.12 (s, CH/CH3), 143.76 (s, C), 142.19 (s, CH/CH3), 129.51 (s, CH/CH3),
126.49 (s, CH/CH3), 123.64 (s, CH/CH3), 112.35 (s, CH/CH3), 92.58 (s, C),
39.83 (s, CH/CH3), 7.95 (s, CH3).
ESI-MS (MeOH): m/z = 589.1 [M – PF6]+
Elemental Analysis: Calc’d for 3•H2O: C: 36.73, H: 4.15, N: 7.45 Found:
C: 36.70 , H: 3.85, N: 7.39.
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Complex 4 – [Cp⇤Ir(azpyNMe2)I]PF6
N
N
N
Ir
I
PF6
N
[
[
[(Cp*)IrI2]2 (70 mg, 0.06 mmol, 1 mol. equiv.) and 4-(2-pyridylazo)-N,N-
dimethylaniline (azpyNMe2) (27 mg, 0.12 mmol, 2 mol. equiv.) were dissolved
in DCM (20 mL) and stirred overnight at ambient temperature. The solvent
was completely removed under vacuum in a rotary evaporator and the com-
pound redissolved in the minimum amount of MeOH. NH4PF6 (49 mg, 0.30
mmol, 5 mol. equiv.) was added and the solution stirred then stored overnight
at 277 K. The resulting mixture was then filtered through a frit and washed
with diethyl ether (3 x 10 mL) and the remaining solid material collected
and redissolved in DCM then filtered once more. Diethyl ether was added to
the filtrate until the onset of precipitation and the mixture left to crystallise
overnight at 277 K. This complex is novel.
Yield: 80 mg (81%)
1H-NMR (500 MHz, CD3CN):  H = 8.70 (1H, d, J = 5.5 Hz), 8.43 (1H,
d, J = 8.0 Hz), 8.14 (1H, t, J = 7.5 Hz), 8.09 (2H, d, J = 9.5 Hz), 7.60 (1H,
t, J = 7.0 Hz), 6.88 (2H, d, J = 9.0 Hz), 3.31 (6H, s), 1.71 (15H, s).
13C-NMR-APT (125 MHz, CD3CN):  C = 166.85 (s, C), 156.47 (s, C),
151.35 (s, CH3), 144.76 (s, C), 142.18 (s, CH3), 130.48 (s, CH3), 126.01 (s,
CH3), 124.14 (s, CH3), 112.62 (s, CH3), 94.18 (s, C), 40.34 (s, CH3), 9.25 (s,
CH3).
ESI-MS (MeOH): m/z = 681.1 [M – PF6]+
Elemental Analysis: Calc’d for 4•2H2O: C: 32.06, H: 3.86, N: 6.50. Found:
C: 32.14, H: 3.33, N: 6.31.
47
Complex 5 – [CpxbiphIr(azpyOH)Cl]PF6
N
N
N
Ir
Cl
PF6
OH
[(Cpxbiph)IrCl2]2 (73 mg, 0.07 mmol, 1 mol. equiv.) and 4-(pyridin-2-
yldiazenyl)phenol (azpyOH) (27 mg, 0.14 mmol, 2 mol. equiv.) were dissolved
in DCM (20 mL) and stirred overnight at ambient temperature. The solvent
was completely removed under vacuum in a rotary evaporator and the com-
pound redissolved in the minimum amount of MeOH. NH4PF6 (48 mg, 0.29
mmol, 5 mol. equiv.) was added and the solution stirred then stored overnight
at 277 K. The mixture was then filtered through a frit and washed once quickly
with cold ether and the remaining solid material collected and redissolved in
acetone then filtered once more the same way. The solution was dried under
vacuum and the solid material redissolved in MeOH. Diethyl ether was added
to the filtrate until the onset of precipitation and the mixture left to crystallise
at 277 K. Recrystallisation of 1 mg in the minimum amount of MeOH/acetone
and slow addition of diethyl ether by vapours using a small vial with pierced lid
in large vial of diethyl ether system over many weeks yielded an x-ray quality
crystal. This complex is novel.
Yield: 74 mg (64%)
1H-NMR (400 MHz, CD3CN):  H = 8.66 (1H, d, J = 8.2 Hz), 8.50 (1H,
d, J = 5.2 Hz), 8.27 (1H, t, J = 7.8 Hz), 7.97 (2H, d, J = 8.6 Hz), 7.77 – 7.70
(5H, m), 7.55 – 7.52 (2H, m), 7.50 – 7.44 (3H, m), 7.18 (2H, d, J = 8.6 Hz),
1.77 (3H, s), 1.65 (6H, m), 1.50 (3H, s).
13C-NMR-APT (125 MHz, CD3CN):  C = 166.49 (s, C), 165.44 (s, C),
150.40 (s, CH/CH3), 147.30 (s, C), 143.42 (s, CH/CH3), 142.16 (s, C), 140.27
(s, C), 131.04 (s, CH/CH3), 129.71 (s, CH/CH3), 128.65 (s, CH/CH3), 128.55
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(s, CH/CH3), 128.25 (s, CH/CH3), 127.96 (s, C), 127.57 (s, CH/CH3), 127.48
(s, CH/CH3), 117.17 (s, CH/CH3), 104.77 (s, C), 100.45 (s, C), 94.41 (s, C),
91.15 (s, C), 86.73 (s, C), 9.85 (s, CH3), 9.53 (s, CH3), 9.02 (s, CH3), 8.59 (s,
CH3).
ESI-MS (MeOH): m/z = 700.1 [M – PF6]+
Elemental Analysis: Calc’d for 5•2H2O: C: 43.61, H: 3.89, N: 4.77. Found:
C: 44.00, H: 3.67, N: 4.85.
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Complex 6 – [CpxphIr(azpyOH)Cl]PF6
N
N
N
Ir
Cl
PF6
OH
Synthesised as above using [(Cpxph)IrCl2]2 (36.9 mg, 0.040 mmol, 1 mol.
equiv.) and 4-(pyridin-2-yldiazenyl)phenol (16.0 mg, 0.080 mmol, 2 mol.
equiv.). This complex is novel.
Yield: 39.4 mg (63%)
1H-NMR (400 MHz, CDCl3):  H = 8.50 (1H, d, J = 7.9 Hz), 8.26 (1H,
d, J = 5.5 Hz), 8.15 (1H, t, J = 7.8 Hz), 7.92 (2H, d, J = 8.6 Hz), 7.56 – 7.46
(4H, m), 7.32 (2H, d J = 7.3 Hz), 7.22 (2H, d, J = 8.4 Hz), 1.79 (3H, s), 1.67
(3H, s), 1.61 (3H, s), 1.43 (3H, s)
13C-NMR-APT (125 MHz, CD3CN):  C = 166.36 (s, C), 164.60 (s, C),
150.47 (s, CH/CH3), 147.43 (s, C), 143.50 (s, CH/CH3), 130.45 (s, CH/CH3),
130.08 (s, CH/CH3), 129.88 (s, CH/CH3), 128.83 (s, C), 128.35 (s, CH/CH3),
127.99 (s, CH/CH3), 116.86 (s, CH/CH3), 104.79 (s, C), 100.74 (s, C), 94.24
(s, C), 91.46 (s, C), 87.35 (s, C), 9.74 (s, CH3), 9.43 (s, CH3), 9.00 (s, CH3),
8.57 (s, CH/CH3).
ESI-MS (MeOH): m/z = 624.0 [M – PF6]+
Elemental Analysis: Calc’d for 6•H2O: C: 46.08, H: 4.17, N: 6.20. Found:
C: 45.59, H: 3.91, N: 6.38.
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Complex 7 – [Cp⇤Ir(azpyOH)Cl]PF6
N
N
N
Ir
Cl
PF6
OH
Synthesised as above using [(Cp*)IrCl2]2 (56 mg, 0.70 mmol, 1 mol. equiv.).
Recrystallisation of 1 mg in the minimum amount of MeOH and slow addition
of diethyl ether by vapours using a small vial with pierced lid in large vial of
diethyl ether system over 5 weeks at ambient temperature yielded an x-ray
quality crystal. This complex is novel.
Yield: 73 mg (73%)
1H-NMR (400 MHz, CD3CN):  H = 8.77 (1H, d, J = 5.5 Hz), 8.66 (1H,
d, J = 8.0 Hz), 8.31 (1H, t, J = 7.7 Hz), 7.95 (2H, d, J = 8.8 Hz), 7.87 (1H,
t, J = 6.7 Hz), 7.28 (2H, d, J = 8.9 Hz), 1.57 (15H, s).
13C-NMR-APT (125 MHz, CD3CN):  C = 166.27 (s, C), 164.25 (s, C),
150.67 (s, CH/CH3), 147.63 (s, C), 143.35 (s, CH/CH3), 129.98 (s, CH/CH3),
128.17 (s, CH/CH3), 127.68 (s, CH/CH3), 116.80 (s, CH/CH3), 94.63 (s, C),
8.54 (s, CH3).
ESI-MS (MeOH): m/z = 562.1 [M – PF6]+
Elemental Analysis: Calc’d: C: 35.67, H: 3.42, N: 5.94. Found: C: 35.67,
H: 3.34, N: 5.90.
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Complex 8 – [Cp⇤Ir(azpyOH)Cl]Cl
N
N
N
Ir
Cl
Cl
OH
[(⌘5-Cp*)IrI2]2 (150 mg, 0.188 mmol, 1 mol. equiv.) and 4-(pyridin-2-
yldiazenyl)phenol (azpyOH) (75.0 mg, 0.376 mmol, 2 mol. equiv.) were dis-
solved in DCM (50 mL) and stirred overnight at 323 K. The solvent was
completely removed under vacuum in a rotary evaporator and the compound
redissolved in the minimum amount of MeOH. Diethyl ether was added to the
filtrate until the onset of precipitation and the mixture left to crystallise at
277 K. The mixture was then filtered through a frit and washed once quickly
with cold ether and the remaining solid material collected and redissolved in
MeOH then filtered once more the same way. Diethyl ether was added to the
filtrate until the onset of precipitation and the mixture left to recrystallise at
277 K. This complex is novel.
Yield: 170 mg (61%)
1H-NMR (400 MHz d6-DMSO):  H = 8.75 (1H, d, J = 5.5 Hz), 8.63 (1H,
d, J = 8.0 Hz), 8.29 (1H, t, J = 7.5 Hz), 7.96 (2H, d, J = 8.0 Hz), 7.85 (1H,
t, J = 6.0 Hz), 7.20 (2H, d, J = 8.0 Hz), 1.57 (15H, s)
13C-NMR-APT (125 MHz, d6-DMSO):  C = 166.66 (s, C), 151.11 (s, C),
146.26 (s, CH/CH3), 143.32 (s, C), 129.59 (s, CH/CH3), 128.37 (s, CH/CH3),
126.85 (s, CH/CH3), 117.12 (s, CH/CH3), 93.86 (s, CH/CH3), 65.39 (s, C),
8.69 (s, CH3).
ESI-MS (MeOH): m/z = 562.1 [M – PF6 – Cl]+
Elemental Analysis: Calc’d for 8•H2O: C: 40.97, H: 4.26, N: 6.83. Found:
C: 40.91, H: 4.15, N: 6.59.
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Complex 9 – [Cp⇤Ir(azpyOH)I]PF6
N
N
N
Ir
I
PF6
OH
[(⌘5-Cp*)IrI2]2 (88.9 mg, 0.08 mmol, 1 mol. equiv.) and 4-(pyridin-2-
yldiazenyl)phenol (azpyOH) (30.5 mg, 0.16 mmol, 2 mol. equiv.) were dis-
solved in DCM (50 mL) and stirred overnight at 323 K. The solvent was
completely removed in a rotary evaporator and the compound redissolved in
MeOH (10 mL). 5 mL of this was taken and used to prepare [Cp⇤Ir(azpyOH)I]I
(Complex 10). NH4PF6 (62.3 mg, 0.38 mmol, 5 mol. equiv.) was added and
the solution stirred then stored overnight at 277 K. The mixture was then fil-
tered through a frit and washed once quickly with cold ether and the remaining
solid material redissolved in acetone then filtered once more the same way. The
solution was dried under vacuum and the solid material redissolved in MeOH.
Diethyl ether was added to the filtrate until the onset of precipitation and the
mixture left to crystallise at 277 K. This complex is novel.
Yield: 39 mg (78%)
1H-NMR (400 MHz d6-DMSO):  H = 8.84 (1H, d, J = 6.0 Hz), 8.77 (1H,
d, J = 8.0 Hz), 8.28 (1H, t, J = 8.0 Hz), 7.99 (2H, d, J = 8.0 Hz), 7.81 (1H,
t, J = 6.5 Hz), 7.08 (2H, d, J = 8.0 Hz), 1.70 (15H, s)
13C-NMR-APT (125 MHz, CD3CN):  C = 165.52 (s, C), 163.53 (s, C),
151.01 (s, CH/CH3), 147.54 (s, C), 142.03 (s, CH/CH3), 128.16 (s, CH/CH3),
128.04 (s, CH/CH3), 126.84 (s, CH/CH3), 115.81 (s, CH/CH3), 94.88 (s, C),
8.52 (s, CH3).
ESI-MS (MeOH): m/z = 654.1 [M – PF6]+
Elemental Analysis: Calc’d for 9•2MeOH: C: 32.03, H: 3.74, N: 4.87.
Found: C: 32.23, H: 2.95, N: 5.28.
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Complex 10 – [Cp⇤Ir(azpyOH)I]I
N
N
N
Ir
I
I
OH
A 5 mL aliquot was taken from the reaction to synthesise complex 9 at the
point described. Diethyl ether was added to this until the onset of precipitation
and the mixture left to crystallise at 277 K. The mixture was then filtered
through a frit and washed once quickly with cold ether and the remaining solid
material collected and redissolved in MeOH then filtered once more the same
way. Diethyl ether was added to the filtrate until the onset of precipitation
and the mixture left to recrystallise at 277 K. This complex is novel.
Yield: 41 mg (82%)
1H-NMR (400 MHz d6-DMSO):  H = 8.85 (1H, d, J = 6.0 Hz), 8.78 (1H,
d, J = 8.0 Hz), 8.29 (1H, t, J = 7.5 Hz), 7.99 (2H, d, J = 8.0 Hz), 7.81 (1H,
t, J = 6.5 Hz), 7.10 (2H, d, J = 8.0 Hz), 1.70 (15H, s)
13C-NMR-APT (125 MHz, CD3CN):  C = 165.50 (s, C), 163.41 (s, C),
151.01 (s, CH/CH3), 147.53 (s, C), 142.02 (s, CH/CH3), 128.12 (s, CH/CH3),
128.09 (s, CH/CH3), 126.89 (s, CH/CH3), 115.76 (s, CH/CH3), 94.89 (s, C),
8.52 (s, CH3).
ESI-MS (MeOH): m/z = 654.1 [M – PF6 – Cl]+
Elemental Analysis: Calc’d: C: 32.11, H: 3.72, N: 5.35. Found: C: 32.30,
H: 3.03, N: 5.27.
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Complex 11 – [CpxbiphIr(azpy(OH)2)Cl]PF6
N
N
N
Ir
Cl
PF6
OHHO
[(Cpxbiph)IrCl2]2 (75.0 mg, 0.070 mmol, 1 mol. equiv.) and 4-(pyridin-2-
yldiazenyl)benzene-1,3-diol (azpy(OH)2) (30.1 mg, 0.139 mmol, 2 mol. equiv.)
were dissolved in DCM (20 mL) and stirred for 4 h at ambient temperature.
The solvent was completely removed under vacuum in a rotary evaporator and
the compound redissolved in the minimum amount of MeOH. NH4PF6 (57 mg,
0.350 mmol, 5 mol. equiv.) was added and the solution stirred then stored
for 4 days at 277 K. The resulting mixture was then filtered through a frit
and washed once with diethyl ether (10 mL) and the remaining solid material
collected and redissolved in DCM then filtered once more. Diethyl ether was
added to the filtrate until the onset of precipitation and the mixture left to
crystallise at 277 K. This complex is novel.
Yield: 28 mg (23%)
1H-NMR (400 MHz d6-acetone):  H = 8.86-8.84 (2H, m), 8.45 (1H, t, J
= 8.0 Hz), 8.09 (1H, d, J = 9.0 Hz), 7.95-7.91 (1H, m), 7.81-7.74 (4H, m),
7.62-7.60 (2H, m), 7.54-7.51 (2H, m), 7.46-7.42 (1H, m), 6.58 (1H, d, J = 2.0
Hz), 6.53-6.50 (1H, dd, J = 9.0, 2.0 Hz), 1.86 (6H, d, J = 9.0 Hz), 1.79 (3H,
s), 1.69 (3H, s).
13C-NMR-APT (125 MHz, d6-acetone):  C = 169.22 (s, C), 165.25 (s,
C), 156.08 (s, C), 149.96 (s, CH/CH3), 142.54 (s, CH/CH3), 141.57 (s, C),
139.69 (s, C), 135.82 (s, C), 134.80 (s, CH/CH3), 130.56 (s, CH/CH3), 129.08
(s, CH/CH3), 128.00 (s, CH/CH3), 127.85 (s, C), 127.53 (s, CH/CH3), 126.83
(s, CH/CH3), 123.72 (s, CH/CH3), 112.70 (s, CH/CH3), 104.03 (s, CH/CH3),
102.64 (s, C), 99.87 (s, C), 92.61 (s, C), 90.28 (s, C), 85.70 (s, C), 40.43 (s,
CH/CH3), 9.23 (s, CH/CH3), 8.96 (s, CH/CH3), 8.33 (s, CH/CH3), 7.97 (s,
55
CH/CH3).
ESI-MS (MeOH): m/z = 680.2 [M – PF6 – Cl – H]+ (Most likely corre-
sponding to the complex with the ortho phenyl oxygen coordinated to the
iridium after loss of the chloride ligand.)
Elemental Analysis: Calc’d: C: 44.63, H: 3.51, N: 4.88. Found: C: 44.82,
H: 3.51, N: 4.72.
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Complex 12 – [Cp⇤Ir(azpy(OH)2)Cl]PF6
N
N
N
Ir
Cl
PF6
OHHO
Synthesised as above using [(Cp*)IrCl2]2 (55.1 mg, 0.069 mmol). This complex
is novel.
Yield: 90 mg (78%)
1H-NMR (400 MHz, d6-acetone):  H = 11.15 (1H, br), 9.03 (1H, d, J =
6.0), 8.77 (1H, d, J = 9.0 Hz), 8.43 (1H, t, J = 9.0 Hz), 8.06 (1H, d, J = 5.0
Hz), 7.98 (1H, t, J = 6.0), 6.80 (1H, d, J = 9.0), 6.56 (1H, s), 1.72 (15H, s)
13C-NMR-APT (125 MHz, d6-acetone):  C = 165.97 (s, C), 151.27 (s,
CH/CH3), 143.39 (s, CH/CH3), 134.95 (s, CH/CH3), 128.35 (s, CH/CH3),
124.95 (s, CH/CH3), 124.95 (s, CH/CH3), 104.83 (s, CH/CH3), 94.21 (s, C),
8.79 (s, CH3).
ESI-MS (MeOH): m/z = 600.1 [M – PF6 – H + Na]+
Elemental Analysis: Calc’d for 12•H2O: C: 34.04, H: 3.54, N: 5.67. Found:
C: 34.38, H: 3.27, N: 5.70.
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Complex 13 – [CpxbiphIr(azpy)Cl]PF6
N
N
N
Ir
Cl
PF6
[(Cpxbiph)IrCl2]2 (74.6 mg, 0.070 mmol) and 2-(phenyldiazenyl)pyridine (azpy)
(25.6 mg, 0.14 mmol, 2 mol. equiv.) were dissolved in DCM (20 mL) and
stirred for 4 hr at ambient temperature. The solvent was completely removed
under vacuum in a rotary evaporator and the compound redissolved in the
minimum amount of MeOH. NH4PF6 (63.6 mg, 0.390 mmol, 5 mol. equiv.)
was added and the solution stirred then stored overnight at 277 K. The mixture
was then filtered through a frit and washed once quickly with cold MeOH (10
mL), the remaining solid material collected and redissolved in acetone then
filtered once more the same way. Next, n-hexane was added to the filtrate
until the onset of precipitation and the mixture left to crystallise overnight at
277 K. Recrystallisation of 1 mg in the minimum amount of MeOH/acetone
and slow addition of diethyl ether by vapours using a small vial with pierced lid
in large vial of diethyl ether system over many weeks yielded an x-ray quality
crystal. This complex is novel.
Yield: 76 mg (76%)
1H-NMR (400 MHz, 80% CD3CN:20% D2O):  H = 8.90 (1H, d, J = 8.0
Hz), 8.60 (1H, d, J = 5.0 Hz), 8.40 (1H, t, J = 8.0 Hz), 7.91 (2H, d, J = 7.0),
7.75 – 7.68 (5H, m), 7.63 – 7.60 (2H, m), 7.53 – 7.49 (2H, m), 7.43 (2H, d, J
= 7.0 Hz), 1.71 (3H, s), 1.61 (3H, s), 1.54 (3H, s), 1.46 (3H, s).
13C-NMR (500 MHz, CD3CN):  C = 166.07 (s, C), 154.20 (s, C), 150.69
(s, CH/CH3), 143.88 (s, CH/CH3), 142.21 (s, C), 140.12 (s, C), 134.68 (s,
CH/CH3), 131.45 (s, CH/CH3), 131.03 (s, CH/CH3), 130.19 (s, CH/CH3),
129.73 (s, CH/CH3), 129.66 (s, CH/CH3), 128.71 (s, CH/CH3), 128.21 (s,
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CH/CH3), 127.55 (s, C), 127.44 (s, CH/CH3), 124.73 (s, CH/CH3), 105.64 (s,
C), 100.85 (s, C), 95.73 (s, C), 91.47 (s, C), 87.86 (s, C), 9.80 (s, CH3), 9.36
(s, CH3), 8.70 (s, CH3), 8.55 (s, CH3).
ESI-MS (MeOH): m/z = 680.2 [M – PF6 – Cl + MeO]+
Elemental Analysis: Calc’d: C: 46.07, H: 4.23, N: 5.04. Found: C: 46.24,
H: 3.54, N: 5.04.
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Complex 14 – [CpxphIr(azpy)Cl]PF6
N
N
N
Ir
Cl
PF6
Synthesised as above using. [(Cpxph)IrCl2]2 (71.5 mg, 0.078 mmol, 1 mol.
equiv.) and 2-(phenyldiazenyl)pyridine (28.4 mg, 0.156 mmol, 2 mol. equiv.)
Recrystallisation of 1 mg in the minimum amount of MeOH/acetone and slow
addition of diethyl ether by vapours using a small vial with pierced lid in large
vial of diethyl ether system over many weeks yielded an enantiomerically pure
x-ray quality crystal. This complex is novel.
Yield: 65 mg (65%)
1H-NMR (400 MHz 80% CD3CN:20% D2O):  H = 8.90 (1H, d, J = 8.0
Hz), 8.57 (1H, d, J = 5.0 Hz), 8.39 (1H, t, J = 8.0 Hz), 7.90-7.87 (3H, m),
7.72 – 7.69 (1H, m), 7.63 – 7.60 (2H, m), 7.53 – 7.44 (3H, m), 7.31 (2H, d, J
= 8.0 Hz), 1.67 (3H, s), 1.60 (3H, s), 1.53 (3H, s), 1.38 (3H, s)
13C-NMR (500 MHz, CD3CN):  C = 166.03 (s, C), 154.20 (s, C), 150.69
(s, CH/CH3), 143.86 (s, CH/CH3), 134.67 (s, CH/CH3), 131.43 (s, CH/CH3),
130.43 (s, CH/CH3), 130.19 (s, CH/CH3), 130.02 (s, CH/CH3), 129.89 (s,
CH/CH3), 129.66 (s, CH/CH3), 128.46 (s, C), 124.70 (s, CH/CH3), 105.58 (s,
C), 100.96 (s, C), 95.44 (s, C), 91.59 (s, C), 88.35 (s, C), 9.69 (s, CH3), 9.26
(s, CH3), 8.70 (s, CH3), 8.53 (s, CH3).
ESI-MS (MeOH): m/z = 608.0 [M – PF6]+
Elemental Analysis: Calc’d: C: 41.19, H: 4.12, N: 5.54. Found: C: 40.87,
H: 3.41, N: 5.46.
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Complex 15 – [Cp⇤Ir(azpy)Cl]PF6
N
N
N
Ir
Cl
PF6
Synthesised as above using [(Cp*)IrCl2]2 (69.6 mg, 0.87 mmol, 1 mol. equiv.).
This complex is novel.
Yield: 57 mg (57%)
1H-NMR (400 MHz 80% CD3CN:20% D2O):  H = 8.86 (1H, d, J = 7.0
Hz), 8.40 (1H, t, J = 7.5 Hz), 8.01 (1H, t, J = 7.0 Hz), 7.91 (2H, d, J = 7.5
Hz), 7.77 – 7.70 (5H, m), 1.51 (15H, s)
13C-NMR (500 MHz, CD3CN):  C = = 165.99 (s, C), 154.39 (s, C), 150.85
(s, CH/CH3), 143.66 (s, CH/CH3), 134.60 (s, CH/CH3), 131.24 (s, CH/CH3),
130.24 (s, CH/CH3), 129.19 (s, CH/CH3), 124.68 (s, CH/CH3), 95.32 (s, C),
8.42 (s, CH3).
ESI-MS (MeOH): m/z = 540.0 [M – PF6 – Cl + MeO]+
Elemental Analysis: Calc’d: C: 36.23, H: 4.20, N: 6.04. Found: C: 36.16,
H: 3.35, N: 6.02.
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Complex 16 – [CpxbiphIr(HOazpyNO2)Cl]PF6
N
N
N
Ir
Cl
PF6
HO
NO2
[(Cpxbiph)IrCl2]2 (60.3 mg, 0.056 mmol) and 6-((4-
nitrophenyl)diazenyl)pyridine-3-ol (HOazpyNO2) (27.4 mg, 0.112 mmol,
2 mol. equiv.) were dissolved in DCM (20 mL) and stirred for 4 hr at
ambient temperature. The solvent was completely removed under vacuum in
a rotary evaporator and the compound redissolved in the minimum amount
of MeOH. NH4PF6 (40.7 mg, 0.280 mmol, 5 mol. equiv.) was added and the
solution stirred then stored overnight at 277 K. The mixture was then filtered
through a frit and washed once quickly with cold MeOH (10 mL) and the
remaining solid material collected and redissolved in DCM then filtered once
more the same way. Next, n-hexane was added to the filtrate until the onset
of precipitation and the mixture left to crystallise at 277 K. This complex is
novel.
Yield: 64 mg (64%)
1H-NMR (400 MHz d6-acetone):  H = 8.28 (2H, d, J = 9.0 Hz), 7.97
(2H, d, J = 9.0 Hz), 7.78 (1H, d, J = 5.0 Hz), 7.76 – 7.72 (4H, m), 7.55 – 7.43
(6H, m), 7.39 (1H, d, J = 9.0 Hz), 1.73 (3H, s), 1.61 (3H, s), 1.56 (3H, s), 1.46
(3H, s).
13C-NMR-APT (125 MHz, CD3CN):  C =166.13 (s, C), 157.34 (s, C),
155.50 (s, C), 149.11 (s, C), 142.00 (s, C), 141.66 (s, CH/CH3), 140.32 (s,
C), 135.83 (s, CH/CH3), 133.56 (s, CH/CH3), 131.84 (s, CH/CH3), 131.10
(s, CH/CH3), 129.68 (s, CH/CH3), 128.59 (s, CH/CH3), 128.19 (s, CH/CH3),
127.47 (s, CH/CH3), 125.42 (s, CH/CH3), 103.96 (s, C), 98.76 (s, C), 93.72 (s,
C), 89.15 (s, C), 86.58 (s, C), 9.65 (s, CH3), 9.37 (s, CH3), 8.66 (s, CH3), 8.63
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(s, CH3).
ESI-MS (MeOH): m/z = 745.1 [M – PF6]+
Elemental Analysis: Calc’d for 16•3(CH3)2CO: C: 46.26, H: 4.45, N: 5.26.
Found: C: 46.52, H: 3.41, N: 6.17.
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Complex 17 – [CpxphIr(HOazpyNO2)Cl]PF6
N
N
N
Ir
Cl
PF6
HO
NO2
Synthesised as above using. [(Cpxph)IrCl2]2 (30.2 mg, 0.033 mmol, 1 mol.
equiv.) and 6-((4-nitrophenyl)diazenyl)pyridine-3-ol (HOazpyNO2) (16.0 mg,
0.066 mmol, 2 mol. equiv.). This complex is novel.
Yield: 35 mg (66%)
1H-NMR (500 MHz, CD3CN):  H = 8.28 (2H, d, J = 9.0 Hz), 7.95 (2H,
d, J = 9.0 Hz), 7.76 (1H, d, J = 5.0 Hz), 7.53 – 7.45 (4H, m), 7.41 (0.6H, d, J
= 1.0 Hz), 7.40 (0.4H, d, J = 1.0 Hz), 7.37 – 7.34 (2H, m), 1.69 (3H, s), 1.60
(3H, s), 1.55 (3H, s), 1.39 (3H, s)
13C-NMR-APT (125 MHz, d6-acetone):  C = 168.56 (s, C), 156.75 (s,
C), 153.52 (s, C), 148.11 (s, C), 144.51 (s, CH/CH3), 132.03 (s, CH/CH3),
130.15 (s, CH/CH3), 129.27 (s, CH/CH3), 129.19 (s, CH/CH3), 128.76 (s, C),
126.99 (s, CH/CH3), 124.83 (s, CH/CH3), 124.61 (s, CH/CH3), 103.40 (s, C),
98.12 (s, C), 92.41 (s, C), 88.39 (s, C), 86.04 (s, C), 8.92 (s, CH3), 8.71 (s,
CH3), 8.12 (s, CH3), 7.99 (s, CH3).
ESI-MS (MeOH): m/z = 669.1 [M – PF6]+
Elemental Analysis: Calc’d for 17•2(CH3)2CO: C: 41.31, H: 4.01, N: 6.02.
Found: C: 41.13, H: 3.08, N: 7.23.
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Complex 18 – [Cp⇤Ir(HOazpyNO2)Cl]PF6
N
N
N
Ir
Cl
PF6
HO
NO2
Synthesised as above using. [(Cp*)IrCl2]2 (25.2 mg, 0.033 mmol, 1 mol. equiv.)
and 6-((4-nitrophenyl)diazenyl)pyridine-3-ol (HOazpyNO2) (16.0 mg, 0.066
mmol, 2 mol. equiv.). This complex is novel.
Yield: 33 mg (66%)
1H-NMR (500 MHz, CD3CN):  H = 8.44 (2H, d, J = 9.0 Hz), 8.28 (1H,
dd, J = 5.0, 1.0 Hz), 8.04 (2H, d, J = 9.0 Hz), 7.84 (0.4, d, J = 5.0 Hz), 7.82
(0.6H, d, J = 5.0 Hz), 7.73 (0.6, d, J = 1.0 Hz), 7.71 (0.4H, d, J = 1.0 Hz),
1.54 (15H, s).
13C-NMR-APT (125 MHz, d6-acetone):  C = 168.38 (s, C), 157.01 (s,
C), 153.80 (s, C), 148.24 (s, C), 144.10 (s, CH/CH3), 131.79 (s, CH/CH3),
126.85 (s, CH/CH3), 124.86 (s, CH/CH3), 124.67 (s, CH/CH3), 92.50 (s, C),
7.80 (s, CH3).
ESI-MS (MeOH): m/z = 607.1 [M – PF6]+
Elemental Analysis: Calc’d for 18•(CH3)2CO: C: 35.58, H: 3.61, N: 6.92.
Found: C: 35.90, H: 3.16, N: 7.66.
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Complex 19 – [CpxbiphIr(Brazpy(OH)NEt2)Cl]PF6
N
N
N
Ir
Cl
PF6
Br
NHO
[(Cpxbiph)IrCl2]2 (63.2 mg, 0.059 mmol, 1 mol. equiv.) and 2-((5-bromopyridin-
2-yl)diazenyl)-5-(diethylamino)phenol (Brazpy(OH)NEt2) (41.1 mg, 0.118
mmol, 2 mol. equiv.) were dissolved in DCM (20 mL) and stirred at am-
bient temperature for 5 h. The solvent was completely removed under vacuum
in a rotary evaporator and the compound redissolved in the minimum amount
of MeOH. NH4PF6 (48 mg, 0.294 mmol, 5 mol. equiv.) was added and the
solution stirred then stored overnight at 277 K. The resulting mixture was
then filtered through a frit and washed once quickly with cold MeOH (10 mL)
then with diethyl ether (3 x 10 mL) and the remaining solid material collected
and redissolved in DCM then filtered once more. Diethyl ether was added to
the filtrate until the onset of precipitation and the mixture left to crystallise
overnight at 277 K. This complex is novel.
Yield: 87 mg (74%)
1H-NMR (500 MHz d6-acetone):  H = 13.32 (0.6H, br), 8.63 (1H, d, J =
2.0), 8.34 (0.4H, d, J = 2.0 Hz), 8.32 (0.6H, d, J = 2.0 Hz), 8.27 (0.6H, s), 8.25
(0.4H, s), 8.89 (1H, d, J = 10 Hz), 7.83-7.81 (2H, m), 7.77 (2H, m), 7.65-7.63
(2H, m), 7.55-7.52 (2H, m), 7.47-7.44 (1H, m), 6.52 (1H, dd, J = 10.0, 2.0 Hz),
6.31 (1H, d, J = 2.0 Hz), 2.84-2.81 (10H, m), 1.95 (3H, s), 1.87 (3H, s), 1.84
(3H, s), 1.83 (3H, s).
13C-NMR-APT (125 MHz, d6-acetone):  C = 164.09 (s, C/CH), 159.33
(s, C/CH2), 156.45 (s, C/CH2), 149.18 (s, CH/CH3), 144.27 (s, CH/CH3),
141.61 (s, C/CH2), 139.71 (s, C/CH2), 137.46 (s, CH/CH3), 135.48 (s, C/CH2),
130.61 (s, CH/CH3), 129.09 (s, CH/CH3), 128.04 (s, CH/CH3), 127.85 (s,
C/CH2), 127.53 (s, CH/CH3), 126.83 (s, CH/CH3), 119.64 (s, CH/CH3),
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116.46 (s, C/CH2), 111.69 (s, CH/CH3), 99.44 (s, C/CH2), 97.88 (s, CH/CH3),
97.18 (s, C/CH2), 91.81 (s, C/CH2), 89.96 (s, C/CH2), 86.62 (s, C/CH2), 46.06
(s, C/CH2), 12.62 (s, CH/CH3), 9.26 (s, CH/CH3), 9.25 (s, CH/CH3), 8.42 (s,
CH/CH3), 7.99 (s, CH/CH3).
ESI-MS (MeOH): m/z = 849.1 [M – PF6]+
Elemental Analysis: Calc’d: C: 43.23, H: 4.33, N: 5.60. Found: C: 43.61,
H: 3.71, N: 5.41.
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3.2.2 Chiral Separation Studies
All initial samples were dissolved in HPLC-grade EtOH at 1 mg/ml, sonicated
for 15 minutes at ambient temperature, and filtered through glass microfibre
filter paper and celite. Chiral separation studies were carried out on an Agilent
1200 series HPLC system equipped with a binary pump, a variable wavelength
detector, and fitted with a 100 µL loop. The column used was a CHIRALPAK
IC column (250 mm x 4.6 mm) in normal phase composed of cellulose-based
packing with tris(3,5-dichlorophenylcarbamate) immobilized on 5 µM silica-gel
from Chiral Technologies Europe with an isocratic gradient of heptane:ethanol
0.5% triethylamine (TEA), 0.3% trifluoroacetic acid (TFA) (v/v), flow-rate
1.00 mL/min, wavelength of detection 254 nm. Initial method development
for the separation of similar complexes on CHIRALPAK IC was carried out
previously103 based on protocols developed by Chiral Technologies Europe
(Figure 3.2).
Cl
Cl
HN
O
R =
Figure 3.2: Composition of the CHIRALPAK IC column used for sep-
aration of chiral enanatiomers: Cellulose-based packing with tris(3,5-
dichlorophenylcarbamate) immobilized on 5 µM silica-gel.
Injection size was initially 25 µL and was increased to 100 µL if it was possible
to do so without compromising separation in order to collect more sample per
run. Separated peaks were collected, combined and dried under vacuum at
ambient temperature then stored at 193 K for 20 h. The same procedure was
then run on the separated peak fractions to determine their stability.
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3.2.3 Genomics of Drug Sensitivity in Cancer (GDSC)
Pharmaco-genomic Screen
Cells were grown in medium supplemented with penicillin/streptomycin and
10% FBS to approximately 15% confluency then seeded in 384-well plates and
left to incubate for 24 h at 310 K, 5% CO2, 95% air and 100% humidity un-
til approximately 85% confluency was reached. For adherent cell lines, cells
were treated with nine concentrations of each compound in a 2-fold dilution
series over a 256-fold concentration range and incubated for 72 h. Cells then
fixed with 4% formaldehyde for 30 min then stained with 1 µM Syto60 for
1 h. Fluorescent signal intensity was measured using a plate reader at ex-
citation/emission wavelengths of 630/695 nm. For cell lines in suspension,
cells were treated with compound immediately after plating, then incubated
for 72 h. Cells stained with 55 µg/mL Resazurin in glutathione-free medium
for 4 h. Fluorescent signal intensity measured using a plate reader at excita-
tion/emission wavelengths of 535/595 nm. MANOVA analysis was performed
by the Sanger Bioinformatics Institute. Data were processed in R.97
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3.3 Results
3.3.1 Synthesis, Characterisation and Purity Determi-
nation
Nineteen organoiridium azopyridine complexes containing six di↵erent azopy-
ridine ligands were synthesised, characterised, and purified (Figure 3.3). Sev-
enteen of these are novel. X-ray crystal structures were obtained for eight
complexes, all of which exhibit the expected half-sandwich pseudooctahedral
structure with bond angles and lengths in the expected range. The complexes
di↵er in either their bidentate azopyridine ligand, their monodentate halido
ligand, their Cp system, or their counterion. In most cases each complex has
an analogue with only one di↵erence in functional group. This allows any
di↵erences in anticancer activity or MoA to be attributed to the presence or
absence of that group. In this way, meaningful conclusions can be drawn about
their activity from their structural di↵erences.
Seventeen complexes bear the PF6 counterion and these have poor aqueous sol-
ubility (<100 µM). Complex 8 instead bears a chloride counterion and complex
10 bears an iodide counterion. Both of these complexes have >100 µM solu-
bility in aqueous solution. Complex purity was determined by a combination
of 1H-NMR, 13C-NMR, CHN elemental analysis and LC-MS. For some com-
plexes, CHN elemental analysis shows some solvent present in the complex
sample. The presence of these solvents is supported by their corresponding
peaks in the NMR spectra. Peaks in LC-MS were shown to be either com-
plex, hydrolysed complex, products of complex breakdown in column, or peaks
present in the blank LC run, further demonstrating that molecules of solvent
are the only possible impurities. LC-MS data for complexes can be found in
Appendix Figures S2 – S19, pg. 273 – 290.
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Figure 3.3: Structures of complexes 1 – 19 studied in this work. A crys-
tal structure was obtained for complexes marked with an asterisk (*) Fam-
ilies of complexes grouped by bidentate azopyridine ligand. The azpyNMe2
family consists of complexes 1 – 4, the azpyOH family of complexes 5 –
10, the azpy(OH)2 family of complexes 11 and 12, the azpy family of com-
plexes 13 – 15, the HOazpyNO2 family of complexes 16 – 18, and the single
Brazpy(OH)NEt2 complex 19.
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3.3.2 X-ray Crystal Structures
For the complexes for which an x-ray crystal structure was determined, the
3D structures and data are presented here (Figures 3.4 – 3.11 and Tables 3.1
– 3.9).
Figure 3.4: Solid state structure of complex 1 with atom labelling and ther-
mal parameters at 50% probability level. Hydrogens placed at geometrically
calculated positions. The asymmetric unit contains the complex and there are
two in the unit cell. Disordered solvent and counter ion have been removed
for clarity.
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Table 3.1: Crystallographic and structure refinement data for complex 1
Complex 1 
 
Empirical formula 
 
C34H35ClF6IrN4P 
Formula weight 872.28 
Temperature (K) 150(2) 
Crystal system triclinic 
Space group P-1 
a (Å) 8.65951(14) 
b (Å) 12.50429(16) 
c (Å) 15.80665(15) 
α (°) 85.2790(9) 
β (°) 86.2334(10) 
γ (°) 78.4092(12) 
Volume (Å3) 1668.85(4) 
Z 2 
ρcalc (g/cm
3) 1.736 
µ (mm‑1) 4.193 
F(000) 860.0 
Crystal size (mm3) 0.24 × 0.18 × 0.08 brown block 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection (°) 4.808 to 62.08 
Index ranges -12 ≤ h ≤ 12, -17 ≤ k ≤ 18, -22 ≤ l ≤ 21 
Reflections collected 97326 
Independent reflections 10164 [Rint = 0.0669, Rsigma = 0.0338] 
Data/restraints/parameters 10164/0/430 
Goodness-of-fit on F2 1.021 	
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Figure 3.5: Solid state structure of complex 3 with atom labelling and thermal
ellipsoids drawn at 50% probability level. Hydrogens placed at geometrically
calculated positions. The asymmetric unit contains the complex with a PF6
counter ion. Four times all this in the unit cell. No disorder or unusual features
to report.
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Table 3.2: Crystallographic and structure refinement data for complex 3
Complex 3 
 
Empirical formula 
 
C23H29ClF6IrN4P 
Formula weight 734.12 
Temperature (K) 150(2) 
Crystal system monoclinic 
Space group P21/n 
a (Å) 8.2820(3) 
b (Å) 14.8766(6) 
c (Å) 21.0325(8) 
α (°) 90 
β (°) 96.921(4) 
γ (°) 90 
Volume (Å3) 2572.49(17) 
Z 4 
ρcalc (g/cm
3) 1.895 
µ (mm‑1) 5.420 
F(000) 1432.0 
Crystal size (mm3) 0.42 × 0.24 × 0.08 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection (°) 5.476 to 63.506 
Index ranges -12 ≤ h ≤ 11, -21 ≤ k ≤ 20, -30 ≤ l ≤ 29 
Reflections collected 38144 
Independent reflections 8161 [Rint = 0.0471, Rsigma = 0.0378] 
Data/restraints/parameters 8161/0/332 
Goodness-of-fit on F2 1.131 	
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Figure 3.6: Solid state structure of the complex 5 with atom labelling and
thermal parameters at 50% probability level. Hydrogens placed at geometri-
cally calculated positions. The asymmetric unit contains an Ir complex, two
PF6 counter ions at half occupancy, and a disordered molecule of methanol.
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Table 3.3: Crystallographic and structure refinement data for complex 5
Complex 5 
 
Empirical formula 
 
C33H30ClF6IrN3O2P 
Formula weight 873.22 
Temperature (K) 150(2) 
Crystal system monoclinic 
Space group P21/n 
a (Å) 19.5364(5) 
b (Å) 8.82093(19) 
c (Å) 23.1386(8) 
α (°) 90 
β (°) 114.633(4) 
γ (°) 90 
Volume (Å3) 3624.6(2) 
Z 4 
ρcalc (g/cm
3) 1.600 
µ (mm‑1) 3.865 
F(000) 1712.0 
Crystal size (mm3) 0.2 × 0.2 × 0.02 brown plate 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection (°) 5.156 to 64.85 
Index ranges -17 ≤ h ≤ 28, -13 ≤ k ≤ 12, -33 ≤ l ≤ 31 
Reflections collected 58453 
Independent reflections 12175 [Rint = 0.0551, Rsigma = 0.0501] 
Data/restraints/parameters 12175/7/473 
Goodness-of-fit on F2 1.042 
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Figure 3.7: Solid state structure of complex 6 with atom labelling and thermal
ellipsoids drawn at 50% probability level. Hydrogens placed at geometrically
calculated positions. The asymmetric unit contains an Ir complex formed from
a C-metallated phenyl azopyridine ligand and a phenyl tetra methyl Cp with
a chloride and a PF6 counter ion. Twice all this in the unit cell.
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Table 3.4: Crystallographic and structure refinement data for complex 6
Complex 6 
 
Empirical formula 
 
C26H26ClF6IrN3OP 
Formula weight 769.12 
Temperature (K) 150(2) 
Crystal system triclinic 
Space group P-1 
a (Å) 8.71914(18) 
b (Å) 9.9018(2) 
c (Å) 15.7288(3) 
α (°) 89.3248(16) 
β (°) 78.0376(16) 
γ (°) 88.7062(17) 
Volume (Å3) 1328.08(5) 
Z 2 
ρcalc (g/cm
3) 1.923 
µ (mm‑1) 5.256 
F(000) 748.0 
Crystal size (mm3) 0.35 × 0.16 × 0.06 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection (°) 5.294 to 75.372 
Index ranges -14 ≤ h ≤ 14, -16 ≤ k ≤ 16, -26 ≤ l ≤ 26 
Reflections collected 66113 
Independent reflections 13636 [Rint = 0.0501, Rsigma = 0.0370] 
Data/restraints/parameters 13636/0/357 
Goodness-of-fit on F2 1.059 	
80
Figure 3.8: Solid state structures of complex 8 with atom labelling and thermal
ellipsoids drawn at 50% probability level. Hydrogens placed at geometrically
calculated positions. The asymmetric unit contains the Ir complex and a
molecule of methanol and a chloride counter ion. The chloride counter ion sits
on an inversion centre (so is at half occupancy), four times all this in the unit
cell.
In the generation of the crystal structures of complex 8, the hydroxyl group
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hydrogens on the methanol and the phenol were not located but placed at
calculated positions. Problems arise as there is only half a chloride counter
ion per Ir complex and the phenol OH forms a hydrogen bond to a symmetry
related phenol so there is a clash of the phenolic OHs. This is because there
is only one proton shared between the two phenol oxygens. This has been ob-
served in organoosmium complexes bearing the same azpyOH ligand.104 This
means that there are two complexes with (2 x Ir(+3) balanced by two pen-
tamethylcyclopentadienyls, two metal bound chlorides and a single chloride
(Cl2) and two phenoxides sharing H12). In reality the hydrogen shuttles be-
tween the phenol oxygen O12 and the symmetry related O12 represented by
Figure 3.8 but this situation cannot be resolved by this X-ray experiment.
82
Table 3.5: Crystallographic and structure refinement data for complex 8
Complex 8 
 
Empirical formula 
 
C22H27.5Cl1.5IrN3O2 
Formula weight 611.34 
Temperature (K) 150(2) 
Crystal system monoclinic 
Space group P21/n 
a (Å) 8.93939(15) 
b (Å) 18.6768(3) 
c (Å) 13.4520(2) 
α (°) 90 
β (°) 94.0660(14) 
γ (°) 90 
Volume (Å3) 2240.28(6) 
Z 4 
ρcalc (g/cm
3) 1.813 
µ (mm‑1) 6.162 
F(000) 1196.0 
Crystal size (mm3) 0.5 × 0.35 × 0.28 (purple block) 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection (°) 5.062 to 65.382 
Index ranges -12 ≤ h ≤ 13, -28 ≤ k ≤ 28, -19 ≤ l ≤ 19 
Reflections collected 36123 
Independent reflections 7716 [Rint = 0.0360, Rsigma = 0.0316] 
Data/restraints/parameters 7716/0/276 
Goodness-of-fit on F2 1.297 	
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Figure 3.9: Solid state structure of complex 10 with atom labelling and ther-
mal parameters drawn at 50% probability level. Hydrogens placed at geomet-
rically calculated positions. The asymmetric unit contains the complex, an
iodide and a solvent methanol. Four times all this in the unit cell.
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Table 3.6: Crystallographic and structure refinement data for complex 10
Complex 10 
 
Empirical formula 
 
C22H28I2IrN3O2 
Formula weight 812.47 
Temperature (K) 150(2) 
Crystal system monoclinic 
Space group P21/n 
a (Å) 9.29339(12) 
b (Å) 13.27724(15) 
c (Å) 20.1881(3) 
α (°) 90 
β (°) 91.3644(12) 
γ (°) 90 
Volume (Å3) 2490.31(6) 
Z 4 
ρcalc (g/cm
3) 2.167 
µ (mm‑1) 7.863 
F(000) 1520.0 
Crystal size (mm3) 0.16 × 0.08 × 0.08 brown block 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection (°) 4.87 to 62.262 
Index ranges -13 ≤ h ≤ 13, -18 ≤ k ≤ 18, -28 ≤ l ≤ 28 
Reflections collected 64660 
Independent reflections 7479 [Rint = 0.0416, Rsigma = 0.0254] 
Data/restraints/parameters 7479/0/279 
Goodness-of-fit on F2 1.093 	
85
Figure 3.10: Solid state structure of complex 13 with atom labelling and
thermal ellipsoids drawn at 50% probability level. Hydrogens placed at ge-
ometrically calculated positions. The asymmetric unit contains the complex
and a PF6 counter ion, four times all this in the unit cell.
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Table 3.7: Crystallographic and structure refinement data for complex 13
Complex 13 
 
Empirical formula 
 
C32H30ClF6IrN3P 
Formula weight 829.21 
Temperature (K) 150(2) 
Crystal system monoclinic 
Space group P21/n 
a (Å) 9.13036(14) 
b (Å) 30.6604(4) 
c (Å) 11.18445(15) 
α (°) 90 
β (°) 94.2735(13) 
γ (°) 90 
Volume (Å3) 3122.27(8) 
Z 4 
ρcalc (g/cm
3) 1.764 
µ (mm‑1) 4.477 
F(000) 1624.0 
Crystal size (mm3) 0.4 × 0.3 × 0.3 brown block 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection (°) 5.204 to 64.802 
Index ranges -13 ≤ h ≤ 13, -46 ≤ k ≤ 45, -16 ≤ l ≤ 16 
Reflections collected 94866 
Independent reflections 10712 [Rint = 0.0444, Rsigma = 0.0260] 
Data/restraints/parameters 10712/0/401 
Goodness-of-fit on F2 1.141 	
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Figure 3.11: Solid state structure of complex 14 with atom labelling and
thermal ellipsoids drawn at 50% probability level. Hydrogens placed at ge-
ometrically calculated positions. The asymmetric unit contains the complex
and a PF6 counter ion, four times all this in the unit cell. The molecule has
crystallised in a chiral space group [(P2(1)2(1)2(1)] so is associated with a
Flack (and Hooft) parameter that give a confidence in the assignment of the
appropriate handedness of the crystal chosen.
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Table 3.8: Crystallographic and structure refinement data for complex 14
Complex 14 
 
Empirical formula 
 
C26H26ClF6IrN3P 
Formula weight 753.12 
Temperature (K) 150(2) 
Crystal system orthorhombic 
Space group P212121 
a (Å) 9.68478(19) 
b (Å) 14.1744(2) 
c (Å) 19.6375(3) 
α (°) 90 
β (°) 90 
γ (°) 90 
Volume (Å3) 2695.76(8) 
Z 4 
ρcalc (g/cm
3) 1.856 
µ (mm‑1) 5.174 
F(000) 1464.0 
Crystal size (mm3) 0.6 × 0.2 × 0.18 brown block 
Radiation MoKα (λ = 0.71073) 
2Θ range for data collection (°) 5.046 to 64.752 
Index ranges -14 ≤ h ≤ 14, -21 ≤ k ≤ 21, -29 ≤ l ≤ 29 
Reflections collected 41771 
Independent reflections 9081 [Rint = 0.0366, Rsigma = 0.0317] 
Data/restraints/parameters 9081/0/347 
Goodness-of-fit on F2 1.039 
Flack parameter -0.017(2) 	
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Table 3.9: Bond lengths of iridium-halide bonds for eight complexes deter-
mined by x-ray experiments. Estimated standard deviation shown in brackets.
Complex Atom 1 Atom 2 Length/Å
1 Ir Cl 2.3857(5)
3 Ir Cl 2.3771(11)
5 Ir Cl 2.3803(9)
6 Ir Cl 2.3719(5)
8 Ir Cl 2.3888(8)
10 Ir I 2.68371(16)
13 Ir Cl 2.3791(6)
14 Ir Cl 2.3796(10)
Bond lengths lie within the expected range for complexes of this structure.94,104
The Ir-I bond of complex 10 is significantly longer than the Ir-Cl bonds of the
other complexes for which crystal structure data were obtained.
90
3.3.3 E↵ect of Structure on Hydrophobicity
Hydrophobicity is a key component in drug design, and there is a general per-
ception that very hydrophobic complexes are unlikely to progress to commer-
cial drugs, due to factors such as di culty in solubilisation and formulation.
Low hydrophobicity is typically desirable as high water-solubility correlates
with high oral availability and easier formulation, although such complexes are
sometimes harder to purify. A desirable feature of the chemotherapeutic oxali-
platin is that it can be orally administered, and, as such, is more favourable for
administration to patients.105 Liplinski’s rule of five106 encourages drug devel-
opment to be focussed on small, moderately hydrophobic/lipophilic molecules.
Moderate lipophilicity is a desirable drug feature, as, to be intracellularly ac-
tive, a drug needs to be able to permeate the lipid bilayer of cell membranes.
Hence, a balance must be struck between hydrophobicity and hydrophilicity
in order to maximise solubility for formulation without impeding the drug’s
ability to permeate cell membranes and reach intracellular target sites. For
non-orally deliverable drugs, there are a variety of other delivery systems that
can be utilised, such as the delivery of the anticancer drugs paclitaxel or dox-
orubicin by encapsulation in liposomes.107,108 The e↵ect of modulation of func-
tional groups of organoiridium complexes 1 – 19 on their relative hydropho-
bicity was measured by LC-MS (Figure 3.12). LC-MS carried out under the
conditions described in Chapter 2.
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Figure 3.12: Relative hydrophobicity measured by LC-MS retention times for
complexes 1 – 19 colour-coded by bidentate azopyridine ligand and shape-
coded by halido ligand.
When comparing structurally similar complexes, the level of hydrophobicity
vs. Y group generally follows the trend: NEt2 > NMe2 > H > NO2 > OH
> (OH)2. The extension of the Cp system system by the addition of phenyl
rings increases hydrophobicity as evidenced by retention times being highest
for Cpxbiph complexes 1, 5, 11, 13, 16 and 19, followed by Cpxph complexes
2, 14 and 17, then the remaining Cp* complexes. A notable exception is
the one Cp* azpyNMe2 iodido complex 4, which has higher hydrophobicity
than all other Cp* and Cpxph complexes. Two other Cp* complexes bearing
the azpyOH ligand, complexes 9 and 10, also bear the iodido ligand. Whilst
they are considerably less hydrophobic than complex 4, both are far more
hydrophobic than their otherwise identical chlorido analogues.
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3.3.4 Relationships Between Hydrophobicity and An-
tiproliferative Activity
Previous literature on the antiproliferative activity of C’N-chelated organoirid-
ium complexes revealed a correlation between LC retention time, cellular up-
take of complex, and anticancer potency. Complexes which were more hy-
drophobic had higher retention times, greater uptake and superior cytotoxic-
ity against cancer cells.86 To determine if this was the case for N’N-chelated
azopyridine ligands, IC50 values were determined in A2780 and compared to
their LC-MS retention times (Table 3.10 and Figure 3.13). A compilation of
IC50 values for complexes 1 – 19 in all cell lines in all chapters of this work
can be found in Appendix Tables S1 and S2, pg. 269 – 270. Antiproliferative
screenings against A2780 carried out by Dr. Isolda Romero-Canelo´n, Ji-Inn
Song and Bindy Heer.
Table 3.10: IC50 values (in µM) in A2780 cells for complexes 1 – 19 and
CDDP. Values and standard deviations obtained from duplicates of triplicate
experiments. LC-MS retention times for complexes 1 – 19 carried out under
identical separation conditions. Lines separate complexes of di↵erent families
by azopyridine ligand (n.d. = not determined).
Complex Structure A2780 IC50 (µM) Ret. Time. (min)
1 [(Cpxbiph)Ir(azpyNMe2)Cl]PF6 0.095 ± 0.006 27.5
2 [(Cpxph)Ir(azpyNMe2)Cl]PF6 0.101 ± 0.001 22.9
3 [(Cp*)Ir(azpyNMe2)Cl]PF6 1.59 ± 0.03 19
4 [(Cp*)Ir(azpyNMe2)I]PF6 n.d. 23.2
5 [(Cpxbiph)Ir(azpyOH)Cl]PF6 0.14 ± 0.09 24.1
6 [(Cpxph)Ir(azpyOH)Cl]PF6 0.108 ± 0.009 19.5
7 [(Cp*)Ir(azpyOH)Cl]PF6 0.12 ± 0.04 15.2
8 [(Cp*)Ir(azpyOH)Cl]Cl 0.17 ± 0.07 19.2
9 [(Cp*)Ir(azpyOH)I]PF6 0.25 ± 0.02 15.6
10 [(Cp*)Ir(azpyOH)I]I 0.34 ± 0.02 19.2
11 [(Cpxbiph)Ir(azpy(OH)2)Cl]PF6 5.0 ± 0.5 24.1
12 [(Cp*)Ir(azpy(OH)2)Cl]PF6 0.776 ± 0.002 15.3
13 [(Cpxbiph)Ir(azpy)Cl]PF6 0.126 ± 0.002 26.7
14 [(Cpxph)Ir(azpy)Cl]PF6 0.22 ± 0.02 22
15 [(Cp*)Ir(azpy)Cl]PF6 1.5 ± 0.2 17.6
16 [(Cpxbiph)Ir(HOazpyNO2)Cl]PF6 0.4 ± 0.1 25.9
17 [(Cpxph)Ir(HOazpyNO2)Cl]PF6 0.184 ± 0.002 22.1
18 [(Cp*)Ir(HOazpyNO2)Cl]PF6 0.43 ± 0.04 18.6
19 [(Cpbiph)Ir(Brazpy(OH)NEt2)Cl]PF6 16 ± 6 30.1
CDDP cis-[Pt(NH3)2Cl2] 1.2 ± 0.2 n.d.
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Figure 3.13: Plot of IC50 values (in µM) in A2780 cells vs. LC-MS retention
times for complexes 1 – 19. Points colour-coded by bidentate azopyridine
ligand, shape-coded by halido ligand and Cp system shown for comparison.
Error bars obtained from IC50 standard deviations. Correlation between IC50
and retention time fitted by weighted linear regression and a line of best fit
plotted (red). Adjusted r-squared value = 0.746.
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There is a weak correlation between retention time and anticancer potency
in agreement with trends observed in previous literature.86 However, there
are multiple significant outliers which are mostly ignored by the weighted line
fitting algorithm, in particular the Cpxbiph Brazpy(OH)NEt2 complex 19, with
the highest retention time, has the least potency, with an IC50 value ca. 1 –
2 orders of magnitude greater than most of the other complexes. However,
complex 19 does have many structural di↵erences to the rest of the complex
families in this work. Conversely, complex 7, which has the lowest retention
time, is one of the most potent.
Further interesting trends can be observed within families of complexes bearing
the same azopyridine ligand. These families of complexes are grouped together
in Tables 3.1 and 3.10. Structures can be found in Figure 3.3.
Complexes 1 – 4 bear the azpyNMe2 ligand. Within this family of complexes,
extension of the Cp system by a phenyl ring imparts an large increase in
potency, however the addition of a second phenyl ring only increases potency
by a negligible amount.
Complexes 5 – 10 which bear the azpyOH bidentate ligand (azpyOH pKa
values investigated in Chapter 5) all have comparatively low retention times,
yet retain potent activity. Of further interest is the almost identical potencies
of complexes 5 – 7, as they bear di↵ering Cp systems. This usually leads to
dramatic di↵erences in activity, however, this is not observed for this family
of complexes.
Another interesting comparison can be made between the Cp* azpyOH chlo-
rido complexes 7 and 8 and their iodido analogues 9 and 10. Unlike the case
for the azpyNMe2 complexes 3 and 4 there is not a large di↵erence in reten-
tion times between the azpyOH chlorido and iodido analogues, however both
iodido complexes are slightly less potent. The azpyOH family of complexes is
investigated further in Chapter 5.
Complexes 11 and 12 bear the azpy(OH)2 ligand. In stark contrast, the
Cpxbiph complex 11 of azpy(OH)2 family is significantly less active than its
Cp* analogue, complex 12. A Cpxph azpy(OH)2 complex was not synthesised
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in this work.
Complexes 13 – 15 bear the azpy ligand. Within this family of complexes the
same relationship between the Cp system and potency is observed as for the
azpyNMe2 complexes.
Complexes 16 – 18 bear the HOazpyNO2 ligand. The HOazpyNO2 family
shows little di↵erence in potency between the Cp* and Cpxbiph complexes,
whereas the Cpxph is the most potent.
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3.3.5 Catalysis of NADH Oxidation
The results shown in this chapter thus far have focused on the characterisation
of the chemical properties of several organoiridium complexes and their level
of antiproliferative activity against cancer cells. However, understanding how
these complexes exert their cytotoxic e↵ect on cancer cells is of great impor-
tance. Therefore, investigations into the MoA of eleven of these complexes
were carried out, beginning with their ability to oxidise the cellular coenzyme
nicotinamide adenine dinucleotide (NAD+). NAD+ has been of recent interest
as a potential target for anticancer complexes86,94,104 and transfer hydrogena-
tion has been shown to be an e↵ective way of selectively killing cancer cells.57
NAD+ and its reduced form NADH play essential roles in cellular metabolism.
The complex accepts or donates electrons in redox reactions (Figure 3.14).109
One of the most important roles of NAD+ is the acceptance of electrons from
the citric acid cycle that occurs in the mitochondrial matrix to generate NADH.
Subsequent oxidation of this NADH releases energy used to pump protons from
the mitochondrial matrix into the intermembrane space. The higher concen-
tration of protons in the intermembrane space relative to the mitochondrial
matrix generates potential energy in the form of a proton gradient. Protons
flow back into the mitochondrial matrix through the transmembrane enzyme
adenosine triphosphate (ATP) synthase, providing the energy required for ox-
idative phosphorylation, generating the universal energy carrier ATP, from
adenosine diphosphate (ADP) and phosphate.110
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Figure 3.14: The structures and oxidation/reduction reactions of
NADH/NAD+.
97
NADH is known to be involved in the production of mitochondrial reactive
oxygen species (ROS), and the primary mitochondrial ROS is superoxide
(SO).111,112 Perturbation of cellular redox balance has proven to be an e↵ective
way to kill cancer cells.113 The ratio of coenzyme NADH and its oxidised form
NAD+ therefore has implications to biological function. A highly potent and
selective organoiridium complex has been shown to catalyse the oxidiation of
NADH by hydride transfer to molecular oxygen to generate H2O2.84 To in-
vestigate whether any of the organoiridium complexes in this work have the
capability to catalyse the oxidation of NADH, UV studies were carried out
on NADH incubated with each of 11 organoiridium complexes for 24 h at 310
K and the solutions tested for H2O2 (Figure 3.15). 1H-NMR spectra of the
reaction mixtures of complexes 1 and 13 were examined 10 min after NADH
addition in an attempt to observe an Ir-H intermediate, however, no corre-
sponding peaks were observed. Turnover number (TON) corresponds to the
µM of NADH oxidised over 24 h, calculated from the known molar extinction
coe cient of NADH at 340 nm (6220 M 1cm 1). Turnover frequency (TOF)
calculated as the gradient of TON vs. time in the first 2 h.
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Figure 3.15: Catalytic oxidation of 150 µM NADH to NAD+ by 11 complexes.
(Top Left) UV spectra of 2.5 µM of complex 18 in 0.5% MeOH/99.5% (v/v) 5
mM Na2HPO4/NaH2PO4 bu↵er pH 7.4 at 310 K. (Top Right) Comparison of
changes in NADH absorbance at 340 nm relative to 0.5% MeOH-bu↵er control
for HOazpyNO2 complexes 16 – 18. (Bottom Left) Test for H2O2 generation
by complex 18 after 24 h using Quantofix peroxide test sticks, which turn from
white to blue in the presence of H2O2. (Bottom Right) Calculated TONs after
24 h and TOF values for the 11 complexes tested.
99
All complexes tested showed some level of NADH oxidation relative to the
MeOH control with no complex, with a measurable reduction in the UV peak
of NADH at 340 nm and a concomitant increase in the peak at 261 nm corre-
sponding to NAD+. The level of catalytic activity varies significantly, depend-
ing greatly on the bound ligands, however further experimental repeats would
be required to obtain more accurate data. The azpyNMe2 complexes 1, 3, and
4 induce little to no oxidation of NADH, demonstrated by very low TONs,
between 3 – 6 µM, compared to the control. The chlorido azpyNMe2 complex
3 shows a slightly higher TON than its iodido analogue, complex 4. The azpy
complexes 13 – 15 have a comparably higher TON. Of these, the Cpxph ana-
logue, complex 14, displayed significantly higher catalytic activity than its Cp*
or Cpxbiph analogues. The azpy(OH)2 complex 12 showed a greater TON and
TOF than the azpy and azpyNMe2 complexes, with the exception of complex
14. The three HOazpyNO2 complexes 16 – 18 all showed significantly higher
TONs than previously mentioned complexes (  100 µM) as well as higher
TOFs. There is a clear trend in the catalytic activity of the HOazpyNO2 com-
plexes. The TON and TOFs are highest in the Cp* analogue, complex 18,
and follow the trend Cp* >Cpxph >Cpxbiph. Additionally, complex 18 is the
only complex tested that generates detectable levels of H2O2, generating an
amount in the range 0.5 mg/L – 2.5 mg/L. Qualitative assessment of H2O2
generation can be found in Appendix Figure S20, pg. 291. Complex 18 and
the BrazpyONEt2 complex 19 have equal TONs, whereas complex 18 has 3⇥
the TOF, demonstrating the most rapid NADH oxidisation in the first 2 h of
any of the 11 complexes tested.
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3.3.6 E↵ect of Functional Groups on Aquation
The azpyNMe2 complex 1 is the most potent complex against A2780 ovar-
ian carcinoma of the nineteen complexes studied (Table 3.10). However all
azpyNMe2 complexes tested have almost no oxidant activity towards NADH
(Figure 3.15), indicating that they possess a MoA that does not involve NADH
oxidation. The remainder of this chapter details further investigations into
possible MoAs of the azpyNMe2 complexes.
To elucidate the MoA of a complex, it is necessary to know what form it
takes when in solution. The activation step of CDDP involves the hydrolysis
of the metal-Cl bond. Many anticancer complexes of other transition metals
share this activation step, in many cases the rate of hydrolysis is dependent
on the bound halide.114 To investigate whether changing the halide bound
to the iridium centre a↵ects hydrolysis, solutions of complexes 1 and 4 were
monitored over 24 h by 1H-NMR in 10% d6-DMSO:D2O, 0.1% 1,4-dioxane at
310 K (Figure 3.16 and 3.17) and the extent of hydrolysis calculated by the
peak integrals (Table 3.11). The presence of DMSO ensured the solubility
of the complexes and 1,4-dioxane was used as the reference peak to calibrate
the spectra. Further experiments were carried out under the same conditions
using 120 mM NaCl to assess whether the presence of excess chloride would
suppress hydrolysis of the Cl bond. This concentration of chloride matches
that of the cell medium in which antiproliferative screenings were carried out,
therefore spectra under these conditions provide an indication of what form
the complexes would likely take in solution under biological conditions.
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Figure 3.16: Hydrolysis of complex 1 studied by 600 MHz 1H-NMR spectra
of a 100 µM solution of complex 1 in 10% d6-DMSO:D2O, 0.1% 1,4-dioxane
(v/v) at 310 K, unbu↵ered at pD 8. Aliphatic region shown above, aromatic
region shown below. Spectra shown 10 min after sample preparation, 24 h
after sample preparation, and 24 h after sample preparation in 120 mM NaCl
solution. Emergent peaks not corresponding to original complex denoted by
red arrows. Traces of acetone/ether from the NMR tube are visible.
102
NN
N
Ir
I
PF6
N
[
[
Complex 4
10 min. 0 mM [Cl] 
24 h. 0 mM [Cl] 
24 h. 120 mM [Cl] 
Cp* methyls 
Cp* methyls 
Emergent Peak 
10 min. 0 mM [Cl] 
24 h. 0 mM [Cl] 
24 h. 120 mM [Cl] 
Azo pyridine ring 
Azo phenyl ring Azo phenyl ring 
Azo pyridine ring 
Emergent Peak 
Figure 3.17: Hydrolysis of complex 4 studied by 600 MHz 1H-NMR spectra of
a 100 µM solution of complex 1 in 10% d6-DMSO:D2O, 0.1% 1,4-dioxane (v/v)
at 310 K, unbu↵ered at pD 8. Spectra shown 10 min after sample preparation,
24 h after sample preparation, and 24 h after sample preparation in 120 mM
NaCl solution. Emergent peaks not corresponding to original complex denoted
by red arrows.
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Table 3.11: Hydrolysis data for complexes 1 and 4 monitored over 24 h by
1H-NMR in 10% d6-DMSO:D2O, 0.1% 1,4-dioxane at 310 K. Aliphatic region
shown above, aromatic region shown below. Experiments were repeated with
the addition of 120 mM NaCl before or after 24 h to assess suppression and
reversibility of hydrolysis by chloride.
Complex Structure % Extent of Hydrolysis (0 mM [Cl])
% Extent of Hydrolysis 
(120 mM [Cl])
1 [CpxbiphIr(azpyNMe2)Cl]PF6 79% 0%
4 [Cp*Ir(azpyNMe2)I]PF6 0% 40%*
*Complex 4 did not hydrolyse in the presence on 120 mM [Cl], instead 40% of the 
complex exchanged its iodido ligand for a chlorido one.
To determine whether the hydrolysis of complex 1 was reversible by post-
hydrolysis addition of chloride, the experiment was repeated without chloride
then 120 mM chloride was subsequently added after 24 h incubation as solid
NaCl, and another spectrum was taken 10 min thereafter.
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Figure 3.18: Aliphatic (top) and aromatic (bottom) regions of a 600 MHz
1H-NMR spectrum of a 100 µM solution of complex 1 in 10% d6-DMSO:D2O,
0.1% 1,4-dioxane (v/v) at 310 K, unbu↵ered at pD 8. Spectrum taken 10
min after addition of 120 mM [Cl] to a previously chloride-free solution that
had been incubated for 24 h. Emergent peaks not corresponding to original
complex denoted by pink arrows. Traces of acetone/ether from the NMR tube
are visible.
Complex 1 has been shown to be stable in 100% DMSO, spectra in Appendix
Figure S21, pg. 292. Therefore the appearance of new peaks in the spectra
of chlorido complex 1 over 24 h in addition to concomitant reduction in the
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peaks corresponding to the original complex can be attributed to the hydrolysis
of complex 1 in the presence of H2O. The spectrum of Cp* iodido complex
4, however, does not change over 24 h, indicating that complex 4 does not
hydrolyse in the presence of H2O. The spectrum of chlorido complex 1 under
the same conditions with 120 mM NaCl shows no change after 24 h. However,
some of the new peaks that appear upon hydrolysis do not disappear upon
subsequent addition of 120 mM NaCl. Conversely, the spectrum of Cp* iodido
complex 4 with 120 mM NaCl contains new peaks after 24 h. The chemical
shifts of these new peaks match exactly that of Cp* chlorido complex 3 under
the same conditions, therefore the most likely explanation is that there is some
I ! Cl exchange occurring when complex 4 is in solution with 120 mM NaCl.
A peak at m/z = 709.2 was observed in the ESI-MS spectrum of complex 1
after 24 h in salt-free aqueous solution which matches the theoretical m/z of
an analogue of complex 1 in which the metal-bound chloride is replaced by
OH.
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3.3.7 E↵ect of Chelating Ligands on Chiral Enantiomer
Separation
The results of the previous section highlight a di↵erence in the behaviours of
the chlorido complex 1 and the iodido complex 4 in aqueous solution. Enan-
tiomers of organoiridium complexes bearing an azpyNMe2 bidentate ligand
have previously been separated successfully, however, isolation of stable enan-
tiomers was not achieved.103 The increased aqueous stability of the iodido com-
plex, however, may allow for successful isolation. It is widely acknowledged
that enantiomers of chemical compounds can exhibit di↵erent behaviours.
Sometimes the pharmacological e↵ects of enantiomers of the same complex are
drastically di↵erent and chirally pure molecules can even epimerise in vivo.115
It is therefore important to investigate the chiral separability of any potential
clinical drug.
To separate and assess the stability of the enantiomers of complexes 1 – 4,
separations by chiral column were carried out (Figure 3.19) using a CHIRAL-
PAK IC column in normal phase (composition detailed in Figure 3.2) from
Chiral Technologies Europe.
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Figure 3.19: Chromatograms of 1 mg/ml solutions of complexes 1 – 4 in EtOH
(blue) separated on a CHIRALPAK IC column. Separated enantiomers were
stored at 193 K for 20 h then re-injected (red/green).
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Two peaks are seen for the injection of complex 1 (blue) which correspond to
its two enantiomers, 1A and 1B. Separation of enantiomers was possible with
impressive resolution, i.e. no peak overlap (Table 3.12), however there are
slight unexpected shifts in retention times of some enantiomers relative to the
initial complex. These separated peaks were collected, dried under vacuum,
stored at 193 K for 20 h then re-injected (red and green). Injection of complex
1A or 1B after 20 h resulted in the same two peaks observed. This is also
the case for complexes 2 and its enantiomers 2A and 2B, as well as complex
3 and its enantiomers 3A and 3B.
Injection of complex 4 results in two peaks corresponding to 4A and 4B,
however re-injection of 4A after 20 h results on only one peak being observed.
The same is true for re-injection of 4B.
Complexes 1 – 3 bear a monodentate chlorido ligand. They are shown here
to exist as racemic mixtures. However, even when dried and stored at 193
K for 20 h their separated enantiomers rapidly epimerise back into a racemic
mixture.
Complex 4 bears a monodentate iodido ligand instead of chlorido, but is other-
wise structurally identical to complex 3. This complex also exists as a racemic
mixture, however the enantiomers of complex 4 were not only separable, but
stable (i.e. did not epimerise), under the same storage conditions as those
used for complexes 1 – 3.
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Table 3.12: Retention times, peak integral area percentages, peak widths and
separation resolutions for the separation of chiral enantiomers of complexes 1
– 4 and their separated enantiomers 1A – 4A and 1B – 4B after storage at
193 K for 20 h by CHIRALPAK IC column. Only enantiomers 4A and 4B
remained enantiomerically pure after storage (highlighted in red). Separation
resolution between two peaks calculated as (Ret. Time (peak 1) - Ret. Time
(peak 2))/(0.5 x (Peak Width (peak 1) + Peak Width (peak 2)))
Complex Sample Ret. Time (min) Area % Peak Width (min) Resolution
28.00 51 1.57
32.45 49 2.12
30.56 57 1.58
35.86 43 1.89
30.43 46 1.56
35.34 54 1.95
25.94 50 1.40
30.27 50 1.78
26.08 51 1.31
30.53 49 1.49
25.98 50 1.28
30.63 50 1.52
31.10 51 1.60
37.36 49 1.92
30.56 51 1.10
36.46 49 1.26
28.41 52 1.05
33.57 48 1.07
46.77 50 1.43
51.93 50 1.60
4
Initial 3.41
Enantiomer 4A n/a
Enantiomer 4B n/a
45.54
50.84
100
100
1.54
1.50
3.56
5.00
4.87
1
2
3
Initial
Enantiomer 1A
2.41
3.05
2.80
2.72
3.18
3.32
Enantiomer 3B
Enantiomer 1B
Initial
Enantiomer 2A
Enantiomer 2B
Initial
Enantiomer 3A
Separation of the enantiomers of azpyOH complex 7 was also attempted but
not achievable under these conditions, most likely due to the di↵erence in
bidentate ligand. Due to the highly specific conditions typically required for
chiral separation no further separations were attempted for any other com-
plexes.
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3.3.8 Antiproliferative Activity against Oesophageal
and Nasopharyngeal Cancers
Like CDDP, complexes 1 – 3 are unstable in aqueous solution. That this is
suppressible by chloride suggests that hydrolysis is occuring at the Ir-Cl bond.
This is supported by the inertness of the iodido complex 4 to hydrolysis and
the instability of the chiral enantiomers of complexes 1 – 3.
Complexes 1 – 3 are shown in Table 3.10 to be highly potent against A2780
ovarian carcinoma, however the MoA is still not well understood. To further as-
sess the e↵ect of the Cp system on antiproliferative activity, and to investigate
whether the MoA of complexes 1 – 3 di↵er in CDDP-sensitive and -insensitive
cell lines, they were tested against OE19 and SUNE-1 (Table 3.13). OE19 is a
cell line derived from aggressive oesophageal carcinoma, against which CDDP
has limited potency. SUNE-1 is a nasopharyngeal carcinoma cell line that is
10⇥ more sensitive to CDDP than OE19. Antiproliferative screenings carried
out by Dr. Isolda Romero-Canelo´n.
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Table 3.13: Comparison of IC50 values (in µM) of complexes 1 – 3 to CDDP
against OE19 and SUNE-1.
Complex OE19 SUNE-1
1 0.195 ± 0.002 0.58 ± 0.04
2 0.3 ± 0.003 1.14 ± 0.01
3 3.6 ± 0.3 10.5 ± 0.6
CDDP 13.43 ± 0.003 1.14 ± 0.01
In both cell lines, the presence of the phenyl ring in the Cp system of complex
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2 confers an order of magnitude increase in potency compared to its Cp* ana-
logue, complex 3. The addition of a second phenyl ring (complex 1) increases
potency by a comparatively small amount.
All 3 complexes are considerably more active than CDDP in OE19, however
in SUNE-1, complex 1 is more active, complex 2 has equal activity to CDDP
and complex 3 is over an order of magnitude less potent than CDDP. This
illustrates the significant impact of the Cp system on the potency of this family
of complexes.
112
3.3.9 MoA Studies in Oesophageal and Nasopharyngeal
Cancers by Flow Cytometry
As shown previously in Tables 3.10 and 3.13, extension of the Cp system
correlates with an increase in potency against A2780 ovarian carcinoma, OE19
oesophageal carcinoma and SUNE-1 nasopharyngeal carcinoma. To investigate
whether this di↵erence in potency is due to changes in MoA, a panel of flow
cytometry experiments were conducted on OE19 and SUNE-1 cells exposed to
complexes 1 – 3 to investigate their ability to generate ROS and SO, depolarise
the mitochondrial membrane, induce apoptosis, and disrupt the cell cycle.
Flow cytometry is a technique used to analyse the size, shape, and properties
of single cells in a mixture by passing them through a capillary narrow enough
to allow only a single cell to pass at a time. Each cell passes through a laser
beam, causing light to scatter and fluorophores in the cell to fluoresce if the
laser light is set to the appropriate wavelength. The flow cytometer detects
both scattering and fluorescence from each cell, allowing the cells to be sorted
into distinct populations. In this work two fluorescence channels, FL1 (green)
and FL2 (orange) are utilised to detect two separate sources of fluorescence
from the cells stained with the various fluorescent dyes used throughout the
experiments (detailed in subsection 2.3.4). Flow cytometry studies carried out
with the help of Dr. Isolda Romero-Canelo´n and Hannah Bridgewater.
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3.3.9.1 ROS and SO Generation
Cancer cells have altered redox states and so are more susceptible to pertur-
bations in their delicate redox balance. Normal cells are less susceptible to
this, and so the use of therapeutics which disrupt redox balance by generat-
ing ROS and SO may be a way to selectively kill cancer cells.116 Metal-based
complexes of platinum,46 ruthenium117 and osmium,118 have been developed
that generate ROS and SO, and/or utilise other redox-based MoAs to exert
anticancer activity.119
The capacity of complexes 1 – 3 to induce changes in the levels of both
general ROS (H2O2, peroxynitrate, NO and peroxy/hydroxyl radicals) and
SO in OE19, complexes 1 and 2 in SUNE-1, and complex 2 in A2780 were
investigated by flow cytometry (Figures 3.20 – 3.22). Pyocyanin, a ROS/SO-
generating toxin produced by the bacterium Pseudomonas aeruginosa, was
used as the positive control.
Gating of the cell populations was determined using the results for the positive
and negative controls and kept constant within each experiment, however, in
many cases, the gate splits a cell population of complex-treated cells into FL2+
or FL2- when there are clearly not two distinct populations. In these cases
the cells classified as FL2- may still be producing SO, however the FL2 gate
acts simply as a threshold by which the % of cells above it can be quantified
to compare the level of FL2 fluorescence between complexes.
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Figure 3.20: (Top) Measurement of ROS and SO generation by flow cytom-
etry of OE19 oesophageal carcinoma carcinoma cells exposed to complexes
1 – 3 for 24 h at IC50 concentrations at 310 K. Pyocyanin used as positive
control (orange). (Bottom) Table of % cell populations obtained from trip-
licate experiments. Statistical significance between cells exposed to complex
vs. negative control was determined by two-sample independent Welch t-tests
assuming unequal variance between populations with asterisks corresponding
to p  0.05 *, p  0.01 **, p  0.001 ***, p  0.0001 ****.
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Figure 3.21: (Top) Measurement of ROS and SO generation by flow cytometry
of SUNE-1 nasopharyngeal carcinoma carcinoma cells exposed to complexes
1 and 2 for 24 h at IC50 concentrations at 310 K. Pyocyanin used as positive
control (orange). (Bottom) Table of % cell populations obtained from trip-
licate experiments. Statistical significance between cells exposed to complex
vs. negative control was determined by two-sample independent Welch t-tests
assuming unequal variance between populations with asterisks corresponding
to p  0.05 *, p  0.01 **, p  0.001 ***, p  0.0001 ****.
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Figure 3.22: (Top) Measurement of ROS and SO generation by flow cytom-
etry of A2780 ovarian carcinoma cells exposed to complex 2 for 24 h at IC50
concentration at 310 K then stained with orange/green fluorescent reagents.
Pyocyanin used as positive control (orange). (Bottom) Table of % cell popu-
lations obtained from triplicate experiments. Statistical significance between
cells exposed to complex vs. negative control was determined by two-sample
independent Welch t-tests assuming unequal variance between populations
with asterisks corresponding to p  0.05 *, p  0.01 **, p  0.001 ***, p 
0.0001 ****.
Complexes 1 – 3 generate high levels of ROS and SO in OE19 cells, complexes
1 and 2 in SUNE-1 cells, and complex 2 in A2780 cells. Complex 2 generates
more SO in A2780 than in OE19 or SUNE-1, evidenced by the greater level of
FL2 fluorescence observed for complex 2-treated cells in A2780 vs. OE19 or
SUNE-1 in addition to a higher % of cell in the FL2+ populations.
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3.3.9.2 Mitochondrial Membrane Depolarisation
Complexes 1 – 3 generate significant amounts of ROS and SO in cancer cells.
This can have an impact on mitochondrial function. To assess whether the
mitochondria of cancer cells were a↵ected, OE19 oesophageal cancer cells ex-
posed to complexes 1 – 3 were assayed for depolarisation of the mitochondrial
membrane potential using the cationic dye JC10 (Figure 3.23). JC10 aggre-
gates in the mitochondria and emits detectable fluorescence, however, if the
membrane is depolarised, the dye disaggregates and a measurable decrease in
fluorescence is observed. 1 µM carbonyl cyanide m-chlorophenyl hydrazone
(CCCP), an inhibitor of oxidative phosphorylation, was used as the positive
control.
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Complex %Polarised %Depolarised
Neg CTL 88.1 ± 0.5 11.9 ± 0.5
Pos CTL 28 ± 1 72 ± 1
1 2.17 ± 0.06 **** 98.83 ± 0.06 ****
2 1.07 ± 0.06 **** 98.93 ± 0.06 ****
3 1.3 ± 0.1 **** 98.7 ± 0.1 ****
Figure 3.23: (Top) Depolarisation of mitochondrial membrane potential of
OE19 oesophageal carcinoma cells exposed to complexes 1 – 3 for 24 h at
IC50 concentration at 310 K measured by reduction in JC10 fluorescence.
(Bottom) Table of % cell populations with polarised/depolarised mitochon-
drial membrane potential obtained from triplicate experiments. Statistical
significance between cells exposed to complex vs. negative control was deter-
mined by two-sample independent Welch t-tests assuming unequal variance
between populations with asterisks corresponding to p  0.05 *, p  0.01 **,
p  0.001 ***, p  0.0001 ****.
Complexes 1 – 3 induce extreme depolarisation of the mitochondrial mem-
brane, greater than that observed in the positive control.
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3.3.9.3 Apoptosis Induction
The presence of excessive ROS and mitochondrial damage can induce cell
apoptosis. To investigate if complexes 1 – 3 induce apoptosis, and to assess
whether extension of the Cp system has any impact, flow cytometry exper-
iments were carried out in OE19, SUNE-1 and A2780 (Figures 3.24 – 3.26)
using annexin V and propidium iodide (PI).
Annexin V binds to membrane-bound phosphatidylserine phospholipids, which
ordinarily face into the cytoplasm. However, in early apoptosis, these translo-
cate to the outside of the cell membrane and annexin V fluorescence can be
detected whilst PI can not. In late apoptosis, the cell membrane becomes
permeable and PI can enter, bind DNA, and fluoresce. If only PI fluores-
cence is observed, the cell has become permeable without apoptosis-induced
phosphatidylserine protein translocation taking place. This usually indicates
cell necrosis as significant membrane rupturing has to occur to allow PI entry.
Therefore, flow cytometry studies using annexin V and PI can reveal if drug
exposure induces early apoptosis, late apoptosis, or cell necrosis.
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Figure 3.24: (Top) Measurement of apoptosis induction by flow cytometry of
OE19 oesophageal carcinoma cells exposed to complexes 1 – 3 for 24 h at IC50
concentrations at 310 K. (Bottom) Table of % cell populations obtained from
triplicate experiments. Statistical significance between cells exposed to com-
plex vs. negative control was determined by two-sample independent Welch
t-tests assuming unequal variance between populations with asterisks corre-
sponding to p  0.05 *, p  0.01 **, p  0.001 ***, p  0.0001 ****.
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Figure 3.25: (Top) Measurement of apoptosis induction by flow cytometry of
SUNE-1 nasopharyngeal carcinoma cells exposed to complexes 1 and 2 for
24 h at IC50 concentrations at 310 K. (Bottom) Table of % cell populations
obtained from triplicate experiments. Statistical significance between cells
exposed to complex vs. negative control was determined by two-sample in-
dependent Welch t-tests assuming unequal variance between populations with
asterisks corresponding to p  0.05 *, p  0.01 **, p  0.001 ***, p  0.0001
****.
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Figure 3.26: (Top) Measurement of apoptosis induction by flow cytometry of
A2780 ovarian carcinoma cells exposed to complex 2 for 24 h at IC50 concen-
tration at 310 K. (Bottom) Table of % cell populations obtained from trip-
licate experiments. Statistical significance between cells exposed to complex
vs. negative control was determined by two-sample independent Welch t-tests
assuming unequal variance between populations with asterisks corresponding
to p  0.05 *, p  0.01 **, p  0.001 ***, p  0.0001 ****.
At IC50 concentration, complexes 1 – 3 induce little to no apoptosis in either
OE19 or SUNE-1 cells after 24 h. All complexes slightly increase the pop-
ulation of non-viable cells in all cell lines tested. At 4⇥ IC50 concentration,
complex 2 has been previously reported to induce early-stage apoptosis after
24 h and late-stage apoptosis after 48 h in A2780 cells.120
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3.3.9.4 Cell Cycle Analysis
Cells progress through a cycle as they proliferate. This cycle consists primarily
of four phases: The G1-phase, in which the cell begins to increase in size,
in preparation for DNA replication, the S-phase in which the cell DNA is
replicated, doubling the amount of DNA present, and the G2/M-phase, in
which the cell continues to increase in size. This culminates in mitosis, when
the cell divides into two daughter cells, each with one copy of the original
cell’s DNA. To ensure this process proceeds correctly, there exists cell cycle
checkpoints. These are points at which the progression of the cell cycle may be
halted in order to repair any damaged DNA or confirm that cell cycle processes
are functioning properly.
The first of these is the G1/S checkpoint, in which the cell will halt cycle
progression if there are are not enough resources to successfully undergo repli-
cation without putting the cell at risk. The second of these is the G2/M check-
point. Here the cell checks that it has enough membrane phospholipids and
cytoplasm to produce two daughter cells. It also checks for DNA-damage, as
improper DNA replication or pharmacological agents can induce damage that
needs to be repaired before the cell cycle can progress safely. This checkpoint
ensures that the cell does not undergo division before it has had an oppor-
tunity to repair the damaged DNA. The third checkpoint is the metaphase
checkpoint, in which the cell checks that the mitotic spindle has formed prop-
erly and the chromosomes are properly aligned prior to cytokinesis. Cancer
cells regularly bypass these checkpoints and continue to proliferate, regardless
of DNA damage, accruing multiple mutations as they do so.
The formation of CDDP adducts on cellular DNA induces an arrest in the S
and G2-phases of the cell cycle, often leading to apoptosis. CDDP-resistant
cells tend to have mutations that cause these adducts to either be tolerated or
rapidly repaired. In this way cell apoptosis induction is avoided.
To assess whether complex 2 can induce cell cycle arrest, flow cytometry was
used to determine the % of the cell population of A2780 cells in each phase,
based on the amount of DNA present in the cells visible when stained with PI
(Figure 3.27).
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Figure 3.27: (Top Left) Cell cycle analysis by flow cytometry of A2780 ovarian
carcinoma cells exposed to complex 2 for 24 h at IC50 concentration at 310
K. (Top Right) Bar chart of % population of cells in each cell cycle phase.
(Bottom) Table of % cell populations obtained from triplicate experiments.
Statistical significance between cells exposed to complex vs. negative control
was determined by two-sample independent Welch t-tests assuming unequal
variance between populations with asterisks corresponding to p  0.05 *, p 
0.01 **, p  0.001 ***, p  0.0001 ****.
Complex 2 induces a slight increase in the G1 population with a reduction in
the number of cells in the G2/M-phase. No significant change in the S-phase
population was observed.
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3.3.10 GDSC Pharmaco-genomic Screen
Complexes 1 – 3 show considerable potency in multiple cell lines, and the
results thus far suggest a unique MoA involving ROS perturbation and mito-
chondrial damage. Further studies in this area of chemical space are there-
fore warranted. The MoAs of metallodrugs can often be complex and involve
multiple targets, making them di cult to determine. A larger scale systems
pharmacology approach may therefore provide a way by which to elucidate
these MoAs.
Complex 2 (CpxphIr(azpyNMe2)Cl]PF6) has been previously reported to be
highly active against the NCI-60 panel of 60 cancer cell lines from 9 di↵er-
ent tissue types displaying superior mean cytotoxicity to CDDP. COMPARE
analysis revealed the potential for polypharmacology of complex 2 along with
an MoA tunable by modification of the chelating ligand.102 To further test the
anticancer properties of this complex and to search for informative patterns
of activity over di↵erent tissue types, the Sanger Institute carried out their
Genomics of Drug Sensitivity in Cancer large-scale screen using complex 2 on
916 cell lines over 28 tissue types. 809 of these lines were also tested against
CDDP for comparison (Figure 3.28).
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Figure 3.28: Box and whisker plots of complex 2 (blue) and CDDP (red) of
IC50 values against 809 di↵erent cancer cell lines. Cell lines grouped by tissue
type where N is the number of cell lines of that tissue type screened. White
circles used to mark outliers. The most significant outlier, OCUB-M, is circled
in blue.
Complex 2 shows significantly superior mean activity to CDDP in all tissue
types, with highest mean activity in cancers of the bladder, cervix, testis,
urogenital and uterus. Lowest mean activity was observed in lymphoma and
myeloma. One outstanding outlier is observed in the triple-negative breast
cancer cell line OCUB-M (denoted by blue ring), in which complex 2 displays
vastly superior activity compared to any other cell line.
Valuable information about the MoA of an anticancer complex can be gleaned
from not only observing which cell lines are most susceptible to it, but also from
those which are least susceptible. Analysis was carried out on the population of
outliers amongst cell lines tested against complex 2. Cell lines were designated
as insensitive if their corresponding IC50 value was above the upper whisker
(Figure 3.29).
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Cell Line Tissue log IC50 (µM)
WSU-DLCL2 lymphoma 2.69
ESO51 aero_dig_tract 2.67
LU-65 lung_NSCLC 2.62
PF-382 leukemia 2.54
A4-Fuk lymphoma 2.47
NCI-H2081 lung_SCLC 2.47
NCI-SNU-1 stomach 2.39
U-266 myeloma 2.34
NCI-H2135 lung_NSCLC 2.29
OACM5-1 aero_dig_tract 2.20
PANC-04-03 pancreas 2.19
EW-7 bone 2.11
KM-H2 lymphoma 2.04
NB(TU)1-10 neuroblastoma 2.02
TT2609-C02 thyroid 2.01
OPM-2 myeloma 2.00
PL18 pancreas 1.98
HPAC pancreas 1.97
THP-1 leukemia 1.97
NCI-H187 lung_SCLC 1.95
Figure 3.29: (Left) Box plots of complex 2 (blue) and CDDP (red) IC50 values
against all 809 cancer cell lines. Cell lines with an IC50 value greater than
the upper quartile + 1.5⇥ the interquartile range designated as ’insensitive’
(threshold denoted by red line). (Right) The top 25 cell lines least sensitive
to complex 2.
The mean activity of complex 2 is superior to CDDP. Only a small proportion
of cell lines tested were insensitive to complex 2 (46 of 916). To examine the
origins of these insensitive lines, the % of cell lines of each tissue type deemed
to be in the insensitive population was calculated (Figure 3.30).
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Figure 3.30: Bar plot of the number of cancer cell lines screened against com-
plex 2 separated by tissue type. Cell lines with low sensitivity to complex 2
are highlighted in green. The % of insensitive cell lines for each tissue type is
shown above each bar. If no percentage is shown, that tissue type contained
no insensitive lines.
The tissues with the largest proportion of cell lines insensitive to complex 2 are
the mesodermally-derived blood cancers: Lymphoma, myeloma and leukemia.
To further investigate the profiles of cell lines insensitive to complex 2, the
potency of other drugs in the screen against them was examined (Table 3.14).
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Table 3.14: The 10 cell lines least sensitive to complex 2 (IC50 > 150 µM) and
their corresponding tissue of origin. The drugs in the screen with the lowest
potencies against each cell line and their MoAs are shown.
Of the 46 cell lines classified as insensitive to complex 2, 19 are least sensitive
to piperlongumine,121 a senolytic agent that kills cancer cells by elevating ROS
levels and causing DNA damage.122,123 In subsection 3.3.9.1. it was shown that
complexes 1 – 3 generate ROS in multiple cell lines. This further supports
the hypothesis that complex 2 and its analogues have ROS-based MoAs.
Information on possible MoAs of a complex can be gained from comparing its
cytotoxic profile to others in a large data set. 253 other drugs were screened
against the same 809 lines as complex 2, and the MoA of many of these are
known. By comparing the pattern of cytotoxicity between complex 2 and
every other drug in the screen across all cell lines, drugs with similar MoAs
were identified (Figure 3.31).
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Figure 3.31: Statistical analysis of the pattern of cytotoxicity of complex 2
against 809 cell lines compared to the other 253 drugs in the screen. For each
drug the di↵erence in IC50 value between itself and complex 2 was taken for
each cell line and the standard deviation of these values calculated. Complexes
within the red circle show a similar pattern of cytotoxicity to complex 2.
Complex 2 showed significant similarity in cytotoxic profile with only two
other drugs in the screen, the previously reported Os(II) complexes: ([(⌘6-
bip)Os(azpyNMe2)I]PF6) and ([⌘6-p-cymene)Os(azpyNMe2)I]PF6)).64,124 In-
terestingly, these two complexes share the same azpyNMe2 bidentate chelat-
ing ligand as complex 2 but have a di↵erent monodentate ligand and coor-
dinated aromatic system. Other organoiridium and organoosmium complexes
with strong structural similarities to complex 2 but di↵erent bidentate ligands,
were included in this screen. That they did not also show similar cytotoxic
profiles to complex 2 is unexpected and of significant interest.
In cell lines in which mutations were present, a multivariate analysis of vari-
ance (MANOVA) was used to identify significant correlations between muta-
tion status and sensitivity/insensitivity to complexes. A Benjamin-Hochberg
multiple testing correction was used to identify significant results and flag false
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positives. This analysis identified a statistically significant correlation between
the KIT gene and sensitivity to complex 2.
The KIT gene coding mutation is associated with the sensitivity of four non
small cell lung carcinoma cell lines to complex 2. KIT encodes the human
homolog of the proto-oncogene C-KIT, a type-III transmembrane receptor for
the stem cell growth factor. Once bound to the growth factor, this protein
activates signal transduction through the cell, a↵ecting cell survival and dif-
ferentiation.
Complex 2 shows great promise as an anticancer agent and demonstrates a
novel MoA. We proceed by generating two similar organoiridium complexes
with di↵erent Cp systems to complex 2 and investigate how these changes
impact both their anticancer potency and their MoAs. In this way, we aim
to improve both the anticancer potency of organoiridium complexes and our
understanding of how they work.
132
3.4 Discussion
3.4.1 Aquation and Separation
The complexes in this work bear either a monodentate chlorido or iodido ligand
bound to the iridium centre. The solution chemistry of the azpyNMe2 com-
plexes 1 and 4 was investigated, revealing that the chlorido complexes readily
hydrolyse in aqueous solution, reaching an equilibrium between chloride-bound
and OH/OH2-bound analogues (Figure 3.16, pg. 102). The iodido complex,
however, was inert to hydrolysis (Figure 3.17, pg. 103). In biological testings,
the complexes were dissolved in cell medium containing 120 mM chloride. This
was shown to suppress hydrolysis completely, indicating that complexes 1 – 3
would remain in their chloride-bound form during cell tests. Once they enter
the cells, the chloride concentration decreases and aquation may be possible.
The iodido complex 4 showed 40% I! Cl exchange over 24 h in solution with
120 mM chloride (Table 3.11, pg. 104), therefore a significant proportion of
complex 4 could be converted to complex 3 by the time it reaches cells.
The 1H-NMR spectra show that addition of chloride 24 h after hydrolysis
causes the disappearance of some, but not all, of the new peaks that ap-
pear during hydrolysis of complex 1 (Figure 3.18, pg. 105). This indi-
cates that, whilst aquation is suppressible and reversible by chloride, cer-
tain species form during aquation that are una↵ected by addition of chloride
post-hydrolysis. High chloride concentration would likely shift the equilibrium
between OH/OH2-bound and Cl-bound Ir species, reverting the Ir-OH/OH2
species in the solution back to almost entirely Cl-bound complex. This suggests
that species other than OH/OH2-adducts are forming, possibly hydroxido-
bridged dimers. This has implications to the form the complex takes in cells,
as chloride concentration varies depending on the intracellular location. More
extensive investigations into the e↵ect of biologically-relevant chloride concen-
trations on complex 1 are carried out in Chapter 4.
The reactivities of Ir-Cl and Ir-OH/OH2 species are likely to di↵er. In the
case of CDDP, the OH/OH2-bound Pt species can react with many o↵-target
molecules, reducing the amount of complex that reaches the target site and
133
therefore also the e cacy of the drug. That complexes 1 – 3 remain their
original Ir-Cl species in a solution at the chloride concentration of cell medium
in an encouraging result, as it may mean that they are less likely to prematurely
hydrolyse and bind o↵-target molecules in cells.
The halido ligand has a profound e↵ect on not only the hydrolysis, but also
the stability of the chiral enantiomers of azpyNMe2 organoiridium complexes.
Whilst separation by chiral HPLC with excellent resolution was possible for
complexes 1 – 4 (Figure 3.19, pg. 108 and Table 3.12, pg. 110), the separated
enantiomers of the chlorido complexes revert readily to a racemic mixture.
Separated enantiomers of the iodido complex, however, remained optically
pure. There are slight shifts in the retention times of some of the separated
peaks, however, this is more likely to be due to slight erroneous variation in the
flow speeds between runs rather than any significant chemical changes. This is
the first time successful separation and/or isolation of stable enantiomers of an
organoiridium iodido complex of this family has been reported. Separation of
stable enantiomers has previously been possible for an organoosmium iodido
complex bearing the same azpyNMe2 bidentate ligand.103
For the chlorido complexes to interconvert, there must be a mechanism facili-
tating it. Given that the aquation results prove the bound chlorides are labile
in aqueous solution, a likely mechanism is simply the approach of a free chlo-
ride to the opposite face of the complex to which a chloride is already bound,
resulting in the binding of the new chloride and the leaving of the previously-
bound chloride (in the manner of an SN2 reaction). The net result of this
would be the conversion from one enantiomer to the other. The iodide has
been shown to be non-labile, and therefore interconversion does not occur for
separated enantiomers of iodido complex 4. Pharmacological development of
therapeutics tends to favour enantiomerically pure substances, meaning that
this is a promising result for complex 4. Future drug development of similar
organoiridium complexes with iodido ligands are likely to have stable, isolat-
able enantiomers which can be tested for di↵ering biological properties. This
is discussed further in Chapter 6.
That the Ir-I bond is more resistant to hydrolysis than Ir-Cl is somewhat
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unexpected. Cl is more electronegative than I and so it may be expected that
the bond with the highly electropositive iridium(III) centre would be stronger
with chlorine. Additionally, comparison of the x-ray crystal structures show
that the Ir-I bond is longer than Ir-Cl bond in similar complexes (Table 3.9,
pg. 90), this is in agreement with literature on similar complexes.94 The
strength of the Ir-I bond may come from the larger van der Waals dispersion
forces associated with bonds with large atoms such as iodine. The hydrolysis of
the Ru-halide bonds of ruthenium arene complexes has been studied, revealing
that in such systems, Ru-I bonds also hydrolyse less readily than Ru-Cl bonds.
Calculations of the related reaction energies and reaction barriers to aquation
confirmed that the resistance of Ru-I bonds to hydrolysis was due to the higher
activation energies inherent in Ru-I hydrolysis relative to Ru-Cl.114 This may
also be the case for Ir-halides.
3.4.2 Structure-Activity Relationships
There is a general correlation of Cpxbiph complexes being more potent than
their Cpxph and Cp* analogues. The cyclopentadienyl ligand does not seem to
have a large e↵ect on the MoA, and most likely contributes to the level of cellu-
lar uptake of the complexes, as is the case in similar organoiridium complexes
previously reported in which extension of the Cp system increased uptake,
leading to greater cytotoxicity.86 There is a more complex relation between
hydrophobicity and potency than simply more hydrophobic complexes having
higher uptake and therefore being more potent, as evidenced in Table 3.10, pg.
93 and Figure 3.13, pg. 94. This is demonstrated by the highly hydrophobic
and weakly active complexes 11 and 19. The reason for the significantly low
activity of complex 19 relative to other complexes may be the high molecular
mass of its cation (995.26 Da) preventing su cient uptake into cells. Addition-
ally, the di↵erence in mass between this, and the cation of complex 1 (727.35
Da), the second largest, and most potent complex, is not overly large. The
presence of the bromine functional group on the pyridine may also be playing
a role in abrogating cytotoxicity, as it is the only feature completely unique to
complex 19 compared to the other complexes investigated in this work. An-
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other possibility is that the phenyl ortho hydroxyl hydrogens on complexes 11,
12 and 19 leave when in aqueous solution at physiological pH, allowing the
Ir to bind the oxygen atom instead of its chlorido ligand, potentially changing
the charge, shape, reactivity and biological properties of the complex. It could,
for example, entirely prevent the Ir from binding a key target site. ESI-MS
fragments of such O-chelated species have been observed for complex 11 but
not for complex 12 or 19. This may explain the surprising di↵erence in activ-
ity between complexes 11 and 12. Further investigations into the pKa values
of hydroxyl hydrogens of azpyOH complexes are in Chapter 5.
The presence of the monodentate iodido ligand increases the overall hydropho-
bicity of the complexes, however the iodido complexes 9 and 10 have lower
potency than their chlorido analogues 7 and 8, respectively. The iodido com-
plexes are inert to hydrolysis, a step that is necessary for the MoA of CDDP
and many other precious metal-based drugs. It is possible that the cytotoxic-
ity of the chlorido complexes arises from multiple MoAs, some of which could
involve hydrolysis at the metal-Cl bond and some not. Abrogation of hy-
drolysis by replacement with an iodido ligand could result in a complex that
cannot exert the same MoA as the chlorido complex, reducing cytotoxicity
as observed, however the remaining MoA/MoAs would allow the iodido com-
plexes to remain cytotoxic. That the iodido complexes remain highly cytotoxic
proves that hydrolysis is not an essential step in the MoA/MoAs of this family
of complexes. Another possibility is that the iodido complexes are activated
once in cells, as is the case for some reported organoosmium complexes.125
The hydrolysis data does, however, show 40% conversion of iodido complex to
chlorido complex at cell media chloride concentration after 24 h. While this
could mean that iodido complexes have the same MoA as chlorido complexes,
that only 40% conversion occurs after 24 h would mean that the the majority
of the complex would still be in the iodido form after 24 h, and even more so
in the hours up to that point after exposure. Additionally the concentration of
chloride in cell cytoplasm is ca. 5⇥ lower than in cell media. If hydrolysis was a
necessary step for anticancer activity, the unconverted iodido complexes would
therefore be significantly less active than their chlorido analogues, however this
is not the case. Therefore it is highly likely that the iodido complexes are able
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to be cytotoxic without prior conversion to chlorido analogues.
Within the Cpxbiph complexes tested, the azpyNMe2 complex 1 was the most
potent in A2780 ovarian carcinoma cells (Table 3.10, pg. 93), followed by
azpyOH complex 5, azpy complex 13, HOazpyNO2 complex 16 and finally
azpy(OH)2 complex 11. There is a noticeable trend that the functional group
or groups on the bidentate ligand have a profound e↵ect on the potency of the
complexes. Complexes with more electron donating groups on the bidentate
ligand. such as NMe2 and OH are more potent than those with neutral or elec-
tron withdrawing groups such as H and NO2. The varying levels of electron
donation by these functional groups a↵ect the nucleophilicity of the azopyri-
dine ligand. This may alter how much the ligand withdraws electron density
from the metal, thereby a↵ecting how readily it hydrolyses and reacts with
intracellular targets. It may also a↵ect the mechanism and rate of ROS/SO
generation, as well as other MoAs yet fully understood. A similar trend is seen
for the Cpxph analogues however this is not observed for the Cp* complexes,
indicating a more complex interplay between the e↵ects of the bidentate and
Cp ligands on potency.
The azpyNMe2, azpyOH and azpy ligands alone have been shown to be inac-
tive against A2780,126 as are the iridium dimers.94 Therefore, coordination to
iridium plays a key role in altering the chemical nature of both the complex
and the iridium-Cp system such that it can interact with biological targets
resulting in cytotoxicity. Complex 1 shows activity in the low nanomolar
range (IC50 = 95 nM) against A2780 cells. In comparison to organoruthenium
complexes bearing the same bidentate and chlorido ligands but di↵erent aro-
matic ligands (biphenyl and para-cymene),126 these organoiridium complexes
are ca. 2 – 4 orders of magnitude more potent, highlighting the importance
of the metal centre to potency. In comparison to organoosmium complexes
with similar structural di↵erences as described for organorutheniums,64 these
organoiridiums are ca. 1 order of magnitude more potent, with the excep-
tion of those bearing the azpy ligand, which are ca. 3 orders of magnitude
more potent. Many of the organoiridium complexes tested also exhibit supe-
rior potency to CDDP in multiple cell lines. In summary, these organoiridum
azopyridine complexes are some of the most potent organometallic anticancer
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complexes yet reported.
3.4.3 Catalysis of NADH Oxidation
An organoiridium complex with structure [(Cpxbiph)Ir(phenylpyridine)Cl]PF6
has been previously reported to catalyse the oxidation of NADH with the
generation of detectable levels of H2O2, as well as generating ROS/SO in
cells.127 A catalytic mechanism for NADH oxidation and H2O2 generation was
postulated: Hydrolysis of the Ir-Cl complex to Ir-OH2 followed by abstraction
of a hydride from NADH forming NAD+ and Ir-H then transfer of that hydride
to molecular oxygen. Supporting this mechanism is the identification of Ir-H
peaks in 1H-NMR spectra.84,86,101
Eleven organoiridium complexes were shown to catalyse NADH oxidation,
however only [Cp*Ir(HOazpyNO2)Cl]PF6 complex 18 generated detectable
levels of H2O2, as well as having the highest TON and TOF values. Inter-
estingly, its Cpxbiph and Cpxph analogues, complexes 16 and 17, respectively,
did not generate H2O2, and have lower TON and TOF values. Complexes 16
and 18 have almost identical IC50 values in A2780 cells and so any di↵erence
in behaviour was unexpected. A possible explanation is that the phenyl and
biphenyl groups sterically hinder the approach of NADH to the complex, thus
reducing the rate of catalysis. Another explanation could simply be that not
enough H2O2 is being generated by any of the other complexes to be detected
by the peroxide test sticks, however complex 19 has the same TON (albeit
lower TOF) as complex 18 yet it does not produce detectable levels of H2O2.
This implies that complexes 18 or 19 catalyse NADH oxidation by a di↵er-
ent mechanism to the other complexes tested. If, however, the mechanism of
NADH oxidation requires hydrolysis as a prerequisite then the TON and TOF
values are not comparable as they would be significantly a↵ected by the rate
of hydrolysis.
There is an inverse correlation between the rate of catalysis and potency. This
is surprising, but suggests that perhaps a factor that contributes to rapid
NADH oxidation, such as the presence of electron withdrawing groups on the
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azopyridine ligand, has the opposite e↵ect on potency, and that the MoA likely
does not involve NADH oxidation. The most potent complex, 1 exhibits the
lowest TON and TOF values whilst the least potent, complex 19, displays the
joint highest TON. Perhaps complexes 16 – 19 hydrolyse readily, contributing
to more rapid catalysis, however in cells this may lead to rapid deactivation
and reactions with o↵-target biomolecules, resulting in lower potency.
The iodido ligand has been shown to be inert to hydrolysis, however complex 4
shows some, if very low, catalytic activity. An alternative method of catalysis
has been previously proposed in which the azopyridine ligand is reduced.126
Such a mechanism would not require the hydrolysis of the Ir-halide bond and
could explain the catalytic activity of complex 4.
There is a strong correlation between the electron donating capacity of the
functional groups on the azopyridine ligand and the catalytic activity of the
complex as a whole. Complexes with the strongly electron-donating NMe2
group has the lowest catalytic activity, the neither electron-donating or -
withdrawing H group correlated with moderate catalytic activity and com-
plexes with the strongly electron-withdrawing group NO2 showed the highest
catalytic activity by ca. 5 – 10⇥. The electron withdrawing e↵ect of the
functional groups may be facilitating catalysis by the previously mentioned
azopyridine ligand reduction mechanism by making the azo nitrogen atoms
more positive, making the redox reaction more probable. Alternatively, the
level of electron donation/withdrawing on the metal centre could be govern-
ing the rate of catalysis, if loss of the halido ligand and formation of an Ir-H
intermediate is the mechanism by which NADH oxidation is taking place.
Complexes 1 – 3 show little capacity for NADH oxidation, suggesting that
NADH is not the primary target for redox perturbation for these complexes.
The opposite may be true for complexes 16 – 18 as they exhibit very high
TON and TOF values (ca. > 1.3⇥ TON and > 3.7⇥ TOF reported Ir(III)
complexes of similar structure under the same conditions.86,128
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3.4.4 Oxidative Stress
Complex 2 ([CpxphIr(azpyNMe2)Cl]PF6) generates higher levels of FL1 and
FL2 fluorescence (103 – 104 and 102 – 104, respectively) in A2780 than in
OE19 (102 – 103 and 101 – 102) or SUNE-1 cells (102 – 103 and ca. 102) and is
more cytotoxic to A2780. A possible explanation for this is that A2780 cells
have mutations in their OXPHOS machinery, and so they are already under
greater levels of oxidative stress.124 As such, they are vulnerable to further
ROS insult. In addition, complex 2 has been shown in previous literature
to prevent up-regulation of the genes coding for superoxide dismutase (SOD)
and catalase (CAT).120 These two enzymes are crucial components of the ROS
stress response pathway. SOD breaks down SO into oxygen and H2O2, which
CAT then breaks down into water and oxygen. This may explain the higher
level of SO observed in A2780 cells relative to the other cell lines tested. Dis-
ruption of SOD and CAT function has downstream e↵ects on other antioxidant
enzymes, further exacerbating the damage caused by ROS.129
ROS production by complex 2 may be occurring through mitochondria, as well
as by other mechanisms. An increase in mitochondrial ROS production has a
cyclic e↵ect on mitochondria, causing them to produce even higher levels of
ROS.130 This can lead to mitochondrial DNA damage, damage to mitochon-
drial proteins, and depolarisation of the mitochondrial membrane.131 The fact
that extreme mitochondrial membrane depolarisation is observed in OE19 cells
exposed to complexes 1 – 3 supports the increase of mitochondrial ROS as an
MoA for these complexes. Complex 2 shows a similar pattern of activity to
the organoosmium complex ([⌘6-p-cymene)Os(azpyNMe2)I]PF6). Disruption
of the mitochondrial membrane releases cytochrome c into the cytoplasm which
could possibly lead to the induction of intrinsic apoptosis pathways at a later
timepoint. This potent complex has been shown to increase ROS in cancer
cells, and Os has been shown to localise in the mitochondria of human ovar-
ian cancer cells exposed to it.132 The mitochondrion is a negatively-charged
organelle and consequently localisation of cations here is unsurprising. Addi-
tionally the hydrophobic and lipophilic nature of these complexes may also be
contributing to mitochondrial localisation.
140
3.4.5 Apoptosis
No significant induction of apoptosis was observed for complexes 1 – 3 after
24 h exposure, however after 48 h higher concentrations of complex 2 have
been shown to induce late apoptosis.120 After 72 h the cell population recovers.
This suggests a wave of apoptotic cell death occurs around the 48 h timepoint.
As the Cp system has proven to exert little e↵ect on the MoA, this is likely
to also be the case for complexes 1 and 3. The release of ROS has been
shown to modulate apoptosis and may therefore be playing a role in delaying
apoptosis.133 In the cytotoxicity assays the cells are exposed to complex for 24
h then allowed a further 72 h before cell survival percentages are determined.
Therefore the low level of cell death observed in the apoptosis assays after only
24 h can be reconciled with the IC50 data.
3.4.6 Cell Cycle Arrest
The e↵ect of complex 2 on the cell cycle after 24 h exposure is minimal at IC50
concentration, however, higher concentrations of 2 have been shown to induce
S-phase arrest in A2780 cells.120 This type of cell cycle arrest is most commonly
associated with DNA damage. Complex 2 could be damaging DNA directly as
part of its MoA, or DNA damage could be occurring as a consequence of ROS
generation, as DNA, especially its guanine bases,134 is a common target for
ROS. Ovarian cancers lack the proper tools for DNA damage repair.135 DNA
damage may therefore be contributing to the potency of complex 2 against
A2780.
It is surprising that the high levels of ROS and SO generated, along with
significant mitochondrial membrane depolarisation after 24 h do not correlate
with apoptosis or cell cycle disruption at the same timepoint. It would be
of interest to carry out future studies on apoptosis and cell cycle disruption
at later timepoint to determine when/if a wave of apoptosis and/or cell cycle
disruption occurs hours or days after mitochondrial membrane depolarisation.
Additionally, investigation into whether other apoptotic events such as caspase
activation and PARP cleavage occur at the 24 h timepoint would be valuable
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in further understanding the e↵ects that these complexes exert on cells and
how cells respond to these e↵ects.
3.4.7 GDSC Pharmaco-genomic Screen
Complex 2 shows great potential as an anticancer agent, exceeding the potency
of CDDP over a wide range of cancers of various tissue types. In particular,
complex 2 is over 5 orders of magnitude more potent than CDDP against the
OCUB-M cell line. OCUB-M is a triple negative breast cancer cell line,136
meaning that it does not express the gene for the estrogen, progesterone or
HER2 hormone receptors.137 As many breast cancer treatments utilise hor-
mone therapies that target these receptors, triple negative breast cancer is
typically more di cult to treat. This is therefore a promising result for com-
plex 2. Additionally, complex 2 has previously been shown to be active against
MDA-MB-468,102 another triple negative breast cancer cell line.
MDA-MB-468 is likely more susceptible to ROS generation as it exhibits
a glucose-6-phosphate dehydrogenase A phenotype. This phenotype means
that the glucose-6-phosphate dehydrogenase enzyme does not function prop-
erly. A consequence of this is that conversion of glucose-6- phosphate to 6-
phosphoglucono- -lactone cannot take place. Because of this, NADPH forma-
tion from NADP+ cannot occur by this pathway. As NADPH formation is
an essential component of gluthathione (GSH) synthesis, MDA-MB-468 cells
may therefore display a degree of GSH deficiency. As GSH is a key cellular
antioxidant, this may result in susceptibility of MDA-MB-468 cells to ROS-
generating agents.102 Complex 2 is shown here to generate high levels of ROS
in A2780, OE19 and SUNE-1 cell lines, and so a ROS-based MoA may be sig-
nificantly contributing to its potent activity against this, and other cell lines.
In a smaller scale screen complex 2 previously exhibited a pattern of antipro-
liferative activity correlating with drugs that have oxidative stress MoAs.102
Postulation of a ROS-based MoA for complex 2 is further supported by its sim-
ilar resistance profile to piperlongumine, a drug that also relies on a ROS-based
MoA to kill cancer cells, involving depletion of cellular GSH, ROS-induced
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DNA damage, and induction of apoptosis.122,123 Piperlongumine, however,
does not generate SO, whereas complexes 1 – 3 do. That half of the 10 cell
lines most resistant to complex 2 are also least sensitive to piperlongumine
over the 251 other drugs in the screen is highly significant. It is feasible that
these cells possess a common factor or factors, such as cellular machinery more
capable of dealing with ROS insults, for example, higher levels of intracellular
antioxidants such as GSH.
The MoAs of complex 2 may be heavily dependent on the bidentate chelating
azpyNMe2 ligand. Comparison of the activity level of this complex to other
complexes of similar structure with di↵erent bidentate ligands revealed that
the azpyNMe2 ligand confers a significant increase in potency.102 The similar-
ity analysis showed that complex 2 has a similar pattern of antiproliferative
activity to two organoosmium complexes, both of which bear the azpyNMe2
ligand. It is particularly interesting that these complexes show such striking
similarities despite having a di↵erent Cp ligand, di↵erent monodentate halido
ligand, and di↵erent metal centre. This highlights the significant impact of
the bidentate ligand on the MoA.
Other organoosmium complexes with similar structures but di↵erent bidentate
ligand included in the screen were not flagged as having a similar cytotoxicity
profile to complex 2, therefore the presence of the azpyNMe2 ligand seems to
have the most significant implications to cytotoxic selectivity and MoA, more
so than the metal centre, Cp system or halide. The e↵ect of the NMe2 func-
tional group of this ligand on the chemical behaviour and anticancer potency
of organoiridium complexes is investigated further in Chapter 4.
The large-scale screen also identified complex 2 as being the only drug out
of the 253 screened to which mutations in the KIT gene conferred sensitiv-
ity. KIT mutations have also been associated with an increased sensitivity to
imatinib. Functional C-KIT often confers chemoresistance by augmenting the
expression of DNA repair genes. The mutated KIT gene may therefore render
cells more sensitive to DNA damage. DNA may therefore be a target for com-
plex 2. This is further supported by correlations of the cytotoxicity pattern of
complex 2 with those of a DNA-damaging drug revealed by COMPARE anal-
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ysis.102 Additionally, investigation into the expression levels of DNA damage
response proteins of A2780 cells exposed to complex 2 revealed the mobili-
sation of a BRCA1 DNA damage response, indicating that complex 2 had
caused DNA damage.120 The capability of complex 1, the Cpxbiph analogue of
complex 2, to damage DNA, is investigated thoroughly in Chapter 4.
3.5 Conclusions
Organoiridium azopyridine complexes represent a largely untapped area of
chemical space, however they show promise as anticancer agents. Most of
the complexes in this work exhibit superior activity to CDDP in multiple cell
lines as well as having lower IC50 values than a large proportion of previously
published precious metal-based drugs. Additionally, some are highly active in
CDDP-resistant cell lines.
Current pharmaco-genomic and experimental evidence supports a redox-based
MoA, involving the disruption of the redox balance in cancer cells by generation
of ROS and SO. This also holds the potential for ROS-based damage to the
mitochondrial membrane, in addition to DNA and proteins, resulting in S-
phase cell cycle arrest, a wave of apoptosis, and necrosis. This is a promising
MoA for organoiridium azopyridine complexes as cancer cells have higher levels
of basal ROS than normal cells and are more sensitive to perturbations in their
redox balance, thus cancer cells can be selectively killed whilst minimising
risk to normal cells. Additionally, MoAs targeting the ROS stress response
pathway hold the potential to circumvent cross-resistance with conventional
DNA-targeting drugs such as CDDP, as well as many other clinically-used
therapeutics.
Organoiridium azopyridine complexes are easily tunable, allowing for the gen-
eration of complexes in high yields with di↵erent Cp systems, halides and
bidentate ligands by simple synthetic procedures. Studies of the structure-
activity relationships of these complexes has revealed how changing these lig-
ands alters their chemical and biological properties in a variety of ways.
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The Cp system stabilises the Ir complex as well as a↵ecting hydrophobicity and
potency, with extension of the Cp system most likely contributing to increased
cellular uptake leading to greater cytotoxicity.
The halide determines whether the complex hydrolyses or not, which may have
implications towards binding to intracellular biomolecules as well as whether
stable chiral enantiomers of the complex can be isolated.
The bidentate ligand has the greatest e↵ect on the MoA of the complexes,
ligands with electron-withdrawing functional groups confer rapid catalytic ox-
idation of NADH whereas those with electron-donating groups confer potent
antiproliferative activity.
The work in this chapter illustrates the potency and versatility of organoirid-
ium complexes as anticancer agents and reveals valuable information about
the e↵ects of the various ligands on their behaviour, thereby informing future
development of these drugs towards clinical application. Not only do they per-
form impressively as antiproliferative agents, but one can dramatically change
the properties of the complexes with small, synthetically trivial adjustments.
This makes an e↵ective basis for future drug discovery with the potential for
uncovering new MoAs against cancer and overcoming the growing problems as-
sociated with acquired chemotherapeutic resistance and ultimately improving
the prognosis of cancer patients.
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Chapter 4
Impact of the Azopyridine
Ligand on MoA
4.1 Introduction
Genomic instability is a substantial factor in cancer formation and progression.
DNA damage, defects in replication or repair, combined with a failure to
halt the cell cycle before the damaged DNA is passed on to daughter cells
all contribute to carcinogenesis. These genomic defects do, however, provide
targets that can be exploited to combat the disease.138
One of the foundations of cancer therapy is drug-induced damage to can-
cer DNA. This is achieved by a variety of chemotherapeutics, such as cis-
platin (CDDP) and its derivatives such as carboplatin, which damage DNA
by crosslinking guanine bases. Other examples are the drug temozolomide,
which alkylates DNA bases, and etoposide, which inhibits the enzyme topoi-
somerase II, thereby inducing single or double strand breaks in DNA.139,140
However, whilst CDDP most e↵ectively kills rapidly proliferating cells such as
cancers,141 it can still cause damage to rapidly proliferating normal cells,142
leading to unpleasant side e↵ects such as nephrotoxicity, ototoxicity, vomiting
and hair loss. Nephrotoxicity is currently the dose limiting factor in CDDP
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treatment.143 This illustrates the need to develop novel, more selective anti-
cancer treatments that attack cancer in new ways with minimal side-e↵ects.
CDDP is of particular relevance as it set a precedent for a great deal of heavy
metal-based chemotherapeutic innovation since its anticancer properties were
discovered in 1965. CDDP is administered alone or in combination with other
therapeutics. Advanced ovarian cancer, for example, is often treated with a
combination of CDDP and the tubulin-targeting drug paclitaxel. Many can-
cers are insensitive to treatment with only one drug and so multiple therapeu-
tics, or indeed one therapeutic with multiple mechanisms of action (MoAs),
provide a way to treat such cancers.
Organoiridium complexes that combat cancer utilising one or more MoAs have
been reported.144–146 Examples include induction of autophagy,147 antiangio-
genesis,146 redox modulation,84,145,148 perturbation of mitochondrial membrane
potential,127 transfer hydrogenation,101,149 induction of apoptosis,150 and DNA
interactions.81,151,152 As such, they show promise as single- and polypharma-
cological anticancer agents.
A second problem hampering the e cacy of many Pt-based DNA-targeting
chemotherapeutics is intrinsic and acquired resistance. Cancer cells can utilise
cellular processes such as nucleotide excision repair (NER), mismatch repair
(MMR), homologous recombination repair (HRR), and translesion synthe-
sis to remove CDDP-DNA adducts and thereby reduce the antitumour e -
cacy of CDDP treatment.153 Other mechanisms such as decreased drug up-
take, increased drug e✏ux, and higher intracellular levels of drug-inactivating
molecules, such as glutathione (GSH), further contribute to CDDP resis-
tance.154
These factors illustrate the need to overcome these obstacles without compro-
mising anticancer activity. New metal-based therapeutics o↵er promising ways
to do so.
Organometallic anticancer complexes that interact with DNA have been
reported.155–157 Ir(III) complexes can do so through a variety of mecha-
nisms158,159 such as intercalation,160 coordination to nucleotides,92,102,161,162
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binding to quadruplex DNA,163 strand cleavage,164 and groove binding.165 In
doing so, they exert cytotoxic and cytostatic e↵ects on cancer cells.
In order to overcome the increasing problem of cancer drug resistance, it is of
paramount importance that new chemotherapeutics are produced that either
target cancer DNA in di↵erent ways to current chemotherapeutics or aug-
ment/replace DNA targeting with other e↵ective MoAs. The Pt drug CDDP
and its derivatives, in particular, have been well-researched. The anticancer
properties of Ir-based chemotherapeutics are comparatively less well explored.
An organoiridium half-sandwich complex incorporating a pentamethyl cy-
clopentadienyl ligand and an N,N-chelating ligand has previously been re-
ported to be active against cancer cell lines displaying both intrinsic and ac-
quired CDDP resistance.158
Synthetic extension of the Cp system by the addition of phenyl rings has been
shown to increase the hydrophobicity, cellular uptake and consequently the
anticancer potency of many organoiridium half-sandwich complexes.86,92,101
Additionally, it has been shown that the coordination of a strong ⇡-acceptor
phenylazopyridine ligand to a metal centre significantly a↵ects the chemical
and biological behaviour, depending on the nature of the substituents on the
phenyl ring, in organometallic complexes of Ru,126 Os66 and Ir.102
The previously reported Ir(III) complex [CpxphIr(azpyNMe2)Cl]PF6 (Complex
2) has shown potent anticancer activity against the A2780 ovarian carcinoma
cell line in vitro, in addition to cell lines of the NCI-60 panel and large-scale
GDSC pharmaco-genomic screen (see Chapter 3), displaying greater average
potency than CDDP.102 The presence of the azpyNMe2 bidentate ligand con-
fers high potency to this complex when compared to others of similar structure
with di↵erent bidentate azopyridine ligands. The NMe2 family of complexes
in particular showed great promise as anticancer agents. The significance of
this functional group, with regards to anticancer potency and MoA, warrants
investigation.
In this chapter, two novel Ir(III) complexes, each bearing a Cpxbiph system,
a bidentate phenylazopyridine ligand, and a monodentate chlorido ligand, are
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studied (Figure 4.1). The sole structural di↵erence between them is the func-
tional group in the para-position of the phenylazopyridine phenyl ring. Com-
plex 1 bears the NMe2 group, whilst complex 13 bears hydrogen (i.e. an
unsubstitued para position). Their stability, anticancer potency, selectivity,
and e cacy against dsDNA virus-infected and CDDP-resistant cell lines have
been assessed and a panel of experiments carried out to investigate di↵erences
in their MoAs.
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Figure 4.1: Complexes 1 and 13 studied in this chapter.
Based on previously reported work on similar complexes, in addition to the
results described in Chapter 3, DNA interaction and induction of oxidative
stress are hypothesised as possible MoAs for these complexes. Thorough in-
vestigations are made into the way these complexes interact with DNA, as well
as their capacity to generate reactive oxygen species (ROS) and interact with
antioxidants.
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4.2 Experimental Methods
4.2.1 DNA Interaction Studies
Oligonucleotide binding studies, UV studies, dichroism studies, ethidium bro-
mide (EtBr) flourescence experiments and gel electrophoresis experiments on
complexes 1 and 13 were carried out by the Brabec Group, Institute of Bio-
physics, Academy of Sciences of the Czech Republic.
4.2.1.1 Nucleotide Interactions
Solutions of 1:1 complex:nucleotide at 300 µM (5-AMP, 5-GMP, 5-CMP or
5-TMP) were prepared in 5% CD3CN:D2O. 1H-NMR spectra were taken on a
600 MHz NMR machine at 310 K 10 min after mixing and after 24 h incubation
at 310 K. All stocks and solids were pre-incubated at 310 K.
4.2.1.2 Bu↵er Preparation
Experiments were carried out in either 0.01 M Tris-HCl bu↵er or phosphate
bu↵er, as detailed in the appropriate section.
Phosphate bu↵er (100 mL, 0.1 M, pH = 7.4) was prepared by mixing 40.5 mL
0.2 M sodium phosphate, dibasic dihydrate (Na2HPO4•2H2O) with 9.5 mL 0.2
M sodium phosphate, monobasic monohydrate (NaH2PO4•H2O) and 50 mL
H2O. This was further diluted as required in 18.2 Milli-Q H2O.
4.2.1.3 Preparation of ctDNA
Deoxyribonucleic acid sodium salt from calf thymus, Type I, fibres (ctDNA)
was purchased from Sigma Aldrich (UK) and a 2 mg/ml solution in 10 mM
bu↵er was prepared by gentle stirring then incubation at 277 K for 24 h fol-
lowed by gentle mixing by inspiration/aspiration by micropipette. This was
diluted as appropriate in bu↵er. The solution was either used immediately
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or frozen at 193 K until the day of the experiment then thawed at ambient
temperature and used immediately.
To confirm the DNA was protein-free the solution was standardized spec-
trophotometrically before freezing and after thawing (Figure 4.2).
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Figure 4.2: UV-Vis spectrum of ctDNA in phosphate bu↵er diluted further in
phosphate bu↵er so A  1. A260/A280   1.8 so the DNA is su ciently pure
and protein-free.166 The base pair concentration of the DNA was calculated
from the spectrum using its known molar absorption coe cient at 260 nm
(6600 M  1cm 1).167
4.2.1.4 Dichroism Studies
Linear and circular dichroism studies carried out on ctDNA in 0.01 M Tris.HCl
(pH 7.4, 310 K) incubated with increasing concentrations of complex 1 or 13.
4.2.1.5 Gel Electrophoresis
Native gel electrophoresis was carried out on supercoiled plasmid DNA
(pBR322) incubated with complex for 24 h at 310 K.
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4.3 Results
4.3.1 Intracellular Aquation
The MoA of a drug is often linked to the behaviour of the complex when
in aqueous solution. CDDP’s MoA is reliant on the lability of the chlorides
bound to the Pt centre. In Chapter 3, the extent of hydrolysis of complex 1
was investigated. More in-depth kinetic investigations are now carried out to
better describe the hydrolysis process for complex 1.
A hydrolysis equilibrium between chloride-bound Ir and water-bound Ir gov-
erned by chloride concentration is hypothesised (Figure 4.3).
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Figure 4.3: Proposed hydrolysis equilibrium for the complexes studied in this
work. Aquation monitored by following the chemical shift of 1H-NMR peaks
corresponding to NMe2 hydrogens for complex 1 or Cpx ring methyl hydrogens
for complex 13 coloured above.
1H-NMR experiments were carried out in which a spectrum of a 100 µM so-
lution of complex 1 in 10% d6-DMSO:D2O, 0.1% 1,4-dioxane (v/v) at 310
K, unbu↵ered at pD 8 with no chloride was taken every hour to monitor the
kinetics of hydrolysis (Figure 4.4). In addition, experiments were carried out
in parallel in 120 mM NaCl solution to simulate the chloride concentration
present in the cell growth medium used for in vitro cancer cell experiments.
152
Figure 4.4: Monitoring of the hydrolysis of complex 1 by 600 MHz 1H-NMR
spectra of a 100 µM solution of complex 1 in 10% d6-DMSO:D2O, 0.1% 1,4-
dioxane (v/v) at 310 K, unbu↵ered at pD 8 by tracking peaks corresponding to
NMe2 hydrogens. (A) 10 min after sample preparation, (B) 24 h after sample
preparation, (C) 24 h after sample preparation in 120 mM NaCl solution, (D)
Relative % integrals of peaks corresponding to NMe2 hydrogens of complex 1
tracked over 24 h.
Further experiments were carried out in the presence of 4 mM, 23 mM and 104
mM NaCl to simulate the chloride concentration in the cell nucleus, cytosol
and blood plasma, respectively168 (Figure 4.5 – 4.8) Thus the nature of the
complexes both in aqueous solution and in an intracellular environment can
be predicted.
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Figure 4.5: Aliphatic region of 600 MHz 1H-NMR spectra of 100 µM solutions
of complex 1 in 10% d6-DMSO:D2O, 0.1% 1,4-dioxane (v/v) at 310 K, un-
bu↵ered at pD 8 incubated with chloride at 4 mM, 23 mM, 104 mM and 120
mM for 10 min.
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Figure 4.6: Aliphatic region of 600 MHz 1H-NMR spectra of 100 µM solutions
of complex 1 in 10% d6-DMSO:D2O, 0.1% 1,4-dioxane (v/v) at 310 K, un-
bu↵ered at pD 8 incubated with chloride at 4 mM, 23 mM, 104 mM and 120
mM for 24 h.
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Figure 4.7: Aliphatic region of 600 MHz 1H-NMR spectra of 100 µM solutions
of complex 13 in 10% d6-DMSO:D2O, 0.1% 1,4-dioxane (v/v) at 310 K, un-
bu↵ered at pD 8 incubated with chloride at 4 mM, 23 mM, 104 mM and 120
mM for 10 min.
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Figure 4.8: Aliphatic region of 600 MHz 1H-NMR spectra of 100 µM solutions
of complex 13 in 10% d6-DMSO:D2O, 0.1% 1,4-dioxane (v/v) at 310 K, un-
bu↵ered at pD 8 incubated with chloride at 4 mM, 23 mM, 104 mM and 120
mM for 24 h. Emergent peaks denoted with red arrows.
The presence of chloride at 4 mM, 23 mM and 104 mM partially sup-
presses the hydrolysis of complex 1, but not 13. For complex 13 ([⌘5-
CpxbiphIr(azpy)Cl]PF6), new peaks are seen after 24 h, even in the presence of
120 mM NaCl and, as is the case for complex 1, two new species are observed.
ESI-MS peaks were observed for the cations of complexes 1 and 13 coordinated
to OH instead of Cl, with m/z = 709.2 and 666.2, most likely corresponding
to 1-OH (calculated m/z = 709.25) and 13-OH (calculated m/z = 666.21),
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respectively.
In Chapter 3, it was determined that the products of hydrolysis of complex 1
do not disappear upon the addition of chloride. To determine whether this is
the case for complex 13, the experiment was repeated without chloride, then
120 mM chloride was subsequently added after 24 h incubation as solid NaCl,
and another spectrum was taken (Figure 4.9).
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Figure 4.9: Aliphatic (top) and aromatic (bottom) regions of a 600 MHz 1H-
NMR spectrum of a 100 µM solution of complex 13 in 10% d6-DMSO:D2O,
0.1% 1,4-dioxane (v/v) at 310 K, unbu↵ered at pD 8. Spectrum taken 10
min after addition of 120 mM [Cl] to a previously chloride-free solution that
had been incubated for 24 h. Emergent peaks not corresponding to original
complex denoted by pink arrows. Traces of acetone/ether from the NMR tube
are visible.
Complex 1 undergoes 79% hydrolysis in 24 h and two new species are observed,
one appearing earlier and more rapidly than the other. This hydrolysis is
partially suppressed by   4 mM NaCl. Complex 13 undergoes hydrolysis
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even in the presence of 120 mM NaCl. Due to multiple overlapping peaks and
the complexity of the spectra, exact quantification of the extent of hydrolysis
was not possible for complex 13.
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4.3.2 Aqua Adduct pKa Determination
As complexes 1 and 13 do not have any bound hydrogens with pKa values
within a biologically-relevant or easily measurable pH range, experiments were
carried out to determine the pKa values for hydrogens on the bound H2O
ligands of their aqua adducts 1-OH2 and 13-OH2.
To investigate this, pH titrations were carried out and the samples analysed
by UV-vis spectroscopy. Data were plotted as absorbance at a maximum vs.
pH, and a Boltzmann sigmoidal curve was fitted to determine the midpoint
and therefore the pKa (Figure 4.10).
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Figure 4.10: UV spectra of pH titrations of complex 1 (Left) and complex 13
(Right) after 24 h incubation in H2O to form aqua adducts. Arrows indicate
the e↵ect of base addition. Plots of absorbances at maxima vs. pH shown
beneath UV spectra.
The changes in the absorbance maximum at 640 nm upon base addition did not
follow the expected Boltzmann sigmoidal curve for 1-OH2 and so determina-
tion of its pKa value was not possible. No significant changes in the spectrum
of complex 13 were observed over pH range ca. 3 – 8, nor was an isosbestic
point observed. Therefore no pKa value could be obtained for 13-OH2.
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4.3.3 Nucleotide Binding Studies
Direct coordination of anticancer complexes to DNA base pairs is a well-known
mechanism of anticancer action. Preliminary investigations into potential nu-
cleotide binding properties of the complexes were carried out by LC-MS (Ap-
pendix Figures S22 – S30, pg. 295 – 303) 1H-NMR studies on 1:1 solutions
of nucleotide:complex. The nucleotides used were 5’-AMP, 5’-GMP, 5’-CMP,
and 5’-TMP (Figures 4.11 – 4.13).
5’-GMP  
24 h 
5’-CMP  
24 h 
5’-TMP  
24 h 
5’-AMP  
24 h 
Figure 4.11: Aromatic region of 400 MHz 1H-NMR spectra of 300 µM of nu-
cleotides 5’-AMP, 5’-GMP, 5’-CMP or 5’-TMP incubated in 50% MeOD:D2O
for 24 h at 310 K.
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Figure 4.12: Aromatic region of 400 MHz 1H-NMR spectra of 300 µM of nu-
cleotides 5’-AMP, 5’-GMP, 5’-CMP or 5’-TMP incubated with 300 µM com-
plex 1 in 50%MeOD:D2O for 24 h at 310 K. Peaks corresponding to nucleotides
denoted with blue triangles. Peaks corresponding to complex 1 or its products
of hydrolysis denoted with orange or red triangles, respectively.
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Figure 4.13: Aromatic region of 400 MHz 1H-NMR spectra of 300 µM of nu-
cleotides 5’-AMP, 5’-GMP, 5’-CMP or 5’-TMP incubated with 300 µM com-
plex 13 in 50% MeOD:D2O for 24 h at 310 K. Peaks corresponding to nu-
cleotides denoted with blue triangles. Peaks corresponding to complex 1 or its
products of hydrolysis denoted with orange triangles.
No significant new peaks that could correspond to complex-nucleotide adducts
appeared in any spectra after 24 h incubation at 310 K.
To further test for di↵erent DNA binding modes in a system more represen-
tative of cellular DNA, further investigations were carried out using oligonu-
cleotides containing a mixture of nucleobases, with one of the strands bear-
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ing only a single guanine for the purposes of detecting direct modification to
guanine, such as that achieved by CDDP. To test for direct modification to
nucleotides in a DNA strand, complexes were incubated for 24 h with a single
stranded (ss) or double stranded (ds) oligonucleotide radiolabelled with 32P at
its 5’-end then subjected to denaturation by 8 M urea, which disrupts the hy-
drogen bonding in DNA needed to maintain its structure (Figure 4.14). These
experiments were carried out by the Brabec Group, Institute of Biophysics,
Academy of Sciences of the Czech Republic.
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Figure 4.14: (Left) Autoradiogram of denaturing 24% PAA/8 M Urea gel.
22-mer single (ss)- or double-stranded (ds) oligonucleotide 32P-labeled at its
5’- end incubated with complexes at a ratio of 10 mol. of complex per one
mol. of oligonucleotide strand for 24 h at 310 K. (Right) Autoradiogram of
the products of the reaction between DMS and the 5’- end, 32P-labelled 22-
mer oligonucleotide. Lanes: 1, a Maxam-Gilbert-specific reaction (T-residues)
for the untreated oligonucleotide; 2, reaction of untreated oligonucleotide with
DMS; 3, DMS reaction with the product isolated from the gel after treatment
with complex 13.
There were no significant di↵erences between complex 1 and the control, how-
ever complex 13 induced the appearance of a new band corresponding to an
adduct of the complex with the oligonucleotide. This adduct was cut from
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the gel, the products eluted and purified by precipitation and subjected to
reaction with dimethyl sulphate (DMS) followed by hot piperidine. If the N7
site of guanine is unmetallated, DMS will specifically methylate this site and
hot piperidine will be able to cleave DNA at guanine, and a band will be
seen corresponding to the cleaved strand. However, no bands for cleaved DNA
were seen for the 13-DNA adduct. Therefore, DMS was unreactive to it.
Therefore, it is highly likely that complex 13 metallates guanine at N7.
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4.3.4 Ultraviolet-Visible (UV-Vis) Spectroscopy of
ctDNA
Preliminary examination of a complex’s a nity for DNA was carried out using
UV-Vis spectroscopy. Increasing amounts of ctDNA were added to 20 µM of
complex in 0.01 M Tris.HCl bu↵er (pH 7.4, 295 K) and the consequential
decrease in relative absorbance at the complex’s maxima measured (Figure
4.15). These experiments were carried out by the Brabec Group, Institute of
Biophysics, Academy of Sciences of the Czech Republic.
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Figure 4.15: Absorption spectra of 20 µM of complex 1 (Top Left) and com-
plex 13 (Top Right) in 0.01 M Tris.HCl bu↵er (pH 7.4, 295 K) after 10 min
incubation with increasing amounts of ctDNA. The arrow indicates the absorp-
tion changes upon increasing concentration of ctDNA. (Bottom) A comparison
of the relative absorbances of the complexes at their corresponding maxima
(those above 300 nm where DNA does not absorb) upon increasing ctDNA
concentration.
After 10 min incubation the absorption change is far more pronounced for
complex 1, however, the size of the absorbance change may vary between
complexes, therefore further experiments are required to better understand
their DNA-interacting properties.
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4.3.5 Linear Dichroism (LD) of ctDNA
Due to the linear nature of its superstructure, ctDNA molecules generate a LD
spectra when aligned in a couette. The e↵ect of complexes on the alignment of
DNA can be measured by LD. As such, solutions of unaligned small molecules
alone, such as the complexes studied in this work, do not produce LD peaks.
However, if the complexes interact with DNA in a specific, regular orientation
they will align and therefore induce an LD peak in the region in which they
absorb. LD titrations were performed on ctDNA incubated with complexes 1
or 13 for 24 h (Figure 4.16). These experiments were carried out by the Brabec
Group, Institute of Biophysics, Academy of Sciences of the Czech Republic.
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Figure 4.16: LD spectra of ctDNA after 24 h incubation with increasing con-
centration of complex 1 (Top Left) and 13 (Top Right) in 0.01 M Tris.HCl
(pH 7.4, 310 K). (Bottom) Comparison of the LD signal of ctDNA at 260 nm
upon addition of complexes 1 or 13.
Complex 1 induces a negative LD signal in the visible light region of the LD
spectrum, at around 600 – 700 nm, mirroring that of its UV-Vis absorbance
spectrum. This shows that it interacts with ctDNA, as ctDNA alone does
not produce an LD signal above 300 nm. The magnitude of this signal is
proportional to the ratio of complex to DNA bases. In contrast, no induced
LD signal is visible upon addition of complex 13 to ctDNA. Additionally, the
LD signal of ctDNA at 260 nm is reduced upon addition of either complex,
indicating delinearisation of the DNA. The magnitude of this reduction is
significantly greater for complex 13 than for complex 1.
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4.3.6 Circular Dichroism (CD) of ctDNA
CD measures the di↵erence in absorbances between left and right-handed cir-
cularly polarised light. Due to its helical nature, ctDNA produces a distinctive
CD spectrum. If a complex interacts with DNA in a specific orientation it can
generate a CD peak due to the induced chirality generated by its presence.
To assess the e↵ects of complexes 1 and 13 on the CD spectrum of ctDNA,
CD titrations were performed on ctDNA incubated with complexes 1 and 13
for 10 min and 24 h (Figure 4.17). These experiments were carried out by
the Brabec Group, Institute of Biophysics, Academy of Sciences of the Czech
Republic.
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Figure 4.17: CD spectra of ctDNA after 10 min incubation with increasing
concentration of complex 1 (Top left) or 13 (Top right) or 24 h incubation
with complex 1 (Bottom left) or 13 (Bottom right) in 0.01 M Tris.HCl (pH
7.4, 310 K).
An induced positive band is observed in the CD spectrum in the 500 – 600 nm
region 10 min after addition of the azpyNMe2 complex 1. However, this is no
longer visible after 24 h. The azpy complex 13 induces no CD signal in the
visible light region after 10 min or 24 h of incubation with complex 13. The
magnitude of the CD signals produced by ctDNA at 244 nm (due to helicity)
and 274 nm (due to base stacking) are significantly reduced by complex 1
and even more so by complex 13 after 24 h. Chiral molecules absorb left
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and right-handed circularly polarised light di↵erently, generating CD spectra.
Conversely, racemic mixtures do not induce any CD signals. That complex 1
has been shown to exist as a racemic mixture in Chapter 3 further confirms
that the induced positive band is due to DNA modification.
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4.3.7 Ethidium Bromide (EtBr) DNA-Binding Studies
EtBr is a fluorescent molecule with a central heterocyclic phenanthroline moi-
ety that intercalates into the major groove of DNA. Intercalating agents force
apart the base pairs of DNA, partially unwinding the double helix and causing
the overall length of the strand to increase. Since viscosity is proportional to
the cube of the length of the DNA in the solution, intercalation can translate
into comparatively large changes in viscosity.169 Measurement of DNA viscos-
ity upon incubation with complexes 1 and 13 for 10 min or 24 h showed no
significant changes in viscosity (Figure 4.18). These experiments were carried
out by the Brabec Group, Institute of Biophysics, Academy of Sciences of the
Czech Republic.
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Figure 4.18: (Left) EtBr. (Right) The relative specific viscosity of ctDNA
solution after 10 min or 24 h incubation with complex 1 or complex 13 in
a 0.01 M Tris.HCl bu↵er at 310 K. ⌘ is the viscosity of the solution in the
presence of complexes and ⌘✓ is the viscosity of the control (DNA without
complex). DNA solution viscosity after 10 min incubation with EtBr also
shown.
When EtBr binds DNA its fluorescence increases ca. 20-fold. This is due to its
outer phenyl ring projecting out into the hydrophobic environment between
the base pairs. Here the rate of transfer of excited state photons to water
molecules is reduced, as is the fluorescence quenching e↵ect of water on EtBr,
and fluorescence increases.170 If EtBr is displaced from DNA, or its binding is
inhibited, there is a measurable decrease in fluorescence. The DNA-interacting
capability of complexes can be deduced from the e↵ects on EtBr fluorescence,
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and so EtBr binding studies were carried out with complexes 1 and 13 (Figure
4.19). Addition of complex 1 to DNA treated with EtBr causes a significant
decrease in EtBr fluorescence after 10 min, whereas only a small decrease is
observed upon complex 13 addition. Conversely, EtBr binding was inhibited
for DNA incubated with the complexes over 24 h. Complex 1 inhibits EtBr
binding slightly more than complex 13, and the level of inhibition is dependent
on complex concentration.
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Figure 4.19: (Left) EtBr displacement by complexes 1 and 13. ctDNA (3.9
µM) pretreated with EtBr (1.3 µM) was titrated and incubated for 10 min
with increasing concentrations of complexes in 0.01 M Tris.HCl bu↵er (pH
7.4, 310 K). (Right) Inhibition of EtBr intercalation by complexes 1 and 13.
ctDNA was incubated with complexes for 24 h then EtBr was added and its
fluorescence measured.
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4.3.8 DNA Unwinding and Scission
Cellular DNA is often supercoiled. Unwinding or damaging cancer DNA can
have implications for cell survival. To unwind supercoiled DNA, a nick must
be made in the DNA deoxyribose-phosphate backbone between two bases to
allow it to unwind into its relaxed form. To investigate the e↵ects of the
complexes on circular supercoiled dsDNA, electrophoresis studies were carried
out using the dsDNA plasmid pBR322 (Figure 4.20). These experiments were
carried out by the Brabec Group, Institute of Biophysics, Academy of Sciences
of the Czech Republic.
Figure 4.20: Native gel electrophoresis studies of unwinding of supercoiled (sc)
plasmid DNA (pBR322) into open-circular (oc) form incubated with complexes
in 0.01 M Tris-HCl bu↵er (pH 7.4) for 10 min or 24 h at 310 K. [Ir]/[DNA]
ratio shown beneath lanes. The endonuclease EcoRI was used as the positive
control for DNA linearisation.
After 10 min incubation with complex 1, some unwinding of the plasmid was
observed, whereas complex 13 induced no changes. Conversely, the magnitude
of unwinding by complex 1 does not change significantly after 24 h incubation,
whereas plasmid incubated with complex 13 for 24 h is significanty unwound
even at concentrations as low as 1:200 complex:base pair. Additionally, com-
plex 13 generates bands in the gel corresponding to linearised (lin) DNA,
confirmed by the positive control of plasmid incubated with the endonuclease
EcoRI, which is known to cleave both DNA strands into linear fragments.
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4.3.9 Potency, Cross-resistance and Selectivity
The results obtained in Chapter 3 against A2780 ovarian carcinoma were com-
pared to A2780cis ovarian carcinoma with acquired CDDP resistance, A549
lung carcinoma and MRC-5 normal human lung fibroblasts. (Table 4.1). An-
tiproliferative screenings against A2780 and MRC-5 carried out by Dr. Isolda
Romero-Canelo´n, Ji-Inn Song and Bindy Heer.
Table 4.1: Comparison of IC50 values (in µM) of complexes 1, 13 and CDDP
across a panel of cell lines with standard deviations obtained from duplicates
of triplicate experiments. Cells were exposed to complex for 24 h, followed
by a 72 h recovery period in complex-free medium. Cell lines tested were
A2780 ovarian carcinoma, A2780cis ovarian carcinoma with acquired CDDP
resistance, A549 lung carcinoma, CNE1 and CNE2 nasopharyngeal carcino-
mas, and MRC-5 normal human lung fibroblasts. CDDP IC50 values obtained
experimentally or from previously published work.145 (n.d. = not determined).
Complex A2780 A2780cis A549 CNE1 CNE2 MRC-5
1 0.095 ± 0.006 0.68 ± 0.03 2.7 ± 0.3 7.1 ± 0.8 0.98 ± 0.04 3.4 ± 0.5
13 0.126 ± 0.002 9.4 ± 0.7 10.9 ± 0.2 11.10 ± 0.009 4.7 ± 0.5 n.d.
CDDP 1.2 ± 0.2 11.5 ± 0.3 3.3 ± 0.1 7.7 ± 0.2 7.7 ± 0.3 16.2 ± 0.6
The cytotoxicity of complex 1 was superior to CDDP in all cell lines tested,
with an especially low nanomolar IC50 value against A2780. This is signifi-
cantly more potent than many reported precious metal-based chemotherapeu-
tics.
The selectivity of complex 1 was measured by comparing its cytotoxicity in
A2780 cells to MRC-5 normal (non-cancerous) lung fibroblasts (Table 4.2) to
allow for comparison with the selectivity of other reported complexes deter-
mined in the same way.84,171 These fibroblasts, like cancers, are fast-replicating,
so low toxicity towards these are likely to translate to even lower toxicity to
other healthy, slower replicating cells in patients. When comparing cytotox-
icity in A549 lung carcinoma to MRC-5 lung fibroblasts, complex 1 is 1.3⇥
selective, whereas CDDP is 4.9⇥ selective.
Acquired resistance to one drug can confer resistance to other drugs with
similar MoAs, resulting in cancers that are ultimately more di cult to treat.
The level of cross-resistance of complex 1 and 13 with CDDP was measured
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by comparing IC50 values in A2780 ovarian carcinoma and A2780cis ovarian
carcinoma with acquired CDDP resistance (Table 4.2).
Table 4.2: Comparison of cross-resistance and selectivity factors for complexes
and CDDP. Cross-resistance factor defined as IC50 in A2780cis/A2780. Selec-
tivity factor defined as IC50 in MRC-5/A2780 (n.d. = not determined).
Complex Cross-resistance Selectivity
1 7x 36x
13 75x n.d.
CDDP 10x 14x
Complex 1 was ca. 36⇥ more cytotoxic to A2780 than to MRC-5. In com-
parison, CDDP is ca. 14⇥ more cytotoxic to A2780 than to MRC-5. Both
complexes show a degree of cross resistance with CDDP, however complex 13
shows an order of magnitude higher cross-resistance than 1.
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4.3.10 MoA Studies in Ovarian Carcinoma by Flow Cy-
tometry
As complexes 1 and 13 are highly active against A2780 ovarian carcinoma,
further experiments were carried out on this cell line by flow cytometry to
assess for possible di↵erences in MoA by investigating the complexes’ ability
to produce ROS and superoxide (SO), induce apoptosis and disrupt the cell
cycle (Figures 4.21 – 4.23), the significance of which is detailed in Chapter 3.
As the complexes di↵er by only one functional group, any di↵erences in MoA
can be attributed directly to the presence of that group. Flow cytometry
studies carried out with the help of Dr. Isolda Romero-Canelo´n and Hannah
Bridgewater.
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4.3.10.1 ROS and Superoxide (SO) Generation
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Figure 4.21: Measurement of ROS and SO generation by flow cytometry of
A2780 ovarian carcinoma cells exposed to complexes 1 (Left) and 13 (Right)
for 24 h at IC50 concentrations at 310 K. Cells stained with orange/green fluo-
rescent reagents. Pyocyanin used as positive control (orange). (Bottom) Table
of % cell populations obtained from triplicate experiments. Statistical signif-
icance between cells exposed to complex vs. negative control was determined
by two-sample independent Welch t-tests assuming unequal variance between
populations with asterisks corresponding to p  0.05 *, p  0.01 **, p  0.001
***, p  0.0001 ****.
Both complexes generated very high levels of ROS and SO, with complex 13
generating slightly higher levels of both overall.
182
4.3.10.2 Cell Cycle Analysis
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Figure 4.22: Cell cycle analysis by flow cytometry of A2780 ovarian carcinoma
cells exposed to complexes 1 (Left) and 13 (Right) for 24 h at IC50 concen-
trations at 310 K. Cells stained with Propidium iodide (PI). (Bottom) Table
of % cell populations obtained from triplicate experiments. Statistical signif-
icance between cells exposed to complex vs. negative control was determined
by two-sample independent Welch t-tests assuming unequal variance between
populations with asterisks corresponding to p  0.05 *, p  0.01 **, p  0.001
***, p  0.0001 ****.
Complex 1 induces a small but statistically significant reduction in the G1-
phase population, whereas complex 13 induces a more significant reduction
in the G2-phase population. No significant accumulation of cells in any phase
was observed.
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4.3.10.3 Apoptosis Induction
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Figure 4.23: Measurement of apoptosis induction by flow cytometry of A2780
ovarian carcinoma cells exposed to complexes 1 (Left) and 13 (Right) for 24
h at IC50 concentrations at 310 K. Cells stained with Propidium iodide (PI).
(Bottom) Table of % cell populations obtained from triplicate experiments.
Statistical significance between cells exposed to complex vs. negative control
was determined by two-sample independent Welch t-tests assuming unequal
variance between populations with asterisks corresponding to p  0.05 *, p 
0.01 **, p  0.001 ***, p  0.0001 ****.
Exposure to complex 1 for 24 h causes a significant increase in the population
of non-viable cells without any visible induction of early or late-stage apopto-
sis. The same increase is seen for cells exposed to complex 13 but to a less
statistically significant degree.
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4.3.11 Interaction with Glutathione
Given that both complexes generate high levels of both ROS and SO in cells,
it is likely that their MoA is linked to the level of oxidative stress. Many
cancer cells counteract ROS level elevation by upregulation of cellular antiox-
idants such as glutathione (GSH). GSH is a redox-active tripeptide molecule
composed of the amino acids glycine, cysteine and glutamate (Figure 4.24).172
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Figure 4.24: (Left) Glutathione in its reduced form (GSH). (Right) Glu-
tathione in its its oxidised dimerised form (GSSG).
GSH is present in millimolar concentrations inside the cell and is involved in
a multitude of metabolic pathways. Inactivation of anticancer therapeutics
by GSH is common,173 and increased levels of intracellular GSH is one of
the mechanisms by which some cancers display resistance to CDDP.154 To
investigate whether GSH or its oxidised form glutathione disulphide (GSSG)
interacts with complex 1 and 13, 1:1 solutions of GSH/GSSG:complex were
studied by 1H-NMR (Figures 4.25 – 4.32) and LC-MS (Appendix Figures S31
– S39, pg. 304 – 312).
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Figure 4.25: Aliphatic region of 600 MHz 1H-NMR spectra of a 300 µM so-
lution of complex 1 in 25% MeOD:D2O, 0.1% 1,4-dioxane (v/v) at 310 K,
unbu↵ered at pH 7 incubated with 300 µM GSH for 10 min. Traces of ace-
tone/ether from the NMR tube are visible.
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Figure 4.26: Aliphatic region of 600 MHz 1H-NMR spectra of a 300 µM so-
lution of complex 1 in 25% MeOD:D2O, 0.1% 1,4-dioxane (v/v) at 310 K,
unbu↵ered at pH 7 incubated with 300 µM GSH for 24 h. Traces of ace-
tone/ether from the NMR tube are visible.
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Figure 4.27: Aliphatic region of 600 MHz 1H-NMR spectra of a 300 µM so-
lution of complex 1 in 25% MeOD:D2O, 0.1% 1,4-dioxane (v/v) at 310 K,
unbu↵ered at pH 7 incubated with 300 µM GSSG for 10 min. Traces of ace-
tone/ether from the NMR tube are visible.
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Figure 4.28: Aliphatic region of 600 MHz 1H-NMR spectra of a 300 µM so-
lution of complex 1 in 25% MeOD:D2O, 0.1% 1,4-dioxane (v/v) at 310 K,
unbu↵ered at pD 7 incubated with 300 µM GSSG for 24 h. Traces of ace-
tone/ether from the NMR tube are visible.
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Figure 4.29: Aliphatic region of 600 MHz 1H-NMR spectra of a 300 µM so-
lution of complex 13 in 25% MeOD:D2O, 0.1% 1,4-dioxane (v/v) at 310 K,
unbu↵ered at pH 7 incubated with 300 µM GSH for 10 min. Traces of ace-
tone/ether from the NMR tube are visible.
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Figure 4.30: Aliphatic region of 600 MHz 1H-NMR spectra of a 300 µM so-
lution of complex 13 in 25% MeOD:D2O, 0.1% 1,4-dioxane (v/v) at 310 K,
unbu↵ered at pH 7 incubated with 300 µM GSH for 24 h. Traces of ace-
tone/ether from the NMR tube are visible.
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Figure 4.31: Aliphatic region of 600 MHz 1H-NMR spectra of a 300 µM so-
lution of complex 13 in 25% MeOD:D2O, 0.1% 1,4-dioxane (v/v) at 310 K,
unbu↵ered at pH 7 incubated with 300 µM GSSG for 10 min. Traces of ace-
tone/ether from the NMR tube are visible.
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Figure 4.32: Aliphatic region of 600 MHz 1H-NMR spectra of a 300 µM so-
lution of complex 13 in 25% MeOD:D2O, 0.1% 1,4-dioxane (v/v) at 310 K,
unbu↵ered at pH 7 incubated with 300 µM GSSG for 24 h. Traces of ace-
tone/ether from the NMR tube are visible.
In the LC trace for complex 1 a small peak (1.9% of total peak area integrals)
corresponding to a GS adduct (1-GS) was observed, however the remaining
peak corresponded to the adduct-free cation of complex 1 only. No adducts
were seen of complex 13. Some very small changes were seen in the 1H-NMR
spectra of both complexes when incubated with GSH for 24 h. No interaction
of either complex with GSSG was observed by 1H-NMR or LC-MS.
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4.3.12 E↵ect of Redox Modulation on Anticancer Ac-
tivity
The rate-limiting step of GSH synthesis in cells is the linkage of the cysteine
and glutamic acid residue. This is catalysed by the enzyme  -glutamylcysteine
synthetase. The activity of this enzyme can be inhibited by L-buthionine-S,R-
sulfoximine (L-BSO), leading to lower cellular GSH levels. N-Acetylcysteine
(NAC) is a synthetic precursor to GSH, and so treatment with NAC will
increase cellular GSH levels. Co-administration of organometallic com-
plexes with L-BSO or NAC has previously been reported to alter cytotoxi-
city.84,102,104,125,171 To investigate how modulation of the level of GSH a↵ects
the anticancer potency of complexes 1 and 13, they were co-administered
with 5 µM of either L-BSO or NAC and their cytotoxicities determined in
EBV-positive OE19 oesophageal carcinoma and compared to the results for
administration of complex only (Figure 4.33). This cell line was selected in
order to compare IC50 values between EBV-negative and EBV-positive OE19
however the data for EBV-positive OE19 could not be fitted to Boltzmann
sigmoidal curves at the concentrations tested and so was instead presented
as complex concentration vs. % cell survival. Complex concentrations tested
were ca. 0.01 µM – 10 µM and 0.01 µM – 100 µM for CDDP and determined
exactly by ICP-OES and % cell survival normalised to negative controls as
described in Chapter 2.
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Figure 4.33: Cytotoxicities of complexes 1 and 13 and CDDP against EBV-
positive oesophageal carcinoma cells, co-administered with 5 µM of L-BSO,
NAC or neither. Drug treatment was for 24 h, followed by 72 h recovery pe-
riod. Data and standard deviations were obtained from duplicates of triplicate
experiments for cells co-administered with 5 µM of L-BSO, NAC. Data and
standard deviations were obtained from quadruplicates of triplicate experi-
ments for cells treated with no modulator (drug only).
Complex 1 displays superior cytotoxicity to both complex 13 and CDDP.
Complex 13 shows higher cytotoxicity than CDDP.
Co-administration of complexes 1 or 13 with NAC has no e↵ect on toxicity
towards this cell line within the standard deviations of the replicates. Co-
administration of complex 1 with L-BSO significantly reduces cytotoxicity
whereas it has is no significant e↵ect on the cytotoxicity of complex 13.
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4.4 Discussion
Discovery of the MoA and biological targets of a drug are important fac-
tors contributing to whether a new drug passes clinical trials. This work
in this chapter has taken significant steps in revealing some of these mech-
anisms for the novel complexes 1 ([⌘5-CpxbiphIr(azpyNMe2)Cl]PF6) and 13
([⌘5-CpxbiphIr(azpy)Cl]PF6). Previous research on organoiridium complexes of
similar structure to these has shown that they can have multiple target sites,145
and possess a variety of possible MoAs including, amongst others, DNA in-
tercalation,158 disruption of cellular redox balance,84 and NADH oxidation.86
Based on the results presented here, and in Chapter 3, it is probable that com-
plexes 1 and 13 utilise one or more of these to kill cancer cells. Considering
the enormous heterogeneity of cancer as a disease, the development of drugs
with polypharmacological MoAs may be a more e↵ective way to combat the
broad and complex range of cancers that exist, as opposed to single target
therapeutics.
4.4.1 Intracellular Aquation
It is apparent that both complexes hydrolyse in aqueous solution (Figure 4.4,
pg. 153) but are stable in organic solvents. This shows that upon addition
of H2O, the rate of the forward reaction, Ir-Cl to Ir-OH2, is far greater than
the backward reaction, Ir-OH2 to Ir-Cl. That the complexes do not appear
to hydrolyse to completion suggests that after 24 h an equilibrium point is
reached in which some of the complex remains in its Ir-Cl form. Surprisingly,
a third species is visible after 24 h in aqueous solution. While not confirmed,
this may be an hydroxido-bridged dimer of the complex, which would explain
why some peaks disappear after post-hydrolysis addition of NaCl (shift in
equilibrium causing OH2/OH species to convert back to Cl species) and some
new peaks remain despite the increase in chloride concentration (OH-bridged
iridium dimer). Hydroxido-bridged Cp* Ir dimers have been reported,94 there-
fore formation of hydroxido-bridged dimers is a feasible hypothesis, although
no ESI-MS peaks corresponding to such a dimer were observed. (Appendix
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Figure S40, pg. 313) A larger molecule such as an iridium dimer could eas-
ily fragment, increasing the di culty of observing its whole molecular ion in
ESI-MS experiments. A softer ionisation technique such as Matrix-assisted
laser desorption ionisation (MALDI) may be able to circumvent this problem.
Formation of DMSO adducts is unlikely as no peaks corresponding to DMSO
adducts were observed in ESI-MS spectra of DMSO:H2O solutions of either
complex.
Since the azpyNMe2, azpy and Cp ligands have been shown to be non-cytotoxic
to cancer cells,126 and both complexes continue to display potent cytotoxicity,
it is unlikely that breakdown of these complexes by loss of these ligands is
occurring, and the emergent NMR peaks are likely due to loss of chloride and
replacement by water. The observation of ESI-MS peaks corresponding to
1-OH and 13-OH, support this.
The pKa value for the aqua adducts of complexes 1 and 13 could not be de-
termined by UV pH titrations (Figure 4.10, pg. 162). However, alteration
of the pH did induce some small changes in their UV spectra. This may be
down to a complicated interplay between the equilibrium between Ir-Cl and Ir-
OH2/OH and that which exists between Ir-OH2 and Ir-OH dependent on pH.
Another possible explanation is that base addition, increasing the concentra-
tion of OH , further complicates the hydrolytic behaviour of the complexes.
The formation of hydroxido dimers, if this is indeed occurring, could even
further complicate the solution chemistry. It may also be possible to over-
come these obstacles by carrying out NMR experiments at varying pH values.
Nothing ws observed that could indicate deprotonation of ring methyls was
observed in NMR spectra of either complex.
Hydrolysis of complex 1 is completely suppressed by 120 mM chloride and
almost entirely suppressed by 4 – 104 mM chloride (Figures 4.4 and 4.5, pg.
153 and 154), suggesting that it will remain in the chloride-bound iridium form
in cell medium (DMEM/RPMI), as medium contains 120 mM chloride. Upon
reaching areas of the cell in which the chloride concentration is markedly lower,
such as the nucleus, some hydrolysis may take place, however the majority of
the complex would likely remain in the Ir-Cl form. This may result in non-
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coordinative interaction with DNA, rather than direct coordination of the
metal centre, such as that which is observed between CDDP and DNA.
That complex 13 hydrolysis is not suppressible by physiologically-relevant
levels of chloride (Figures 4.6 and 4.7, pg. 155 and 156) indicates that it
would likely hydrolyse in the cell nucleus. This could allow it to directly
coordinate to DNA. It could, however, also hydrolyse in the cell cytosol. This
may cause it to bind o↵-target molecules and could contribute to its lower
potency relative to complex 1.
Azopyridine ligands are strong ⇡-acceptors and will withdraw electron den-
sity from the metal to some extent. The only di↵erence between complexes
1 and 13 is the NMe2 functional group on the azopyridine ligand. This,
therefore, must be the reason behind the di↵erence in hydrolytic behaviour
between the two complexes. The electron donating e↵ect of complex 1’s
NMe2 group pushes electron density onto the Ir, which should weaken the
Ir-Cl bond thereby promoting hydrolysis, however complex 1 hydrolyses less
readily than complex 13. Additionally, the previously reported complex 2
([⌘5-CpxphIr(azpyNMe2)Cl]PF6) (structure in section 3.2.1) bearing the same
azpyNMe2 and chlorido ligands as 1 has been shown to be resistant to hy-
drolysis.102 Density functional theory (DFT) calculations could be used to
accurately determine the e↵ect of the NMe2 group on the Ir centre.
Conversely, in the case of complex 13, the lack of the electron donating e↵ect
of the NMe2 group may be altering the electronic state of the iridium to enough
of a degree, such that binding of water is greatly favoured over chloride, and
the presence of high levels of chloride does not shift the equilibrium enough to
entirely prevent hydrolysis.
These results indicate that, in cells, complex 1 would exist predominantly in
its chloride-bound form whereas most of complex 13 would be in its OH2/OH-
bound form. Therefore, complex 1 can still display nanomolar potency in mul-
tiple cell lines without activation by hydrolysis being necessary, unlike CDDP.
This is especially interesting as it exhibits much lower cross-resistance than
complex 13. Previously reported precious metal-based complexes of similar
structure have been shown to display cytotoxicity without hydrolysis.126,145
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4.4.2 DNA Binding and Cleavage
Exploration of the DNA-interacting properties of the complexes has revealed
some surprising di↵erences between complexes 1 and 13, despite their strong
structural similarities. The e↵ect of the di↵erence in just one functional group
between complexes 1 and 13 (NMe2 vs. H) on their e↵ects on DNA is large.
Given that another highly similar complex, bearing both the extended cy-
clopentadienyl system, an N,N-chelated bidentate ligand and a monodentate
chlorido ligand,158 showed DNA intercalation, it was surprising that neither
complex 1 nor 13 intercalates into DNA. While both can displace and inhibit
EtBr binding to DNA (Figure 4.19, pg. 177), this is not proof of intercala-
tion, as EtBr binding can be disturbed by other non-intercalative e↵ects on
the DNA, such as minor groove-binding. Furthermore, were intercalation oc-
curring, the viscosity of DNA would increase upon complex addition, which
it does not (Figure 4.18, pg. 176). Additionally, the UV-Vis spectra would
likely have shown a red or blue shift for the peaks of the complex if they were
intercalating into DNA, instead they remain at the same wavelengths (Figure
4.15, pg. 170). Furthermore, the LD signal would become more negative as
intercalation would lengthen the DNA and increase its rigidity, instead, the
opposite is observed (Figure 4.16, pg. 172). Thus intercalation with DNA is
unlikely for either complex.
Complex 13 has been shown to coordinate directly to guanine at N7, forming
a stable enough adduct as to persist after treatment with 8 M urea, which
disrupts the hydrogen bonding between bases and would remove any complex
not strongly bound to the oligonucleotide (Figure 4.14, pg. 167). CDDP is
also coordinates to guanine and this similarity may be a contributing factor
to the high cross-resistance of complex 13 with CDDP (Table 4.2, pg. 180),
if this was the case, then they may have similar MoAs. However, this has
only been observable in oligonucleotides and not in single nucleotides (Figure
4.13, pg. 165), although an oligonucleotide is a more representative model of
cellular DNA than single nucleotides are. An even more representative system
is ctDNA, in which CD and LD studies show a clear interaction with both
complexes (Figures 4.16 and 4.17, pg. 172 and 174). The induction of a CD
band by complex 1 proves its interaction with the DNA, and the LD signal
199
induced by complex 1 further supports this. Considering that intercalation
and direct nucleotide coordination have been ruled out for complex 1 yet it
can still interact with DNA and inhibit/displace EtBr (although DNA cleavage
may also be playing a part in displacing EtBr), the most likely binding site
for it is the DNA minor groove.
The di↵erences in mechanism of DNA modification and cleavage must be due
to the e↵ect of the NMe2 group. The electron donating e↵ect of this group
would make the iridium centre of complex 1 less positive than that of com-
plex 13, reducing its electrophilicity and possibly explaining its inability to
strongly coordinate to the N7 of guanine. Complex 13 would therefore have a
more electropositive centre allowing it to coordinate to N7 within 24 h. The
mechanism of cleavage may be hydrolytic, by nucleophilic attack on the DNA
phosphate backbone, with the metal acting as a Lewis acid activating water,
hydroxide, or the phosphate group. The more electropositive centre of com-
plex 13 may allow it to behave as a more e↵ective Lewis acid resulting in its
greater DNA cleaving ability.
Another possible explanation for the guanine adduct observed for complex 13,
but not complex 1, may be due to the hydrolytic behaviour of the complexes.
Complex 1 appears to be more resistant to hydrolysis than complex 13, there-
fore complex 1 may remain in its chloride-bound form, rendering it unable to
modify guanine. This, in fact, may also explain the di↵erence in timescale
over which the two complexes exert e↵ects on DNA: Complex 1 interacts non-
coordinatively with DNA inducing measurable changes and generating SSBs
after only 10 min (Figure 4.20, pg. 178). Conversely, complex 13 shows little
to no measurable e↵ect on DNA after 10 min however, after 24 h, the mag-
nitude of its DNA distorting e↵ects, nuclease activity and binding strength
are significantly superior to complex 1. All DNA experiments were, however,
carried out in chloride-free aqueous solution. Therefore complex 1 would be
even less likely to hydrolyse in cells where chloride is present. If rapid hydrol-
ysis of complex 13 is occurring, but not of complex 1, then upon reaching the
DNA/oligonucleotides, complex 1 would still be in its chloride-bound form,
whereas complex 13 would be predominantly an aqua adduct.
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Complex 1 exists as a cation in solution, therefore rapid noncoordinative in-
teraction with negatively charged DNA molecules is unsurprising. Complex
13-OH2/OH may interact less readily with DNA in this way, exhibiting only
minor noncovalent preassociation. Instead, over 24 h, 13-OH2/OH coordi-
nates directly to guanine, likely by a mechanism involving loss of H2O, similar
to CDDP. Another reason why complex 1 preferentially binds to the minor
groove may be its 3D structure, as shown in Chapter 3. The crystal structure
shows a flatter, more planar bidentate ligand than that of complex 13. This
may fit in the DNA minor groove more readily.
Complex 13 can induce SSBs and DSBs in DNA even at very low concentra-
tions, an ability not present in CDDP and only weakly in complex 1, which
produces SSBs when at high concentrations and does not generate DSBs. Un-
like the drug etoposide, these complexes generate strand breaks in cell-free
systems and thus do not rely on cell topoisomerases to do so. This nuclease
activity may explain the concentration-dependent reduction of the CD, and
LD DNA bands as cleavage of the DNA would significantly alter the DNA
superstructure manifesting as a visible reduction in CD and LD bands as both
the aligment and helicity of the DNA are disrupted by cleavage. This is in
contrast to dichroism studies of CDDP with DNA, in which the intensity of the
positive CD band of B-DNA at 275 nm is increased as a consequence of DNA
modification by CDDP that reflects distortions in DNA of a nondenaturational
nature.174 Again, the explanation of the di↵erence between the DNA-cleaving
abilities of complex 1 and 13 may be their hydrolytic behaviour. If DNA
cleavage requires, or is more easily facilitated by, direct coordination of the
complex, then complex 13’s ready and rapid hydrolysis would favour direct
DNA coordination and cleavage by either a hydrolytic or oxidative mecha-
nism.175 Additionally, both complexes generate ROS/SO in cells which could
be partially responsible for DNA cleavage, although in Chapter 3 it has been
shown that neither produce H2O2 in cell-free systems.
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4.4.3 Antiproliferative Activity
That both complexes exhibit such potent anticancer activity over a range of
cancer cells of di↵erent tissue types is encouraging. The more potent a complex
is, the lower the dose that can be given to patients to treat the cancer. Ad-
ditionally, the high selectivity of complex 1 ([⌘5-CpxbiphIr(azpyNMe2)Cl]PF6)
for A2780 vs. MRC-5 normal fibroblasts indicates its potential for lower side-
e↵ects and dose-limiting organ toxicity in patients. Current Pt-based drugs
are facing a number of clinical di culties, including dose-limiting organ tox-
icity143 and other side e↵ects caused by CDDP-induced damage to normal
proliferating cells.142 In addition, many cancers exhibit both acquired and in-
trinsic CDDP-resistance. Complex 1 provides a promising example of how an
organoiridium complex can exceed the potency, selectivity, and resistance pro-
file of CDDP. Complex 1 is significantly more potent (A2780 IC50 = 95 nM)
and selective (36⇥) than many other reported precious metal-based complexes
in the same cell lines under the same conditions. These include: CDDP (A2780
IC50 = 1,200 nM, 14⇥ selective), the highly potent and selective organoiridium
complex ZL105 ([⌘5-Cpxbiph)Ir(2-phenylpyridine)pyridine]PF6, A2780 IC50 =
120 nM, 13⇥ selective)84 and the highly potent and selective organoosmium
complex FY26 ([⌘6-p-cymene)Os(azpyNMe2)I]PF6) (A2780 IC50 = 160 nM,
28⇥ selective).171 This is extremely promising for complex 1.
4.4.4 Glutathione and Redox Modulation
After activation, CDDP is susceptible to deactivation by glutathione (GSH),
as the platinum centre binds strongly and irreversibly to the thiolate sulphur
of GSH and so can no longer modify DNA.176 Additionally, higher levels of glu-
tathione are often present in CDDP-resistant cancer cells.177,178 That complex
1 is more resistant to hydrolysis may contribute to its low level of interaction
with glutathione. However, complex 13 does not appear to interact with glu-
tathione to any extent, even in a chloride-free system, hence these complexes
both seem to be resistant to inactivation by glutathione. The relative unreac-
tivity of both complexes with equimolar amounts of GSH is encouraging, as
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they are more likely to be able to overcome GSH-based resistance mechanisms
in cancer cells, especially since many previously reported organoiridium com-
plexes with monodentate chlorido ligands are susceptible to rapid GSH binding
and possibly subsequent deactivation.101 Resistance to deactivation by GSH
may partially explain the high potency of complex 1 against A2780cis. It is
somewhat surprising that complex 13 does not interact with GSH, as it dis-
plays high cross-resistance with CDDP. This indicates that one or more of the
other mechanisms of CDDP resistance are responsible for the lower potency
of complex 13 in A2780cis.
Neither increasing, nor decreasing, the levels of cellular GSH by L-BSO or NAC
appears to significantly a↵ect the potency of 13, however co-administration
with L-BSO surprisingly reduces the cytotoxicity of complex 1. While this is in
contrast to many previously reported precious metal-based complexes, redox
modulation has not previously been carried out on organoiridium azopyridine
complexes. A possible explanation for the reduction of complex 1’s potency
by L-BSO is that its MoA is somehow reliant on the presence of GSH. That
the activity of complex 1 is una↵ected by NAC correlates with the fact that
it shows significant potency in A2780cis, a cell line resistant to CDDP, as one
of the known mechanisms by which it resists CDDP’s cytotoxic e↵ect is by
increasing GSH levels. These results are also further supported by both com-
plexes’ observed low/unreactivity to GSH in 1H-NMR spectra (Figures 4.25 –
4.32. pg. 186 – 193) and LC-MS experiments (Appendix Figures S31 – S39,
pg. 304 – 312). L-BSO modulation has been shown to be a way of increasing
potency and selectivity,171 however, complex 1 is already highly potent and
selective. Resistance to inactivation by GSH, as well as the retention of potent
antiproliferative activity in cells when co-administered with NAC, increasing
the cellular GSH levels, are highly desirable traits and promising results for
both complexes.
4.4.5 MoA Investigations
Mechanistic insights into an organoiridum complex of similar structure showed
a correlation with agents with oxidative stress-based MoAs.179 Both complexes
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induce a significant ROS and SO response in A2780 after 24 h (Figure 4.21, pg.
182). Cell mitochondria are a major source of both ROS and SO.112 Therefore,
it is possible that both complexes a↵ect cell mitochondria. The mitochon-
dria are primarily negatively-charged organelles, and so considering that both
complexes exist as cations, the targeting of a proportion of these complexes
to mitochondria is plausible. Os complexes bearing structural similarities to
complexes 1 and 13 have recently been shown to do so.132 Additionally, A2780
cells harbour mutations in their mitochondrial DNA which translate into de-
fects in NADH dehydrogenase, an important enzyme in the mitochondrial
respiratory chain.124 This may be contributing to the extremely high cytotox-
icity of complex 1 to A2780. These results are further supported by those in
Chapter 3, showing ROS/SO generation by complex 1 in OE19 and SUNE-1
cells, in addition to depolarisation of the mitochondrial membrane potential
by complex 1 in OE19. This impaired capacity of cancer cells to respond to
ROS insults relative to healthy cells highlights a way to selectively target and
kill cancer cells with these organoiridium complexes.
CDDP has been shown to reduce the % population of cells in the G1-phase
in A2780 cells after 24 h exposure by inducing S-phase arrest.145 Complex 1
induces no significant increase in any cell population (Figure 4.22, pg. 183),
indicating that there is no significant cell cycle arrests caused after 24 h ex-
posure, thus exhibiting a di↵erent e↵ect on the cell cycle to CDDP and other
precious metal-based complexes bearing structural similarities.145 Complex 13
induces a more significant reduction in the G2/M population, however, there
is no significant accumulation of cells in any other phase. CDDP is known
to induce significant S-phase arrest, therefore these results support a di↵erent
MoA to CDDP for these complexes.
Complex exposure appears to induce low levels of cell necrosis in the first 24
h (Figure 4.23, pg. 184), with no visible induction of apoptosis, mirroring the
results for complex 1 in OE19 and SUNE-1 described in Chapter 3. Similar
results are observed in previous work on highly similar complexes, however a
wave of necrosis after 24 h is followed by apoptosis induction after 48 h.120
Therefore, it is likely that the majority of cell death occurs 48-72 h after drug
exposure. This correlates with the high level of cytotoxicity determined by
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the antiproliferative assays in which the cells are given 72 h to recover before
cell survival percentages are determined. It is possible that these complexes
do not exert their primary MoA until > 24 h after exposure. Since there is no
significant accumulation of cells in the sub-G1 phase of the cell cycle, which
would be indicative of apoptotic cell death, it is unsurprising that no induction
of apoptosis is seen here, at least in the 24 h timeframe measured. Therefore,
either the complexes take > 24 h to induce apoptosis or cell cycle arrest, or
they do not at any point. In either case, both display a very di↵erent cytotoxic
profile to CDDP. This is encouraging, as cancers resistant to CDDP are best
treated by drugs which attack them in di↵erent ways.
4.5 Conclusions
In conclusion, these organoiridium anticancer complexes show very high
potency against a variety of cancer cell lines, with complex 1 ([⌘5-
CpxbiphIr(azpyNMe2)Cl]PF6) showing selectivity exceeding that of CDDP, as
well as other highly potent and selective precious metal-based drugs, in ad-
dition to considerably lower cross-resistance with CDDP than complex 13
([⌘5-CpxbiphIr(azpy)Cl]PF6).
A single small change in the bidentate ligand of these complexes has a profound
e↵ect on not only their level of potency, but also the mechanism by which they
interact with DNA and kill cells. Polypharmacology is probable for both com-
plexes including cancer cell death induced by DNA modification and cleavage,
and disruption of cellular redox balance by ROS and SO production.
The NMe2 group appears to be of vital importance to the potency and MoA
of the complex. The electon-donating e↵ect of the group results in a complex
that is more inert to hydrolysis, rapidly binds the DNA minor groove, is more
potent against various cancers, selective, and less cross-resistant. The guanine-
binding azpy complex 13, is a more e↵ective DNA cleaver, induces higher ROS
and SO, and is unreactive to GSH.
The results in this chapter further elucidate the MoAs and anticancer proper-
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ties of organoiridium azopyridine complexes, in addition to revealing how the
para-group on bidentate ligand can determine the MoA. These results show
that complex 1, in particular, holds great promise as an anticancer thera-
peutic, warranting in vivo experiments to determine anticancer potency and
selectivity in a model more representative of human cancer.
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Chapter 5
Complexes Bearing azpyOH
Bidentate Ligands
5.1 Introduction
The azpyOH ligand has previously been utilised as a bidentate ligand in
organoosmium and organoruthenium systems, generating potent anticancer
complexes.104,126 The potential of this ligand in organoiridiums, however, has
not been previously explored.
The results in Chapter 3 show that azpyOH complexes 5 – 10 are highly potent
and more hydrophilic in comparison with the other organoiridiums studied.
These are both highly desirable properties for anticancer therapeutics. Dis-
solution of the complex in purely aqueous solution remains another obstacle
hampering the elevation of organoiridium complexes into clinical drugs, as the
majority of complexes studied in Chapters 3 and 4 have low water solubility.
Many such complexes require the presence of DMSO to ensure the complex is
fully dissolved in preparation for biological experiments. The azpyOH com-
plexes, however, may be the key to overcoming this obstacle.
In this chapter, the properties of novel azpyOH anticancer complexes described
in Chapter 3 are investigated to further understand the impact of the various
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ligands on the properties, potency, and MoAs of organoiridium complexes.
The e↵ect of the halide and counterion on water solubility is explored, as
well as the relationship between the complex structure and the pKa of the
azpyOH hydroxyl group. The antiproliferative activity of the complexes are
investigated in a larger panel of cell lines including CDDP-resistant ovarian
carcinoma, and MoA investigations are made into the complexes’ ability to in-
teract with DNA, generate ROS and SO, depolarise mitochondria, and induce
apoptosis. The toxicity of two azpyOH complexes are compared in a zebrafish
model, to demonstrate the e↵ect of the halido ligand on in vivo toxicity.
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5.2 Experimental Methods
5.2.1 pKa Determination by UV-Vis Spectrophotome-
try
The pKa values of hydroxyl groups in complexes were determined by addi-
tion of µL amounts of either dilute perchloric acid in acetic acid or a weak
solution of KOH to a solution of complex in 5% DMSO:H2O or H2O and
the changes monitored by UV-Vis spectroscopy. Changes in absorbance max-
ima over di↵erent pH values were plotted and a sigmoid curve fitted using
a Maxwell-Boltzmann curve fitting algorithm and the midpoint calculated to
determine the pKa.
5.2.2 Linear Dichroism
Stocks of complexes were prepared in HPLC-grade acetonitrile and added to
the DNA in 10 mM phosphate bu↵er solution so that the final solution com-
prised of 5% acetonitrile. This was kept constant for all samples in the titration
series. The concentration of the DNA was kept at 90 µM and the complex
concentration increased from 0 – 90 µM in 10 µM increments. Complexes were
incubated with DNA at 310 K for 24 h.
LD spectra were measured over 190 – 350 nm range at a couette spin speed of
3,000 rpm, using a bandwidth of 2 nm, and a data pitch of 0.2 nm. Scanning
speed used was 100 nm/min, with a response time of 2 s. Baseline spectra of
an appropriate bu↵er were recorded for LD. Baseline spectra for each of the
LD samples were recorded with spinning turned o↵. All measurements were
carried out at 310 K before LD measurements were taken.
5.2.3 Circular Dichroism
Stocks of complexes were prepared in HPLC-grade acetonitrile and added to
the DNA in 10 mM phosphate bu↵er solution so that the final solution com-
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prised of 5% acetonitrile. This was kept constant for all samples throughout
the experiment. The concentration of DNA was kept at 90 µM throughout
and the complex:DNA ratio varied from 1:1 to 1:3. Complexes were incubated
with DNA at 310 K for 24 h before CD measurements were taken. CD mea-
surements were taken from 180 nm – 800 nm. A scanning speed of 100 nm/min
was used, with a response time of 1 s, a bandwidth of 2 nm, a data pitch of
0.2 nm at 310 K with 9 accumulations taken for each data point. Baseline
spectra of an appropriate bu↵er were recorded for CD.
5.2.4 Toxicity in Zebrafish
Zebrafish experiments were carried out at the University of Warwick School
of Life Sciences using Singapore wild-type zebrafish embryos. Maintenance of
animals was carried out in accordance with ASPA1986 and approved by the
University Ethical Review Committee. Zebrafish were housed in 3.5 L tanks
and checked daily or as required. Zebrafish were fed 2 – 4 times a day and
daily checks were carried out to ensure water quality was maintained. Fish
were mated once a week starting at two pairs per 1 L breeding tank. Em-
bryos were collected and transferred to petri dishes. New, healthy zebrafish
embryos were harvested and seeded in 24-well plates at one embryo/well. A
serial dilution of six concentrations of the complex to be tested was added
to 20 of these wells with the remaining 4 used as negative controls. DMSO
at an identical % to that present in the complex solutions was used as the
solvent control and 3,4-dichloroaniline used as the positive control. Embryos
incubated at 301.5 K for 96 h after which zebrafish % survival was assessed by
embryo coagulation, visible heartbeat, tail detachment and somite formation.
Experiments were carried out in duplicates of triplicates. Complex concentra-
tions were corrected by ICP-OES, used to determine the concentration of Ir
in the drug stocks and % survival was plotted against complex concentration.
Boltzmann sigmoidal curves were fitted to determine the LC50 values and stan-
dard deviations. Zebrafish maintenance carried out by Ian Bagley and In vivo
toxicity experiments were carried out by Hannah Bridgewater and Dr. James
P. Coverdale under the guidance of Dr. Karuna Sampath at the University of
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Warwick School of Life Sciences.
5.2.5 Water Solubility Determination
A saturated solution of the complex was prepared by the addition of complex
to DDW, followed by sonication for 1 h at ambient temperature. This was
repeated until visible solid remained in the solution after sonication. The
mixture was then filtered through glass microfibre filter paper and celite. The
resulting filtrate was analysed by UV-Vis spectrometry.
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5.3 Results
5.3.1 pKa Determination
The protonation/deprotonation of the para-OH group on the phenyl ring of
azpyOH complexes has a large e↵ect on the level of electron density in the
bidentate ligand, such that a dramatic colour change occurs between yellow
and purple when the solution pH exceeds/deceeds the pKa of the hydroxyl
hydrogen. Not only does the loss of a proton a↵ect the electronic state of the
complex, but also the overall charge. Since the complexes were synthesised as
cations paired with a negatively charged counterion, the loss of a proton leaves
them as neutral complexes. Global charge can have a significant impact on
the behaviour and potency of a complex, therefore, the pKa values of relevant
hydrogens in the complexes were determined by UV-Vis spectroscopy (Figures
5.1 and 5.2).
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Figure 5.1: (Left) UV spectra of a pH titration of complex 8 in H2O. Each line
represents the spectrum at a particular pH value. (Right) A Boltzmann sig-
moidal curve fitted to a plot of pH vs. absorbance at a maximum to determine
pKa.
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Figure 5.2: The pKa values of OH groups in complexes determined by pH
titration and analysed by UV-Vis spectroscopy. Boltzmann sigmoidal curve
fitted to determine pKa. Error obtained from curve-fitting algorithm rather
than experimental replicates. (n/a = not applicable. n.d. = not determined.)
Interestingly, the pKa values for the hydroxyl hydrogens of Cpxph complex 6
and its Cp* analogue, complex 7, are identical, whereas their Cpxbiph analogue,
complex 5, has a lower pKa. These are also comparable with similar Os and
Ru complexes bearing the same azpyOH ligand.104 Complexes 7 and 8 have
di↵ering pKa values despite only di↵ering in counterion. The iodido complex
9 has a significantly higher pKa value than its chlorido analogue, complex
7. The para hydroxl hydrogen of azpy(OH)2 complex 12 has a much lower
pKa than any of the azpyOH complexes investigated, however, the pKa of its
ortho hydroxyl hydrogen is far higher. The pKa value of the ortho hydroxyl
hydrogen of Brazpy(OH)NEt2 complex 19 is lower than that of the ortho
hydroxyl hydrogen of azpy(OH)2 complex 12.
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5.3.2 Water Solubility
Whilst many advances have been made in drug formulation and delivery sys-
tems, high water solubility remains a very desirable factor for drug candidates.
Many of the complexes in this work have very low water solubility, requiring the
presence of DMSO for biological experiments. Further synthesis experiments
were therefore carried out to improve the water solubility without sacrificing
complex anticancer potency. To achieve this, complexes were synthesised with
alternative counterions and the amount of solid complex required to saturate
a solution of 18.2 MilliQ water at 298 K after 10 min sonication recorded.
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Solutions of complexes 7 and 9 bearing the PF6 counterions became saturated
at < 2 mg complexes, even after sonication. Solutions of complexes 8 and
10, chloride and iodide counterion analogues of complexes 7 and 9, remained
unsaturated even after 30 mg of complex was dissolved. Quantitative ICP-OES
studies into the e↵ect of the counterion on complex solubility are warranted.
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5.3.3 Aquation Studies
As previously mentioned in Chapters 3 and 4, organoiridium complexes bearing
azopyridine bidentate ligands and monodentate chlorido ligands can undergo
hydrolysis at the Ir-Cl bond (Figure 5.3). This has been shown to have im-
plications for potency and MoA. Hydrolysis is also dependent on the chloride
concentration, which is known to vary in di↵erent cellular compartments. To
replicate the chloride concentration in cell medium, experiments were repeated
in 120 mM [Cl] solution.
Due to the limited water solubility of many of the complexes in this work,
10% DMSO was used to augment complex solubility in the in vitro experi-
ments. DMSO has been known to detrimentally a↵ect the anticancer activity
of chemotherapeutics such as CDDP.180 To examine whether this is true for
these complexes, their stability in DMSO was examined by 1H-NMR (Ap-
pendix Figure S21, pg. 292 – 294). Spectra of all complexes were identical
both 15 min, and 19 days after sample preparation, and no DMSO adducts
were detected by ESI-MS experiments.
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Figure 5.3: Proposed hydrolysis equilibrium for the complexes studied in this
work. Aquation monitored by following the chemical shift of 1H-NMR peaks
corresponding to Cpx ring methyl hydrogens for complexes 5 – 10 coloured
above.
To investigate whether changing the Cp system or halide bound to the iridium
centre of azpyOH complexes a↵ects hydrolysis, solutions of complexes 5 –
10 were monitored over 24 h by 1H-NMR in 10% d6-DMSO:D2O, 0.1% 1,4-
dioxane at 310 K (Figures 5.4 – 5.9) and the extent of hydrolysis calculated
by the peak integrals (Table 5.1).
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Figure 5.4: Hydrolysis of complex 5 studied by 600 MHz 1H-NMR spectra of a
100 µM solution of complex 5 in 10% d6-DMSO:D2O, 0.1% 1,4-dioxane (v/v)
at 310 K, unbu↵ered at pD 8. Spectra shown 10 min after sample preparation,
24 h after sample preparation, and 24 h after sample preparation in 120 mM
NaCl solution. Emergent peaks not corresponding to original complex denoted
by red arrows.
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Figure 5.5: Hydrolysis of complex 6 studied by 600 MHz 1H-NMR spectra of a
100 µM solution of complex 6 in 10% d6-DMSO:D2O, 0.1% 1,4-dioxane (v/v)
at 310 K, unbu↵ered at pD 8. Spectra shown 10 min after sample preparation,
24 h after sample preparation, and 24 h after sample preparation in 120 mM
NaCl solution. Emergent peaks not corresponding to original complex denoted
by red arrows.
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Figure 5.6: Hydrolysis of complex 7 studied by 600 MHz 1H-NMR spectra of a
100 µM solution of complex 7 in 10% d6-DMSO:D2O, 0.1% 1,4-dioxane (v/v)
at 310 K, unbu↵ered at pD 8. Spectra shown 10 min after sample preparation,
24 h after sample preparation, and 24 h after sample preparation in 120 mM
NaCl solution. Emergent peaks not corresponding to original complex denoted
by red arrows.
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Figure 5.7: Hydrolysis of complex 8 studied by 600 MHz 1H-NMR spectra of a
100 µM solution of complex 8 in 10% d6-DMSO:D2O, 0.1% 1,4-dioxane (v/v)
at 310 K, unbu↵ered at pD 8. Spectra shown 10 min after sample preparation,
24 h after sample preparation, and 24 h after sample preparation in 120 mM
NaCl solution. Emergent peaks not corresponding to original complex denoted
by red arrows.
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Figure 5.8: Hydrolysis of complex 9 studied by 600 MHz 1H-NMR spectra of a
100 µM solution of complex 9 in 10% d6-DMSO:D2O, 0.1% 1,4-dioxane (v/v)
at 310 K, unbu↵ered at pD 8. Spectra shown 10 min after sample preparation,
24 h after sample preparation, and 24 h after sample preparation in 120 mM
NaCl solution. Emergent peaks not corresponding to original complex denoted
by red arrows.
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Figure 5.9: Hydrolysis of complex 10 studied by 600 MHz 1H-NMR spectra of a
100 µM solution of complex 10 in 10% d6-DMSO:D2O, 0.1% 1,4-dioxane (v/v)
at 310 K, unbu↵ered at pD 8. Spectra shown 10 min after sample preparation,
24 h after sample preparation, and 24 h after sample preparation in 120 mM
NaCl solution. Emergent peaks not corresponding to original complex denoted
by red arrows.
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Complex Structure % Extent of Hydrolysis (0 mM [Cl])
% Extent of Hydrolysis 
(120 mM [Cl])
5 [CpxbiphIr(azpyOH)Cl]PF6 50% 0%
6 [CpxphIr(azpyOH)Cl]PF6 66% 0%
7 [Cp*Ir(azpyOH)Cl]PF6 53% 0%
8 [Cp*Ir(azpyOH)Cl]Cl 66% 0%
9 [Cp*Ir(azpyOH)I]PF6 0% 19%*
10 [Cp*Ir(azpyOH)I]I 0% 15%*
*Complexes 9 and 10 did not hydrolyse in the presence on 120 mM [Cl], instead 
exchanging a % of their iodido ligands for chlorido ones.
Table 5.1: Hydrolysis data for complexes 5 – 10 monitored over 24 h by 1H-
NMR in 10% d6-DMSO:D2O, 0.1% 1,4-dioxane at 310 K. Experiments were
repeated with the addition of 120 mM NaCl to assess suppression of hydrolysis
by chloride.
To better assess the relationship between the structure of azpyOH organoirid-
ium complexes and their rates of hydrolysis, timescale 1H-NMR experiments
were carried out on 100 µM solutions of each complex in 10% d6-DMSO:D2O,
0.1% 1,4-dioxane (v/v) at 310 K, unbu↵ered at pD 8 over 24 h taking spectra
every hour (Figure 5.10).
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Figure 5.10: Monitoring of the hydrolysis of complexes 5 – 10 studied by
600 MHz 1H-NMR spectra of a 100 µM solution of complex 1 in 10% d6-
DMSO:D2O, 0.1% 1,4-dioxane (v/v) at 310 K, unbu↵ered at pD 8 by tracking
relative % integrals of peaks corresponding to Cpx ring methyl hydrogens for
complexes 5, and 7 – 10. Complex 6 hydrolysis was monitored by tracking %
integral of aromatic doublet due to overlaps in the Cp methyl hydrogen peaks
making accurate quantification impossible in this region.
Complexes 5 – 8 bearing the monodentate chlorido ligand hydrolyse in water,
whereas complexes 9 and 10 that bear the monodentate iodido ligand are
completely inert to hydrolysis. The half-lives of complexes 7 and 8 are <10
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min whereas the half-life for complex 5 is ca. 128 min, and for 6, ca. 248
min. Complexes 7 [Cp*Ir(azpyOH)Cl]PF6 and 8 [Cp*Ir(azpyOH)Cl]Cl di↵er
only in their counterion, however this appears to have implications towards
hydrolysis. For complex 8, which bears a Cl counterion, the appearance of
new peaks occurs more slowly than for its analogue, complex 7, which bears
a PF6 counterion.
The Cp ligand appears to have little impact on the extent of hydrolysis, how-
ever the Cpxbiph complex 5 and Cpxph complex 6 appear to hydrolyse more
slowly than their Cp* analogue, complex 7, as evidenced by the slower rate of
the disappearance of the peaks corresponding to the complex in its Ir-Cl form.
As is the case for azpyNMe2 complexes 1 – 3, investigated in Chapter 4, a third
species appears when the chlorido complexes undergo hydrolysis (indicated in
red for complexes 7 and 8). This peak appears only after hydrolysis begins,
and, in the case of complex 8, it appears alongside a concomitant reduction
in the other emergent peak, hypothesised to correspond to an Ir-OH2 species
(indicated in black). The appearance of a third species is not observed in
the aromatic region of the spectra of complex 6 however this is likely still
occurring, causing the complexity seen in the aliphatic region of the 1H-NMR
spectra.
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5.3.4 Antiproliferative Activity
In Chapter 3, azpyOH complexes 5 – 10 were shown to have potency exceeding
that of CDDP against A2780 ovarian carcinoma cells in vitro. Of the library
of complexes investigated in Chapter 3, the azpyOH family of complexes were
the least hydrophobic. High hydrophobicity usually correlates with high po-
tency,86 however, the azpyOH complexes displayed higher potency than nearly
all other complexes in this work. Additionally, their pattern of activity was
unusual. Usually a potency trend of Cpxbiph > Cpxph > Cp* is observed,
however for azpyOH complexes the potencies of the Cpxbiph, Cpxph and Cp*
analogues, complexes 5 – 7 did not follow this expected trend. To further
investigate the antiproliferative properties of complexes 5 – 10, experiments
were carried out on a panel of cancer cells of various tissue types (Table 5.2).
Antiproliferative screenings against A2780, OE19 and SUNE-1 carried out by
Dr. Isolda Romero-Canelo´n, Ji-Inn Song and Bindy Heer.
Table 5.2: Comparison of IC50 values (in µM) of azpyOH complexes 5 – 10
against a panel of cell lines. CDDP values obtained experimentally or from
previously published work.145 (n.d. = not determined)
Complex A2780 A2780cis A549 CNE1 CNE2 OE19 SUNE-1
5 0.14 ± 0.09 0.25 ± 0.06 5.2 ± 0.3 5 ± 1 10.62 ± 0.04 0.40 ± 0.03 0.72 ± 0.04
6 0.108 ± 0.009 0.22 ± 0.02 0.89 ± 0.03 5.03 ± 0.06 1.6 ± 0.2 0.30 ± 0.01 1.7 ± 0.2
7 0.12 ± 0.04 0.114 ± 0.003 1.5 ± 0.3 5.7 ± 0.2 2.3 ± 0.3 1.15 ± 0.02 1.5 ± 0.2
8 0.17 ± 0.07 0.062 ± 0.004 5.12 ± 0.09 1.2 - 6.2 1.12 ± 0.09 n.d. n.d.
9 0.25 ± 0.02 n.d. 1.01 ± 0.08 n.d. 1.26 ± 0.04 n.d. n.d.
10 0.34 ± 0.02 0.049 ± 0.001 1.5 ± 0.4 1.2 - 6.2 2.2 ± 0.2 n.d. n.d.
CDDP 1.2 ± 0.2 11.5 ± 0.3 3.3 ± 0.1 7.7 ± 0.2 7.7 ± 0.3 13.43 ± 0.003 1.14 ± 0.01
All complexes tested are ca. 1 – 2 orders of magnitude more potent than CDDP
in A2780cis (ovarian carcinoma with acquired CDDP resistance). Complexes
5 and 6 are less potent in A2780cis than in A2780, i.e. they exhibit some
cross-resistance with CDDP, whilst complex 7 shows no significant di↵erence
in toxicity towards A2780 vs. A2780cis. Conversely, [(Cp*)Ir(azpyOH)Cl]Cl
complex 8 and [(Cp*)Ir(azpyOH)I]I complex 10, both exhibit low nanomolar
IC50 values of 62 nm and 49 nm against A2780cis and are ca. 185⇥ and 235⇥
more potent than CDDP, respectively.
In A549 and CNE2, the Cpxbiph complex 5 is, surprisingly, significantly less
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potent that its Cpxph and Cp* analogues, complexes 6 and 7, although all
three have similar activity in CNE1.
The Cp* iodido complex 9 is slightly less potent in A2780 than its Cp* chlorido
analogue. Complex 7, however, is significantly more potent in A549 and CNE2.
Chlorido complexes 7 and 8 display similar potencies in most cell lines, which
is expected as they only di↵er in their counterion, however there are some
surprising exceptions in A2780 and A549. This is also the case for their iodido
analogues complexes 9 and 10.
The Cpxbiph, Cpxph and Cp* analogues, complexes 5 – 7 are considerably more
active than CDDP in OE19, however in SUNE-1 only complex 5 is more active.
The expected potency trend of of Cpxbiph > Cpxph > Cp* was, again, not
observed for these complexes. In OE19, the Cpxph analogue, complex 6, was
the most potent, whereas in SUNE-1 it was the least potent. In some cases,
the IC50 di↵erences amongst these complexes are small and may therefore
not be biologically significant, however the Cp system clearly has an impact
on potency in these azpyOH complexes, however, their e↵ect is likely more
complicated than in other families of organoiridium complexes.
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5.3.5 MoA Studies in Oesophageal and Nasopharyngeal
Cancers by Flow Cytometry
The e↵ect of the Cp system does not follow the expected potency trend in
azpyOH complexes 5 – 7. To investigate whether this is due to changes in
MoAs, a panel of flow cytometry experiments were conducted on OE19 and
SUNE-1 cells exposed to complexes 5 – 7. Flow cytometry studies carried out
with the help of Dr. Isolda Romero-Canelo´n and Hannah Bridgewater.
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5.3.5.1 ROS and SO Generation
The capacity of complexes 5 – 7 to generate ROS/SO in OE19 and complex
5 in SUNE-1 were investigated (Figures 5.11 and 5.12).
OE19
Figure 5.11: (Top) Measurement of ROS and SO generation by flow cytom-
etry of OE19 oesophageal carcinoma carcinoma cells exposed to complexes 5
– 7 for 24 h at IC50 concentrations at 310 K then stained with orange/green
fluorescent reagents. Pyocyanin used as positive control (orange). (Bottom)
Table of % cell populations obtained from triplicate experiments. Statistical
significance between cells exposed to complex vs. negative control was deter-
mined by two-sample independent Welch t-tests assuming unequal variance
between populations with asterisks corresponding to p  0.05 *, p  0.01 **,
p  0.001 ***, p  0.0001 ****.
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SUNE-1
Figure 5.12: (Top) Measurement of ROS and SO generation by flow cytome-
try of SUNE-1 nasopharyngeal carcinoma carcinoma cells exposed to complex
5 for 24 h at IC50 concentrations at 310 K then stained with orange/green
fluorescent reagents. Pyocyanin used as positive control (orange). (Bottom)
Table of % cell populations obtained from triplicate experiments. Statistical
significance between cells exposed to complex vs. negative control was deter-
mined by two-sample independent Welch t-tests assuming unequal variance
between populations with asterisks corresponding to p  0.05 *, p  0.01 **,
p  0.001 ***, p  0.0001 ****.
Complexes 5 – 7 generate similarly high levels of ROS and SO in OE19, as
does complex 5 in SUNE-1.
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5.3.5.2 Apoptosis Induction
Flow cytometry experiments were carried out on complexes 5 – 7 in OE19 and
complex 5 in SUNE-1 to investigate their ability to induce apoptosis (Figures
5.13 and 5.14).
OE19
Figure 5.13: (Top) Measurement of apoptosis induction by flow cytometry of
OE19 oesophageal carcinoma cells exposed to complexes 5 – 7 for 24 h at IC50
concentrations at 310 K. (Bottom) Table of % cell populations obtained from
triplicate experiments. Statistical significance between cells exposed to com-
plex vs. negative control was determined by two-sample independent Welch
t-tests assuming unequal variance between populations with asterisks corre-
sponding to p  0.05 *, p  0.01 **, p  0.001 ***, p  0.0001 ****.
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SUNE-1
Figure 5.14: (Top) Measurement of apoptosis induction by flow cytometry of
SUNE-1 nasopharyngeal carcinoma cells exposed to complex 5 for 24 h at IC50
concentrations at 310 K. (Bottom) Table of % cell populations obtained from
triplicate experiments. Statistical significance between cells exposed to com-
plex vs. negative control was determined by two-sample independent Welch
t-tests assuming unequal variance between populations with asterisks corre-
sponding to p  0.05 *, p  0.01 **, p  0.001 ***, p  0.0001 ****.
Complexes 5 – 7 induce little to no apoptosis in OE19 after 24 h. The same
is true for complex 5 in SUNE-1.
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5.3.5.3 Mitochondrial Membrane Depolarisation
To determine if complexes 5 – 7 could induce mitochondrial membrane depo-
larisation and to investigate if the Cp system had any impact, investigations
were carried out by flow cytometry in OE19 (Figure 5.15).
Complex %Polarised %Depolarised
Neg CTL 88.1 ± 0.5 11.9 ± 0.5
Pos CTL 28 ± 1 72 ± 1
5 3.4 ± 0.3 **** 96.6 ± 0.3 ****
6 2.93 ± 0.06 **** 97.07 ± 0.06 ****
7 2.47 ± 0.06 **** 97.53 ± 0.06 ****
Figure 5.15: (Top) Depolarisation of mitochondrial membrane potential of
OE19 oesophageal carcinoma cells exposed to complexes 5 – 7 for 24 h at
IC50 concentration at 310 K measured by reduction in JC10 fluorescence.
(Bottom) Table of % cell populations with polarised/depolarised mitochon-
drial membrane potential obtained from triplicate experiments. Statistical
significance between cells exposed to complex vs. negative control was deter-
mined by two-sample independent Welch t-tests assuming unequal variance
between populations with asterisks corresponding to p  0.05 *, p  0.01 **,
p  0.001 ***, p  0.0001 ****.
Complexes 5 – 7 induce extreme depolarisation of the mitochondrial mem-
brane, greater than that observed for the positive control.
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5.3.6 E↵ect of Redox Modulation on Anticancer Activ-
ity
In Chapter 4, two organoiridium complexes were shown to generate ROS and
SO in cells. It was then shown that co-administration of L-BSO or NAC with
organoiridium complexes can have an e↵ect on their cytotoxicity. Complexes
5 – 7 have been shown to generate ROS and SO and so investigations into
the e↵ects of redox modulators on their cytotoxicity is warranted.
To investigate how modulation of the level of GSH a↵ects the anticancer po-
tency of complexes 5 – 7, they were co-administered with 5 µM of either
L-BSO or NAC and their cytotoxicities determined in EBV-positive OE19 oe-
sophageal carcinoma and compared to the results for administration of complex
only, and CDDP (Figure 5.16).
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Figure 5.16: Cytotoxicities of complexes 5 – 7 and CDDP against EBV-
positive oesophageal carcinoma cells, co-administered with 5 µM of L-BSO,
NAC or neither. Drug treatment was for 24 h, followed by 72 h recovery pe-
riod. Data and standard deviations were obtained from duplicates of triplicate
experiments for cells co-administered with 5 µM of L-BSO, NAC. Data and
standard deviations were obtained from quadruplicates of triplicate experi-
ments for cells treated with no modulator (drug only).
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Complexes 5 – 7 are highly cytotoxic to EBV-positive OE19, more so than
CDDP, with Cpxph complex 6 exhibiting the highest cytotoxicity of the three,
as it does in A2780, A549, CNE2 and OE19. Co-administration of NAC has
no observable e↵ect on the cytotoxicity of any of the three complexes. Co-
administration of L-BSO has no observable e↵ect on the cytotoxicity of com-
plexes 5 or 6 three complexes, however an increase in cytotoxicity is observed
for complex 7.
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5.3.7 Circular Dichroism (CD)
The e↵ect of two organoiridium complexes, 1 and 13, on ctDNA was investi-
gated by CD in Chapter 4. Complexes can induce peaks in the CD spectra
of DNA by associating with the helix in a specific orientation. To investigate
whether azpyOH complexes 5 and 7 can interact with helical DNA, prelimi-
nary CD experiments were carried out with 1:3, 2:3 and 1:1 ratios of [Ir]:[DNA]
(Figure 5.17).
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Figure 5.17: CD spectra of 90 µM ctDNA incubated for 24 h with increasing
concentrations of complex 5 (Left) or complex 7 (Right)
Both the Cpxbiph azpyOH complex 5 and its Cp* analogue, complex 7, induce
a CD peak in the 500 – 600 nm region, matching their corresponding UV-
Vis spectra. Additionally, both complexes reduce the magnitude of the CD
signal of ctDNA at 260 nm, and this e↵ect increases with increasing complex
concentration.
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5.3.8 Linear Dichroism (LD)
The e↵ect of two organoiridium complexes, 1 and 13, on ctDNA was investi-
gated by LD in Chapter 4. Both complexes cleaved and distorted the DNA
superstructure, reducing the magnitude of the LD signal at 260 nm. To investi-
gate whether azpyOH complexes 5 and 7 can a↵ect the DNA superstructure,
preliminary LD experiments were carried out with a 1:1 ratio of [Ir]:[DNA]
(Figure 5.18).
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Figure 5.18: Linear dichroism spectra of 90 µM ctDNA incubated for 24 h
with 90 µM of complex 5 (Left) or complex 7 (Right).
The Cpxbiph azpyOH complex 5 induces a slight decrease in the magnitude
of the ctDNA LD signal at 260 nm, whereas its Cp* analogue, complex 7,
induces almost no change in the spectrum.
In comparison with the significant e↵ects azpyNMe2 complex 1 and azpy com-
plex 13 exert on DNA at ratios as low as 1:100 [Ir]:[DNA], azpyOH complexes
5 and 7 exert little to no e↵ects observable by CD or LD. Therefore no further
DNA interaction investigations were carried out.
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5.3.9 Toxicity in Zebrafish
The properties of organoosmium and organoruthenium azopyridine anticancer
complexes bearing monodentate chlorido or iodido ligands has been investi-
gated.145 The iodido complexes were more potent than their chlorido ana-
logues, did not exhibit cross-resistance with CDDP, and were more selective.
The azpyOH chlorido complex 7 and its iodido analogue, complex 9, have
already been shown to be highly potent. Additionally, the chlorido complex
readily hydrolyses, whereas the iodido does not, potentially having implica-
tions in uptake and MoA. To assess whether changing the halide of organoirid-
ium azopyridine complexes has an impact on in vivo toxicity, experiments were
carried out in an animal model.
The zebrafish (Danio rerio) is a well-established model organism in develop-
mental biology. Strikingly, 70% of protein-coding human genes are related
to genes found in the zebrafish and 84% of genes known to be associated
with human disease have a counterpart in zebrafish.181 Zebrafish represent a
whole-organism vertebrate with many of the high-throughput advantages of
cell-screening assays as they can live in a 96-well plate and readily absorb
chemicals from the water. Additonally, they develop most of their major or-
gans within a week, allowing for rapid assays. These properties make zebrafish
ideal for early in vivo drug-toxicity screening.182–184 To investigate the di↵er-
ence in toxicity between the Cp* chlorido complex 7 and its iodido analogue,
complex 9, their toxicities to zebrafish were compared (Figure 5.19).
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Figure 5.19: LC50 values (in µM) of complexes 7 and 9 in zebrafish (Danio
rerio). Higher LC50 values indicate lower toxicity.
Strikingly, the iodido complex 9 is ca. 25⇥ less toxic to zebrafish than its
otherwise identical chlorido analogue, complex 7. However, the toxicities of
both complexes are higher than that of the clinically-utilised drugs CDDP
and carboplatin, which have zebrafish LC50 values of 0.6 µM and 5.7 µM,
respectively.
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5.4 Discussion
The azpyOH family of organoiridium complexes are novel and previously un-
explored. In chapter 3, it was shown how azpyOH complexes 5 – 7 exhibited
an unusual pattern of activity in A2780 ovarian carcinoma, as well as being
highly potent and more hydrophilic than the majority of the other complexes
studied in this work. The work carried out in this chapter has shed consider-
able light on the properties of azpyOH complexes, as well as elucidating their
potential as anticancer agents and their possible MoAs.
5.4.1 Water Solubility
Solubility in water is a highly desirable feature in drugs. The vast majority
of organoiridium complexes, and indeed many precious metal-based drugs, are
not completely soluble in water and require additional solvents such as DMSO
or more complex delivery systems, such as vesicles or nanoparticles. Chang-
ing the counterions of azpyOH complexes from PF6 to chloride or iodide is
demonstrated to dramatically increase solubility without compromising po-
tency (Table 5.2, pg. 226). This may also hold true for other organoiridium
complexes and could result in more favourable formulation if a drug of this
family were to reach clinical trials as high solubility in water obviates the need
for complex and expensive delivery mechanisms. Water soluble drugs, such as
picoplatin, are also highly favourable for patients as they can be administered
orally as opposed to the less pleasant intravenous administration required for
CDDP.
5.4.2 Aquation
The azpyOH complexes 5 – 8 bearing the chlorido monodentate ligand hy-
drolyse readily in water, whereas the iodido complexes 9 and 10 do not. This
is also the case for their azpyNMe2 analogues, complexes 3 and 4, studied in
Chapter 3. Therefore, the monodentate halido ligand is the primary structural
feature governing hydrolysis of organoiridium azopyridine complexes. This is
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unsurprising as ruthenium complexes bearing the same bidentate ligand and
monodentate halido ligand also hydrolyse,96 as do many reported Ir(III) com-
plexes or similar structure bearing chlorine as a monodentate ligand.86,94
There is a small di↵erence in rate and extent of hydrolysis between Cpxbiph
and Cpxph azpyOH complexes 5 and 6 and their Cp* analogue, complex 7
(Table 5.1, pg. 223 and Figure 5.10, pg. 224). The slower hydrolysis of com-
plexes 5 and 6 relative to complex 7 could be due to the extended rings on the
Cp systems of complexes 5 and 6 sterically hindering the approach of water
molecules and/or the release of the chlorido ligand. Another possible explana-
tion of this could be the slight di↵erence in the pKa values of their azopyridine
phenyl hydroxyl groups. The hydroxyl group of complex 5 has a lower pKa
value than that of complexes 6 and 7 (Figure 5.2, pg. 214), therefore, at pH
7, slightly more of the complex will be in its deprotonated form, resulting in a
complex with a global charge of 0, instead of +. Perhaps the deprotonated neu-
tral complex accepts water as a ligand (and concomitant loss of chloride) less
readily than the protonated complex does. Another possible explanation for
the di↵erence in rate between these complexes, observable by the significantly
steeper curve of Cp* complex 7 compared to Cpxbiph complex 5, is that the
biphenyl group may play a part in sterically hindering the approach of water
molecules to the iridium centre of complex 5, slightly reducing its ability to
hydrolyse.
There is a di↵erence in the rates and extents of hydrolysis between Cp* com-
plex 7 and its analogue, complex 8, which bears a chloride counterion instead
of PF6. This is likely due to the presence of additional chloride suppressing
hydrolysis, as increasing chloride concentration has been shown to slow and
suppress hydrolysis in Chapters 3 and 4.
As is the case for the azpyNMe2 complexes 1 – 3, the 1H-NMR studies indicate
three species present when hydrolysing in aqueous solution. The same is true
for their otherwise identical azpyOH analogues, complexes 5 – 7. Due to the
structural similarities between the complexes, the hypothesis that OH-bridged
dimers were forming between azpyNMe2 complexes is a sensible conclusion for
azpyOH complexes also.
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As is the case for its azpyNMe2 analogue, complex 4, azpyOH iodido complexes
9 and 10 undergo conversion from iodido to chlorido when in 120 mM chloride
solution. As this is the concentration of chloride in cell medium, there is a
possibility that a proportion of molecules of complex 9 and 10 are converted
to chlorido analogues before they reach cells. This is unlikely to be an issue,
however, as after 24 h incubation at 310 K, only 19% of complex 9 and 15%
of complex 10 are converted. During antiproliferative assays, the solution of
complex in 120 mM chloride medium is applied to cells within one hour of
preparation from solid. Therefore the time for iodido to chlorido conversion
in cell medium before the complexes reach cells is minimised.
5.4.3 MoA Investigations
Flow cytometry studies indicate that azpyOH complexes are likely to have
similar MoAs to azpyNMe2 complexes. Both azpyNMe2 and azpy OH com-
plexes generate significant ROS and SO in OE19 oesophageal carcinoma cells,
with the azpyNMe2 complexes generating slightly more than their azpyOH
analogues. This may be due to the slightly higher electron donating property
of the NMe2 group relative to the OH group.
None of the azpyNMe2 complexes 1 – 3 or the azpyOH complexes 5 - 7 induced
apoptosis after 24 h, and all slightly increased the proportion of non-viable
cells. This indicates that, for all of the complexes tested, either apoptosis is
not an MoA, or it occurs after > 24 h.
All complexes tested induced extreme depolarisation of the mitochondrial
membrane, the azpyOH complexes doing so to a slightly lesser degree than the
azpyNMe2 ones. Whilst this indicates that this could be an MoA for azpyOH
complexes, they are less likely to localise to the negatively charged mitochon-
dria than the cationic azpyNMe2 complexes due to their neutral global charge
at physiological pH, although this does not rule out mitochondrial damage as
a possible MoA.
Unlike its azpyNMe2 and azpy analogues, complexes 1 and 13, the otherwise
identical Cpxbiph azpyOH complex 5 has very little e↵ect on the LD spectrum
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of DNA and its Cp* analogue, complex 7 has no e↵ect, even at a 1:1 [Ir]:[DNA]
ratio after 24 h incubation. Conversely, complexes 1 and 13 can cleave DNA
at concentrations as low as a 1:100 [Ir]:[DNA] ratio and distort the LD spectra
at a 1:10 [Ir]:[DNA] ratio under the same conditions. The reason behind this
is most likely the neutral global charge of azpyOH complexes at physiological
pH, as DNA is a negatively charged molecule and the azpyNMe2 and azpy
analogues are cationic. The slight association of the Cpxbiph azpyOH complex
to ctDNA, relative to its non-interacting Cp* analogue, may be due to base
stacking of the biphenyl rings with DNA bases, inducing a slight change in
the spectrum. Whilst this indicates little to no DNA interaction for azpyOH
complexes, there does, however, appear to be slight induction of a CD signal at
the wavelengths corresponding to the azpyOH complexes, as well as reducing
the magnitude of the ctDNA CD signal at 260 nm, indicating that there may be
some association of the complexes with DNA. This does only occur at relatively
high concentrations and, were it cleaving DNA like complexes 1 and 13, would
also induce changes in the LD spectrum. As neither azpyOH complex do
so, the most likely explanation of the changes in the CD spectra is that the
complexes induce very low levels of DNA unwinding at high concentrations
after 24 h. These results indicate that DNA interaction is unlikely to be an
MoA for azpyOH complexes.
5.4.4 Hydroxyl pKa and Antiproliferative Activity
Whilst healthy cells tend to maintain an intracellular pH of 7.1 – 7.2, tumours
often have a more acidic microenvironment. This is due to increased reliance
on glycolysis, poor vascular perfusion, and hypoxia, especially in the central
region of tumours. This can lead to an extracellular pH of as low as 6.5.185 The
intracellular pH, however, remains around 7.2 – 7.4 even in acute acidosis.186
Cancer cells have the cellular apparatus to sense extracellular pH, and adapt,
driving disease progression.187
Unlike the azpyNMe2 complexes, the azpyOH complexes bear hydrogens with
pKa values within physiological pH range (Figure 5.2, pg. 214). These pKa
values lie in the range of 5.5 – 6.5. This means that, in cell medium, and in
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most biological compartments, the complexes will exist primarily in a form
in which the hydroxyl group will be deprotonated. This changes the global
charge from + to 0. Global charge can have a significant impact on drug uptake
mechanisms and reactions with cellular targets, setting them apart from the
other complexes studied in this work. Many conventional drug targets, such
as the mitochondria or DNA, are negatively charged, therefore, whilst cationic
complexes may be more likely to target these sites, neutral complexes may
instead target elsewhere.
The presence of the iodido ligand causes a significant shift in the pKa value
(from 5.88 to 6.50) relative to its chlorido analogue. This is likely due to
the additional electron density contributed by the iodido ligand. This is a
significant shift in pKa, and as pH is measured on a log scale, means that
significantly more of iodido complex 9 would be in its protonated form when in
a significantly acidic tumour microenvironment relative to its chlorido analogue
complex 7. As healthy, non-cancerous cells do not tend to generate an acidic
microenvironment, this may be a way by which to tune azpyOH complexes to
utilise di↵erent uptake mechanisms to selectively kill cancer cells over healthy
ones. The mechanism of cellular uptake of organoruthenium complexes has
been shown to be di↵erent for those bearing the monodentate iodido ligand vs.
those with the chlorido ligand.188 This may also be the case for organoiridium
complexes.
The presence of one phenyl ring on the Cp system has no e↵ect of the pKa,
whereas the presence of a biphenyl ring on the Cp system reduces pKa slightly
(from 5.88 to 5.52). The biphenyl may be slightly withdrawing electron density
from the metal, lowering the pKa. This may be the cause of the unusual trend
in potency observed in azpyOH complexes, where a general trend of Cpxph
>Cp* >Cpxbiph is observed, instead of the more common trend of Cpxbiph
>Cpxph >Cp*. Another possible reason for the lower potency of Cpxbiph com-
plex 5 may be that the large, bulky biphenyl ring hinders uptake for neutral
azpyOH complexes. This is unlikely to be the case for non-azpyOH organoirid-
ium complexes due to the highly potent activities displayed by non-azpyOH
Cpxbiph complexes, however it is possible that neutral organoiridium complexes
follow di↵erent uptake pathways to cationic ones.
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All azpyOH complexes tested were highly potent in multiple cell lines. A trend
of particular interest is that the Cp* azpyOH complexes are significantly more
potent than their azpyNMe2, azpy, azpy(OH)2 ad HOazpyNO2 analogues. This
is particularly promising as the Cp phenyl ring could be hydroxylated in the
liver during detoxification, for example, by cytochrome P-450.189 The more
water-soluble and hydrophilic Cp* azpyOH complexes may be more easily
excreted by the body than complexes with other Cp systems or bidentate
ligands, whilst still retaining potent anticancer activities. For this reason,
they show further promise as potential clinical therapeutics.
The azpyOH complexes show a much lower degree of cross resistance with
CDDP than any other family of organoiridium complexes in this work. This
may again be due to their main structural di↵erence, a neutral global charge
at physiological pH, possibly necessitating a di↵erent mechanism of cell up-
take. One of the mechanisms of CDDP resistance is reduced uptake/increased
e✏ux, so perhaps the neutral azpyOH complexes are taken up more readily
and/or pumped out less readily than other, positively-charged organoiridium
complexes. Alternatively, one of the other common mechanisms of CDDP re-
sistance, intracellular deactivation by thiol-containing molecules such as GSH
or increased DNA damage repair, may be contributing to the lower activity
of non-azpyOH Cp* complexes relative to azpyOH complexes. In Chapter 4
an azpyNMe2 complex and an azpy complex are shown to be mostly or com-
pletely unreactive with GSH, and both complexes display moderate to signfi-
cant cross-resistance with CDDP as well as interacting with DNA, indicating
a DNA damage-based MoA. The azpyOH complexes 5 and 7 show little to
no interaction with ctDNA, therefore increased DNA damage repair may be
the major contributor to CDDP cross-resistance for non-azpyOH complexes.
The azpyOH family, therefore, remains a candidate for overcoming all three
of these mechanisms of cross-resistance, highlighted by the extremely potent
IC50 values of 62 nm and 49 nm in A2780cis for Cp* azpyOH complexes 8
and 10, respectively, although A2780 is an unusually sensitive cell line and
therefore lower IC50 values are to be be expected.
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5.4.5 E↵ect of Halido Ligand on Zebrafish Toxicity
The iodido complex 8 is ca. 25⇥ less toxic to zebrafish than is otherwise
identical chlorido analogue, complex 7 (Figure 5.19, pg. 240). This striking
di↵erence in toxicity between otherwise identical chlorido and iodido azpyOH
complexes is highly encouraging, indicating a way to reduce toxicity in vivo.
In cancer cells, the iodido complex 9 also retains potency, in some cases it is
more potent than its chlorido analogue, complex 7. The use of organoiridium
iodido complexes, therefore, presents a way by which to e↵ectively kill cancer
cells, whilst reducing in vivo toxicity, and warrants future research in other
organoiridium azopyridine systems. Possible reasons for the reduced toxicity
of the iodido complex could be its inertness to hydrolysis, preventing it from
subsequently binding to o↵-target molecules, which could contribute to toxic-
ity, or lower uptake by normal cells relative to cancerous ones. As previously
mentioned, the di↵erence in pKa values, and therefore global charge at di↵er-
ent pH environments, may also a↵ect drug uptake into various intracellular
compartments, contributing to di↵erences in toxicity. Previous research into
organoosmium and organoruthenium complexes has shown that their iodido
complexes were more potent than their chlorido analogues, as well as being
more selective for cancer cells over normal cells.145
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5.5 Conclusions
The azpyOH complexes 5 – 10 represent a novel set of organoiridiums that
have not been previously investigated. They have been shown to be the most
hydrophilic of the complexes studied in this work (Chapter 3, Figure 3.12, pg.
92), as well as becoming highly water soluble when the counterion is changed.
In addition to this, they exhibit significant anticancer potency down to the
low nanomolar range. The complexes show little to no cross-resistance with
CDDP, and the alteration of the halido ligand from chloride to iodide has been
shown to reduce in vivo toxicity in zebrafish by ca. 25⇥, as well as increasing
potency in multiple cancer cell lines. Unlike the azpyNMe2 and azpy family of
complexes, the azpyOH complexes have a global charge of 0 at physiological
pH and display little to no interaction with DNA, however they do appear to
share ROS and SO generation as an MoA. The azpyOH family of complexes
remain highly potent even with Cp* as the stabilising ligand, which reduces
potency in most non-azpyOH complexes tested. In conclusion, azpyOH com-
plexes represent an avenue of research into organoiridium complexes with the
potential to generate complexes with higher solubility, greater potency, and
lower in vivo toxicity than previously reported organoiridiums, with the po-
tential to become clinically-utilised therapeutics in the future.
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Chapter 6
Conclusions and Future Work
6.1 Summary
This work has explored a previously untapped area of chemical space, gen-
erating, characterising, and purifying 17 novel organoiridium(III) azopyridine
complexes. The anticancer activity of these, and other complexes in this work,
has been thoroughly investigated in multiple cancer cell lines. The potency of
many of these complexes is greater than that of cisplatin (CDDP), and that
of many other clinically-utilised pharmaceuticals, in addition to being more
potent that many prominent metal-based complexes reported in literature.
Many of these complexes are also cytotoxic to CDDP-resistant cancer cells.
The complexes in this work are tunable by synthetically trivial adjustments.
The charge, solubility, hydrophobicity, hydrolytic behaviour, and mechanism
of action (MoA) can all be modified, in some cases dramatically, by changes
in a single functional group. This demonstrates the versatility of organoirid-
ium(III) azopyridine complexes as a platform for e↵ective drug design.
The MoA of some of these complexes has been investigated by small- and
large-scale screens, revealing a MoA based on reactive oxygen species (ROS)
and superoxide (SO) generation in addition to mitochondrial membrane de-
polarisation, with DNA a possible additional target. Cancer cells have higher
levels of basal ROS, therefore a ROS-based MoA holds the potential to selec-
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tively kill cancer cells over normal ones. Complex 1 is demonstrated to be
more selectively cytotoxic for A2780 ovarian carcinoma vs. MRC-5 normal
lung fibroblasts than CDDP, as well as many reported metal-based complexes.
Whilst these complexes are not yet ready for clinical trials, great steps have
been made towards developing e↵ective organoiridium(III) azopyridine drugs
and understanding their MoA. Further research could progress one or more of
these complexes into the first stage of clinical trials and beyond. Suggestions
of the most pertinent experiments to be carried out follow.
6.2 Future Work
6.2.1 Improved Drug Design
Many of the complexes in this work exhibit superior cytotoxicity to CDDP,
as well as many other clinically utilised therapeutics in multiple cell lines.
Complex 2, in particular, displayed impressive cytotoxicity in the GDSC large-
scale pharmaco-genomic screen against ca. 900 cell lines.
The Cp system, bidentate azopyridine ligand, monodentate halido ligand, and
counterion, each have significant implications for anticancer activity, selec-
tivity, and solubility of organoiridium complexes. This work has revealed
structure-activity relationships and trends within this family of complexes that
can be applied to future drug design to improve upon their anticancer activity,
selectivity, and solubility.
In regards to generating novel organoiridium azopyridine complexes, further
exploration of chemical space is warranted. Additionally, the combination of
multiple separate structural features that have been shown to confer desirable
traits into novel complexes may result in drugs that exceed the already consid-
erable potency of previous organoiridium complexes. A selection of potential
complexes to be synthesised that, based on this work, are likely to possess
higher potency, selectivity and solubility than existing organoiridium drugs
are shown (Figure 6.1).
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Figure 6.1: Structures of suggested complexes A – F likely to prove promising
in future research.
Complex A is an iodido analogue of the extremely potent novel complex 1
([CpxbiphIr(azpyNMe2)Cl]PF6) described in Chapters 3 and 4. Complex 1 ex-
hibited higher potency than a vast majority of existing precious metal-based
drugs in A2780 ovarian carcinoma with a low nanomolar IC50 value (95 nm). In
Chapter 5, the presence of the iodido ligand conferred a net increase in potency,
as well as a ca. 25⇥ decrease in in vivo toxicity in a zebrafish model. Ad-
ditionally, in Chapter 3, separation and isolation of stable chiral enantiomers
of azpyNMe2 iodido complex 4 ([Cp*Ir(azpyNMe2)I]PF6) was achieved. Thus
separation, isolation, and purification of suggested complex A ought to be
possible by the same method, as the Cp system did not have any e↵ect on the
separability of the chlorido analogues of the same complexes, and therefore a
Cpxbiph azpyNMe2 iodido complex is highly likely to be separable under the
same conditions. Prior to this, the previously separated stable enantiomers
of complex 4 should be desalted, purified, and their antiproliferative activity
assessed and compared to a racemic mixture. If the antiproliferative activi-
ties of the enantiomers di↵er this would be highly informative and could have
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significant implications on MoA.
Suggested complexes A – C, E and F have an iodide counterion. In Chapter 5
it was shown how switching from a PF6 counterion to either a chlorido or iodide
counterion dramatically increased the water solubility of complexes without
compromising anticancer potency. For ease of synthesis and purification, an
iodide counterion is suggested for complexes bearing a monodentate iodido
ligand. By generating complexes with more clinically desirable counterions,
high water solubility and easier drug formulation can be more easily achieved.
In Chapter 3 it was shown that the novel azpyOH complex 6 bearing an Cpxph
system displayed high potency in multiple cancer cell lines. This complex was
further investigated in Chapter 5. The iodido analogue of the Cp*azpyOH
complex 7 exhibited higher net potency and lower toxicity in zebrafish, sug-
gesting that generating an iodido analogue of Cpxph complex 6 may result in
an even more potent and selective complex.
Coordination of a pyridine monodentate ligand to an organoiridium complex
has been previously reported for a complex bearing a C’N-chelated bidentate
ligand, resulting in a highly potent and selective complex.84 Attempts to coor-
dinate a pyridine monodentate ligand to N’N-chelated azopyridine complexes
1 – 3 were unsuccessful. This was likely due to the fact that coordinating
a pyridine ligand in place of a chlorido one would increase the global charge
by +1. Such a complex would then have a net global charge of 2+, which
may not be energetically feasible or stable. In Chapter 5, the pKa values of
azpyOH complexes were investigated. Their pKa values ranged from 5.52 –
6.50. This means that the complexes will exist in a mostly deprotonated form
at physiological pH, resulting in neutral complexes with a global charge of 0.
This may then make it possible to coordinate a pyridine monodentate ligand
to the Ir centre, resulting in complex D with a global charge of 1+, which is
more likely to be stable. Additionally, were complex D synthesised in a basic
environment, it may be able to release its monodentate ligand when placed
into an acidic environment, such as in a cancer cell, depending on the pKa of
its hydroxyl group. Cancer cells have an acidic microenvironment, so such a
complex could be both a cytotoxic agent and a pH-dependent delivery system
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for a variety of ligands.
The novel HOazpyNO2 complexes 16 – 18 showed high potency in A2780
carcinoma. They were also shown to be capable of oxidising coenzyme NADH.
This could be a possible MoA. Such complexes may be reduceable under the
right conditions, forming complexes with an NH2 group instead of NO2. This
group could be used to form a peptide bond with a carboxylic acid group,
possibly with a polymer, opening up a variety of new possible drug delivery
mechanisms, such as linking multiple organoiridium complexes onto a polymer
or nanoparticle.
Complex 13 ([CpxbiphIr(azpy)Cl]PF6) showed significant DNA cleavage capa-
bilities. The exact mechanism of this is currently unknown. Synthesis of
complex F, an iodido analogue of complex 13, would likely be inert to hydrol-
ysis, as are all the iodido complexes studied in this work. If the DNA cleavage
activity of complex 13 depends on the presence of the chlorido ligand, or its
release and concomitant hydrolysis, the complex F would be unable to cleave
DNA. Therefore, complex F could be used to elucidate the DNA-cleavage
mechanism of complex 13. Additionally, if complex F does not cleave DNA,
and is shown to be significantly less cytotoxic than complex 13, then DNA
cleavage would be implicated as a probable MoA for complex 13.
6.2.2 Further MoA Investigations
Elucidation of the MoA of a drug is one of the most important and challenging
steps in progressing a novel complex from the lab to clinical trials and beyond.
In this work, steps have been taken towards discovering and understanding
the anticancer MoAs of a variety of organoiridium azopyridine complexes, as
well as the impact that the chelating ligands have on the MoA. Further inves-
tigations into the MoAs of these complexes could provide valuable avenues for
future research.
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6.2.3 GDSC Pharmaco-genomic Screening
Of all the MoA investigations carried out as part of this work, the GDSC
pharmaco-genomic screen represents the greatest in scale. As well as assess-
ing the potencies of potential drugs against hundreds of cancer cell lines of
various tissue types, such screens also have the potential to yield a significant
amount of valuable information about MoAs due to the genomic information
documented for each cell line. Additionally, the pattern of activity can be
compared to other clinically-utilised therapeutics, revealing similarities and
further elucidating the MoA of novel anticancer complexes. Four complexes
of particular interest in this work, complexes 1, 7, 9 and 13, may yield par-
ticularly interesting results if submitted for such a screen.
6.2.4 Uptake and Subcellular Distribution
Part of elucidating the MoA of a drug involves discovering its cellular targets.
The uptake and subcellular distribution of Ir complexes can be determined by
cell testings followed by microwave digestion and ICP-MS.86 Further subcellu-
lar localisation information can be obtained by synchrotron X-ray fluorescence
experiments.132 These can both direct future MoA investigations as well as
support previous ones. In particular, complexes 1 and 13, which have been
shown to interact with DNA as a possible MoA, would benefit greatly from
quantification of their level of nuclear accumulation.
6.2.5 DNA Binding
Complexes 1 and 13 were both shown to interact with DNA in di↵erent ways.
The results suggested that complex 1 noncoordinatively binds DNA in the
minor groove. Experiments investigating whether complex 1 can displace or
inhibit the binding of the known minor groove binding agent Hoescht 33258
would be valuable in definitively proving this as a method of binding. Isola-
tion of a crystal of either complex 1 or 13 bound to DNA would be extremely
valuable if an X-ray structure could be determined. Alternatively, DFT exper-
254
iments could be carried out to determine the electrostatic potential surfaces of
complexes 1 and 13, potentially allowing their mechanism of binding to DNA
to be calculated theoretically. DFT calculations may also aid in elucidating
the exact mechanism of DNA cleavage for both complexes, as well as possi-
bly explaining why complex 13 possesses significantly higher cleavage activity
than complex 1.
6.2.6 Tumour Xenograft Experiments
The potent organoosmium complex FY26 ([⌘6-p-
cymene)Os(azpyNMe2)I]PF6), bearing the same azpyNMe2 bidentate
ligand as complexes 1 – 4, was tested in a nude mouse tumour HCT-116
xenograft model, showing no significant toxicity at a dose 6 times higher
than the maximum tolerated dose of CDDP in the same tumour model.64
Additionally, this complex induced a statistically significant delay in tumour
growth in the HCT-116 model.68 Complex 1 has shown higher potency in
A2780 cells, in addition to lower relative toxicity in MRC-5 normal fibroblasts
than FY26, indicating the potential for even greater anti-tumour activity and
lower toxicity than FY26 in a tumour xenograft model.
6.3 Conclusions
Organoiridium(III) azopyridine complexes hold potential as a new family of
anticancer drugs. They bear an MoA that has the potential to kill cancer cells
more e↵ectively and selectively than many clinically-utilised therapeutics by
perturbation of their delicate ROS balance. Further research is required to
fully understand the MoA of these complexes and to determine their in vivo
toxicity before they can be evaluated for entry into clinical trials.
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Appendix
IC50 Data
Table S1: Compilation of IC50 values (in µM) for complexes 1 – 19 in all cell
lines in all chapters of this work. Data obtained from triplicate experiments.
Cell lines tested were A2780 ovarian carcinoma, A2780cis ovarian carcinoma
with acquired CDDP resistance, A549 lung carcinoma, and CNE1 nasopha-
ryngeal carcinoma. CDDP values obtained experimentally or from previously
published work,145 continued on next page (n.d. = not determined).
Complex A2780 A2780cis A549 CNE1
1 0.095 ± 0.006 0.68 ± 0.03 2.7 ± 0.3 7.1 ± 0.8
2 0.101 ± 0.001 n.d. n.d. n.d.
3 1.59 ± 0.03 n.d. n.d. n.d.
4 n.d. n.d. n.d. n.d.
5 0.14 ± 0.09 0.25 ± 0.06 5.2 ± 0.3 5 ± 1
6 0.108 ± 0.009 0.22 ± 0.02 0.89 ± 0.03 5.03 ± 0.06
7 0.12 ± 0.04 0.114 ± 0.003 1.5 ± 0.3 5.7 ± 0.2
8 0.17 ± 0.07 0.062 ± 0.004 5.12 ± 0.09 1.2 - 6.2
9 0.25 ± 0.02 n.d. 1.01 ± 0.08 n.d.
10 0.34 ± 0.02 0.049 ± 0.001 1.5 ± 0.4 1.2 - 6.2
11 5.0 ± 0.5 n.d. n.d. n.d.
12 0.776 ± 0.002 n.d. n.d. n.d.
13 0.126 ± 0.002 9.4 ± 0.7 10.9 ± 0.2 > 10
14 0.22 ± 0.02 n.d. n.d. n.d.
15 1.5 ± 0.2 n.d. n.d. n.d.
16 0.4 ± 0.1 n.d. n.d. n.d.
17 0.184 ± 0.002 n.d. n.d. n.d.
18 0.43 ± 0.04 n.d. n.d. n.d.
19 16 ± 6 n.d. n.d. n.d.
CDDP 1.2 ± 0.2 11.5 ± 0.3 3.3 ± 0.1 7.7 ± 0.2
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Table S2: Compilation of IC50 values (in µM) for complexes 1 – 19 in all
cell lines in all chapters of this work. Data obtained from triplicate experi-
ments. Cell lines tested were CNE2 nasopharyngeal carcinoma, MRC-5 normal
human lung fibroblasts, OE19 oesophageal carcinoma, and SUNE-1 nasopha-
ryngeal carcinoma. CDDP values obtained experimentally or from previously
published work,145 continued from next page (n.d. = not determined).
Complex CNE2 MRC-5 OE19 SUNE-1
1 0.98 ± 0.04 3.4 ± 0.5 0.195 ± 0.002 0.58 ± 0.04
2 n.d. n.d. 0.3 ± 0.003 1.14 ± 0.01
3 n.d. n.d. 3.6 ± 0.3 10.5 ± 0.6
4 n.d. n.d. n.d. n.d.
5 10.62 ± 0.04 n.d. 0.40 ± 0.03 0.72 ± 0.04
6 1.6 ± 0.2 n.d. 0.30 ± 0.01 1.7 ± 0.2
7 2.3 ± 0.3 n.d. 1.15 ± 0.02 1.5 ± 0.2
8 1.12 ± 0.09 n.d. n.d. n.d.
9 1.26 ± 0.04 n.d. n.d. n.d.
10 2.2 ± 0.2 n.d. n.d. n.d.
11 n.d. n.d. n.d. n.d.
12 n.d. n.d. n.d. n.d.
13 4.7 ± 0.5 n.d. n.d. n.d.
14 n.d. n.d. n.d. n.d.
15 n.d. n.d. n.d. n.d.
16 n.d. n.d. n.d. n.d.
17 n.d. n.d. n.d. n.d.
18 n.d. n.d. n.d. n.d.
19 n.d. n.d. n.d. n.d.
CDDP 7.7 ± 0.3 16.2 ± 0.6 13.43 ± 0.003 1.14 ± 0.01
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Structures of Complexes Synthesised in this Thesis
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Figure S1: Structures of complexes 1 – 19 studied in this work. A crys-
tal structure was obtained for complexes marked with an asterisk (*) Fam-
ilies of complexes grouped by bidentate azopyridine ligand. The azpyNMe2
family consists of complexes 1 – 4, the azpyOH family of complexes 5 –
10, the azpy(OH)2 family of complexes 11 and 12, the azpy family of com-
plexes 13 – 15, the HOazpyNO2 family of complexes 16 – 18, and the single
Brazpy(OH)NEt2 complex 19.
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LC-MS Characterisation Data
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Figure S2: (Top) LC trace of complex 1. (Bottom) Primary MS fragment of
highlighted LC peak.
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Figure S3: (Top) LC trace of complex 2. (Bottom) Primary MS fragment of
highlighted LC peak.
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Figure S4: (Top) LC trace of complex 3. (Bottom) Primary MS fragment of
highlighted LC peak.
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Complex 5
Figure S5: (Top) LC trace of complex 5. (Bottom) Primary MS fragment of
highlighted LC peak.
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Complex 6
Figure S6: (Top) LC trace of complex 6. (Bottom) Primary MS fragment of
highlighted LC peak.
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Complex 7
Figure S7: (Top) LC trace of complex 7. (Bottom) Primary MS fragment of
highlighted LC peak.
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Complex 8
Figure S8: (Top) LC trace of complex 8. (Bottom) Primary MS fragment of
highlighted LC peak.
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Complex 9
Figure S9: (Top) LC trace of complex 9. (Bottom) Primary MS fragment of
highlighted LC peak.
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Complex 10
Figure S10: (Top) LC trace of complex 10. (Bottom) Primary MS fragment
of highlighted LC peak.
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Complex 11
Figure S11: (Top) LC trace of complex 11. (Bottom) Primary MS fragment
of highlighted LC peak.
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Complex 12
Figure S12: (Top) LC trace of complex 12. (Bottom) Primary MS fragment
of highlighted LC peak.
283
NN
N
Ir
Cl
PF6
Complex 13
Figure S13: (Top) LC trace of complex 13. (Bottom) Primary MS fragment
of highlighted LC peak.
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Figure S14: (Top) LC trace of complex 14. (Bottom) Primary MS fragment
of highlighted LC peak.
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Figure S15: (Top) LC trace of complex 15. (Bottom) Primary MS fragment
of highlighted LC peak.
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Complex 16
Figure S16: (Top) LC trace of complex 16. (Bottom) Primary MS fragment
of highlighted LC peak.
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Complex 17
Figure S17: (Top) LC trace of complex 17. (Bottom) Primary MS fragment
of highlighted LC peak.
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Complex 18
Figure S18: (Top) LC trace of complex 18. (Bottom) Primary MS fragment
of highlighted LC peak.
289
NN
N
Ir
Cl
PF6
Br
NHO
Complex 19
Figure S19: (Top) LC trace of complex 19. (Bottom) Primary MS fragment
of highlighted LC peak.
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Peroxide Generation Test
Figure S20: Test for H2O2 generation using Quantofix peroxide test sticks on
a solution of (2.5 µM) complex 18 incubated with (150 µM) NADH in 0.5%
MeOH/99.5% (v/v) 5 mM Na2HPO4/NaH2PO4 bu↵er pH 7.4 at 310 K for 24
h.
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Stability in DMSO Data
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100 % DMSO, 30 min incubation at ambient temp. 
100 % DMSO, 19 day incubation at ambient temp. 
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Complex 2
100 % DMSO, 30 min incubation at ambient temp. 
100 % DMSO, 19 day incubation at ambient temp. 
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100 % DMSO, 30 min incubation at ambient temp. 
100 % DMSO, 19 day incubation at ambient temp. 
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Complex 6
100 % DMSO, 30 min incubation at ambient temp. 
100 % DMSO, 19 day incubation at ambient temp. 
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100 % DMSO, 30 min incubation at ambient temp. 
100 % DMSO, 19 day incubation at ambient temp. 
Figure S21: 400 MHz 1H-NMR spectra of a solution of complexes 1 – 6 in
100% d6-DMSO:D2O at 298 K incubated for 30 min and 19 days at ambient
temperature. No unexpected peaks are observed and di↵erences are visible
between the spectra.
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LC-MS Nucleotide Binding Data
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Complex 1
Figure S22: (Top) LC trace of 300 µM of complex 1 incubated with 300 µM of
nucleotide 5’-AMP in 50% MeOD:D2O for 24 h at 310 K. (Bottom) Primary
MS fragment of highlighted LC peak 1 of 1.
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Figure S23: (Top) LC trace of 300 µM of complex 1 incubated with 300 µM of
nucleotide 5’-GMP in 50% MeOD:D2O for 24 h at 310 K. (Bottom) Primary
MS fragment of highlighted LC peak 1 of 2.
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Figure S24: (Top) LC trace of 300 µM of complex 1 incubated with 300 µM of
nucleotide 5’-GMP in 50% MeOD:D2O for 24 h at 310 K. (Bottom) Primary
MS fragment of highlighted LC peak 2 of 2.
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Figure S25: (Top) LC trace of 300 µM of complex 1 incubated with 300 µM of
nucleotide 5’-CMP in 50% MeOD:D2O for 24 h at 310 K. (Bottom) Primary
MS fragment of highlighted LC peak 1 of 1.
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Figure S26: (Top) LC trace of 300 µM of complex 1 incubated with 300 µM of
nucleotide 5’-TMP in 50% MeOD:D2O for 24 h at 310 K. (Bottom) Primary
MS fragment of highlighted LC peak 1 of 1.
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Figure S27: (Top) LC trace of 300 µM of complex 13 incubated with 300 µM
of nucleotide 5’-AMP in 50% MeOD:D2O for 24 h at 310 K.
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Figure S28: (Top) LC trace of 300 µM of complex 13 incubated with 300 µM
of nucleotide 5’-GMP in 50% MeOD:D2O for 24 h at 310 K.
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Figure S29: (Top) LC trace of 300 µM of complex 13 incubated with 300 µM
of nucleotide 5’-CMP in 50% MeOD:D2O for 24 h at 310 K.
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Figure S30: (Top) LC trace of 300 µM of complex 13 incubated with 300 µM
of nucleotide 5’-TMP in 50% MeOD:D2O for 24 h at 310 K.
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LC-MS GSH Interaction Data
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Complex 1
Figure S31: (Top) LC trace of complex 1 incubated with GSH at 310 K for
24 h. (Bottom) Primary MS fragment of highlighted LC peak 1 of 2.
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Figure S32: (Top) LC trace of complex 1 incubated with GSH at 310 K for
24 h. (Bottom) Primary MS fragment of highlighted LC peak 2 of 2.
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Figure S33: (Top) LC trace of complex 1. (Bottom) Primary MS fragment of
highlighted LC peak 1 of 2.
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Figure S34: (Top) LC trace of complex 1. (Bottom) Primary MS fragment of
highlighted LC peak 2 of 2.
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Figure S35: (Top) LC trace of complex 1 incubated with GSSG at 310 K for
24 h. (Bottom) Primary MS fragment of highlighted LC peak 1 of 1.
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Figure S36: (Top) LC trace of complex 1 incubated with GSSG at 310 K for
24 h. (Bottom) Primary MS fragment of highlighted LC peak 1 of 4.
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Figure S37: (Top) LC trace of complex 13 incubated with GSSG at 310 K for
24 h. (Bottom) Primary MS fragment of highlighted LC peak 2 of 4.
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Figure S38: (Top) LC trace of complex 13 incubated with GSSG at 310 K for
24 h. (Bottom) Primary MS fragment of highlighted LC peak 3 of 4.
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Figure S39: (Top) LC trace of complex 13 incubated with GSSG at 310 K for
24 h. (Bottom) Primary MS fragment of highlighted LC peak 4 of 4.
312
Figure S40: ESI-MS trace of complex 1 incubated in H2O for 14 days. Only
two peaks are prominent most likely corresponding to Ir-Cl and Ir-OH species.
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